feel better live longer annual report b gsk annual report mission gsk mission notice regarding limitations director liability english law uk companies act safe harbour limits improve quality liability directors respect statements omissions report directors contained pages includes business review pages english law directors human life enabling would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would people feel otherwise liable report directors pages inclusive comprise report directors drawn presented better live longer accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law website glaxosmithklines website wwwgskcom gives additional information group notwithstanding references make annual report glaxosmithklines website none information made available website constitutes part annual report shall deemed incorporated reference herein cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released front cover image oral statements made public future behalf group may contain forwardlooking child seen doctor working brazils statements forwardlooking statements give groups unified health system provides current expectations forecasts future events investor identify statements fact scheduled vaccinations country relate strictly historical current facts use words anticipate estimate expect longstanding relationship government intend project plan believe words funded science institution oswaldo cruz foundation terms similar meaning connection discussion future operating financial performance manufacture vaccines public health priorities particular include statements relating future brazil began first alliance actions prospective products product approvals future performance results current anticipated polio vaccines continues products sales efforts expenses outcome contingencies legal proceedings financial recent technology transfers products like results group undertakes obligation update pneumococcal vaccine brazil one number forwardlooking statements whether result new information future events otherwise large emerging market countries forwardlooking statements involve inherent risks present quarter groups total uncertainties group cautions investors revenues generated countries number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report number adjusted measures used report performance business measures defined brand names brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies exception bonivabonviva trademark roche nicoderm trademark johnson johnson merrell novartis sanofi glaxosmithkline potiga trademark valeant prolia xgeva trademarks amgen vesicare trademark astellas pharmaceuticals many countries yamanouchi pharmaceuticals certain countries volibris trademark gilead xyzal trademark ucb glaxosmithkline zyrtec trademark ucb glaxosmithkline used certain countries licence group nozbazs xelagsk annual report strategic review financial review risk governance remuneration financial statements investor information overview gsk strategic review chairmans statement ceos review strategic review performed market deliver responsible business global healthcare company financial review risk financial review commercial success depends us financial position resources creating innovative new medicines financial review risk factors vaccines healthcare products making accessible many people need possible characterised challenging global economic climate despite continued governance remuneration board make good progress strategy corporate executive team chairmans letter grow business sustainable board report shareholders committee reports way deliver new medicines remuneration committee chairmans letter healthcare products valued total remuneration use simplify pay performance remuneration policy operations directors emoluments total remuneration directors senior management allowed us deliver significant returns shareholders financial statements directors statement responsibilities read wwwgskcom independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap highlights bn bn bn investor information total group turnover core operating total operating profit profit product development pipeline products competition intellectual property bn quarterly trend p p five year record returned core earnings total earnings share capital share price shareholders per share per share dividends annual general meeting us law regulation st tax information shareholders analysis shareholdings shareholder services contacts key medicines submitted access regulatory approval medicines index glossary terms index calculation core results described reconciliation provided gsk annual report chairmans statement despite challenging environment believe marked another year progress gsk delivery strategy generating sustainable returns shareholders past five years sir continue make changes andrews leadership group board plan future fundamentally changing improve implement proactive succession growth prospects reduce risk deliver planning would like thank sir enhanced returns shareholders crispin davis standing years agm larry culp benefits strategy retired board september evident year strong outstanding contributions performances emerging markets recent years growth businesses offsetting much impact significantly april appointed lynn elsenhans worsening outlook europe jing ulrich nonexecutive time gsks rd organisation delivered directors respectively lynn jing unparalleled output six key new brought experience running global products submitted approval companies deep knowledge growing evidence replenish emerging markets board discussions late stage pipeline sustainable additionally january announced basis clearly critical importance hans wijers currently chairman longerterm prospects group designate heineken previously ceo akzo nobel join gsk ultimately aim strategy nonexecutive director deliver sustainable earnings per share years agm growth eps improved returns shareholders gsk delivered flat core eps would also like thank sir robert p returned billion wilson agreeing remain shareholders via dividends buybacks board additional year provide brings nearly billion continuity advice new board amount returned shareholders members settle roles since sir andrew joined board met original aspiration start female operating responsible ethical representation board way essential commercial remain committed continuing success gsk chairman improve geographic gender diversity corporate responsibility committee board level pleased see continued progress summary operating year efforts improve environment remains challenging global access medicines also without substantial agreements reached supply opportunity companies deliver vaccines worlds poorest countries innovation act responsibility low prices encourage research board every confidence neglected diseases group also strength resilience sir andrew took industryleading steps improve senior management team transparency clinical trial research believes group taking oversight management risk necessary steps build stronger gsk remains key focus board generate sustainable value july group successfully shareholders society resolved series longstanding legal matters us government primarily related historical sales marketing practices board recognises matters reflect company gsk today fundamental changes made compliance marketing sir christopher gent selling procedures recent years chairman significant progress made embed culture company puts patients first demands integrity behaviours activitiesgsk annual report strategic review financial review risk governance remuneration financial statements investor information ceos review diversified sources growth rd productivity significantly improved processes simpler efficient confident strategy delivering five years ago set strategy clear adverse impact reshape gsk increase growth reduce performance weaker risk improve longterm financial expected sales european performance made good business government progress provided austerity measures adversely impacted evidence growth approximately percentage points year however doubt operating challenging rd productivity provides environment platform growth particularly evident europe despite able maintain core rd group made significant earnings per share cer generate net progress six key cash inflows operating activities new products regulatory review billion legal settlements expect phase iii data assets return billion shareholders total next also made outstanding progress three years gsk potential research development launch around new medicines year advance potential new medicines vaccines globally across multiple disease areas including also confident respiratory oncology diabetes hiv sustain level productivity investment growth markets deliver longterm goal improving returns rd investment although reported sales year around cer sales flat simplifying changing adjusting disposal non core consumer healthcare brands business reflects continued strong performance growth businesses helping continue make changes simplify offset pressure western markets operating model operational excellence programme delivered emerging markets benefits annual savings billion investments made increase remains track hit target set exposure pharmaceuticals billion annual savings vaccines well consumer healthcare february announced new evident total sales emerging major change programme markets account expect produce incremental annual business grew cost savings least billion year divisional level consumer healthcare sales flat grew programme include series excluding divested otc products technological advances opportunities eliminate complexity pharmaceutical vaccines japans believe transform longterm cost sales fell reflecting impact competitiveness manufacturing cervarix vaccine sales catch rd programme help us programme prior year excluding simplify supply chain processes cervarix sales grew sales usa shorten cycle times lower inventory improvement levels reduce carbon footprint sales declined reshaping us business reflect changing market dynamics prepare launch multiple new products continue view usa japan positively markets reward willing pay healthcare innovation gsk annual report strategic review addition given sustained shift outside consumer healthcare chairman notes review witnessed european continue strengthen core business july also settled multiple reimbursement pricing environment acquisitions equity investigations us government plan initiate restructuring investments completed states primarily relating historical european pharmaceuticals business three significant transactions sales marketing practices reduce costs improve efficiencies human genome sciences shionogi matters originated different era reallocate resources support identified theravance increase share company continue growth opportunities markets economics key future growth assets take action levels improve also evaluating strategic time delivered targeted procedures compliance marketing options ensure able maximise divestments periphery selling embed valuesbased value current future group realise value shareholders culture gsk portfolio europe divesting vesicare multiple noncore otc brands australian pharmaceutical outlook additional restructuring supports tail products strategy change shape gsks globally diversified sales base business deliver sustainable long operating responsibility improved rd output provide clear term growth short term platform growth marking also help offset pressure remain committed operating start series seeing margin structure responsibly year made growth years group resulting changes business advances agenda ensure mix remain confident behaviour actions meet exceed specifically expect deliver core eps pipeline begins contribute expectations society growth cer sales growth end drive improvement around cer year core operating margin example taken several steps also expect deliver strong medium term increase transparency clinical cash generation remain research already publish trial committed using free cash flow strengthening core results whether positive negative support increasing dividends share business committed go repurchases returns enable independent researchers attractive bolton acquisitions consumer healthcare business access detailed data lies closing would like thank continues make excellent progress behind results employees partners suppliers increase focus around core portfolio open hope help scientific continued commitment healthcare brands emerging understanding research support confident markets seeing also continue expand access ever gsk well placed succeed positive consumption trends benefit medicines people living emerging proinnovation markets sales distribution synergies poorest countries world rd model working pharmaceuticals gsk ranked number creating clear longterm capacity investments maximise returns access medicines atm index gsk deliver continued innovation markets continue last year opened assesses healthcare companies activities benefit patients sustained new innovation centre china field addition expanded performance returns shareholders increased shareholding efforts tackle neglected tropical indian subsidiary line diseases supply lowprice vaccines strategic focus decided gavi alliance use worlds initiate review evaluating strategic poorest countries also received options lucozade ribena data candidate malaria drinks brands primarily vaccine additional analysis marketed established western markets needed vaccine continues sir andrew witty brands iconic review potential save lives hundreds chief executive officer look best ways ensure thousands children africa continued growth forward looking statements based restated numbers adjusted ias r eps p cer barring unforeseen circumstances see cautionary statement regarding forwardlooking statements inside front cover explanation cergsk annual report strategic review financial review risk governance remuneration financial statements investor information strategic performed create value market review deliver grow diversified global business deliver products value simplify operating model responsible business capital investment ulverston lake district north england location new biopharmaceutical manufacturing centre first new factory gsk built uk almost years forms part series uk investments million made possible introduction new patent box rules uk sppihw mot gsk annual report strategic review performed measure performance number key indicators use core results planning reporting purposes group turnover free cash flowbc bn bn reported growth cer reported growth reported growth growth excluding legal settlements h reo pw rw tee p se ar lf eo sr ed flat h fro ew e cw ase h p fle orf wo r wm ae sd billion excluding adjusting disposal noncore otc legal settlements adjusted free cash flow consumer healthcare brands overall strong billion performances emap growth businesses largely offset declines usa important europe measure shows cash generate available return shareholders reinvest important business well effectiveness key objective strategy deliver converting earnings cash effective sustainable broadlysourced sales growth working capital control investment discipline core operating profit margina total operating profit margin bn bn reported growth cer reported growth cer reported growth reported growth performed performed core operating profit billion core total operating profit billion total operating margin declined percentage operating margin declined percentage points percentage points percentage points due expected impact points due expected impact acquisition human genome sciences acquisition human genome sciences important objective remains improve operating leverage margin indicates costs managed sales grow core earnings per sharea total earnings per share p p reported growth cer reported growth cer reported growth reported growth performed performed effective cost control delivery financial noncore items included tax charge efficiencies enabled group deliver core million p arising eps p centralisation pharmaceutical intellectual property product inventory ownership important uk transactions completed eps shows portion profit allocated resulted number significant noncash share key indicator accounting entries however largely performance returns generating offset gsk annual report strategic review financial review risk governance remuneration financial statements investor information cash returned shareholders bn reported growth performed gsk returned billion shareholders via dividends share buy backs important continue focus delivering dividend growth returning free cash flow shareholders share buybacks offers attractive return alternative investments dnedivid yub skcab dnedivid dnedivid yub skcab turnover major growth areasb new pharmaceuticals vaccines product performanceb bn bn share total turnover reported growth cer performed performed saw continued growth emerging markets total sales new products billion japan excluding vaccines consumer grew year represented healthcare excluding disposals performance pharmaceutical vaccines turnover vaccines impacted reduced sales impacted rolloff products cervarix following hpv vaccination five years old catchup programme japan important important measure shows delivery sales measure focuses major growth products launched prior five areas vaccines consumer healthcare emap years creates incentives improved japan dermatology rd performance relative total shareholder returnbd glaxosmithkline total return glaxosmithkline pharma peers return indexcid ftse total return index use number adjusted measures report performance b remuneration executives linked marked key business include core results used indicators information executive pay policy management planning reporting purposes may found remuneration report directly comparable similarly described measures used c calculation free cash flow described companies core results exclude number items total reconciliation provided calculation cer results full definition core results found described reconciliation core results total results provided constituents pharma peers return index listed gsk annual report strategic review scienceled global healthcare company researches develops broad range innovative products business three primary areas business pharmaceuticals bn vaccines consumer healthcare objective deliver group turnover sustainable growth across portfolio pharmaceuticals vaccines consumer healthcare bn bn bn turnover group turnover group turnover group pharmaceuticals business develops vaccines business one largest develop market range makes available medicines treat world producing paediatric consumer health products based broad range serious chronic diseases adult vaccines range infectious scientific innovation brands portfolio made established diseases distributed nearly four main categories total wellness brands newer innovative patent million doses countries oral care nutrition skin health protected medicines supplied developing countries sales therapy area sales vaccine sales category respiratory boostrix total wellness antivirals cervarix oral care central nervous system fluarix flulaval nutrition cardiovascular urogenital hepatitis skin health metabolic infanrix pediarix antibacterials rotarix oncology emesis synflorix dermatology rare diseases immunoinflammation viiv healthcare hiv read read read rd business sustained investment rd bn c spent billion noncore items billion total search develop new medicines vaccines innovative core rd assets late consumer products expenditure stage pipeline year saw significant delivery late stage pipeline six key medicines filed regulators core rd expenditure allocation dedicated research programmes diseases affect developing world one healthcare companies pharmaceuticals researching new vaccines new medicines three vaccines world health organizations priority diseases hivaids malaria consumer healthcare tuberculosis read calculation core results noncore items set gsk annual report strategic review financial review risk governance remuneration financial statements investor information geographic presence covers countries global reach shape business shifting capitalise markets highgrowth potential including asia pacific latin america japan territories outside usa europe employees account total sales employees region significant global manufacturing rd presence network manufacturing sites large rd centres uk usa spain belgium china usa europe emap japan turnover region usa europe emap japan structured commercial businesses structured around regional units turnover segment areas focus bn pharmaceuticals vaccines operate geographical us pharmaceuticals vaccines segments combine two businesses consumer europe pharmaceuticals vaccines healthcare business functions global unit viiv healthcare emap pharmaceuticals vaccines specialist hiv company founded pfizer japan pharmaceuticals vaccines viiv healthcare trading turnover includes canada puerto rico australasia trading central vaccine tender sales contract manufacturing sales consumer healthcare read gsk annual report overview create value delivering innovation expanding access products create value society shareholders context see opportunities challenges meanwhile worlds population continues operating environment scientific research grow pressures healthcare costs continuously uncovering new understandings notable intensification developed markets disease processes technologies following recent macroeconomic downturn innovation western markets developed new reimbursement approaches core business model medicines agree risksharing achieve objectives use knowledge development arrangements payers utilising assets executing intellectual property create value strategic priorities operating adopted flexible pricing researching manufacturing making business responsibly approaches reflect countries wealth available products improve peoples ability pay resulted past five years made health wellbeing significant increases demand significant progress delivery healthier society enables people live products emerging economies strategic priorities life fullest allowing increase access products developed balanced business communities prosper sustained worlds leastdeveloped countries geographic diversity new flow innovative products enables held price patented platforms growth particular business grow profits deliver medicines region advancement latestage improved returns shareholders developed world prices pipeline changes rd model aim develop new products reinvest fifth profits make time also simplified offer significant improvements sales territories back business reduce costs ensure existing treatment options therefore local healthcare infrastructure projects retain longterm competitiveness provide value patients pay governments sustainable commitment responsible valuesbased business underlies insurers third parties developing new medicine takes many everything values applied invested billion years substantial investment across group focused core research development new able bring scale significant integrating culture medicines vaccines consumer resources expertise required decisionmaking work products currently evaluating average successful medicine values operate transparency around investigational medicines require significant investment demonstrate respect people act diseases cancer diabetes year period integrity patientfocused ask heart disease respiratory illnesses every one employees embody next three years sustainability business values potential bring around new performance critically important medicines patients deliver continued innovation approach access products must produce responsible business see rd profitable performance ensure discovery process see pages remain competitive funds invest people assets key access element environment appropriately rewards innovation across manufacture distribute patentprotected branded billion packs products products countries around world extensive global presence approach striving make products widely intellectual property see accessible possiblegsk annual report strategic review financial review risk governance remuneration financial statements investor information create value shareholder returns assets intellectual property people infrastructure deliver innovative strategic priorities products expand benefits patients consumers society grow deliver simplify access values transparency respect integrity patient focused reinvestment wider contributions company also contributes progress highlights countries operate primary contribution tax system charge bn develop new products improve taxation profits amounted peoples health also create value billion direct contributions global company making direct support health wellbeing amount returned shareholders indirect economic social local communities relevant gsk via dividends buybacks contributions countries also made via global community past five years operate programmes amount million year global diverse employee base consisting close finally believe create value employees contract goods acting catalyst partner number new product approvals usa services significant scale last year organisations value new europe past five years manufacturing supply chain spent different perspectives around billion suppliers groups bring thinking st across countries open working research charities academia companies nongovernmental organisations access medicines index gsk annual report strategic review market environment remains challenging optimistic longterm future healthcare market general overview usa markets stagnated healthcare market end year ahead fears remains significant need fiscal cliff created federal budget healthcare industry remains medicines healthcare treatments legislation though crisis averted one worlds largest industries around world optimistic significant uncertainty remains felt effects government ability grow business strength economy austerity measures mandated longterm researching likely impact legislation intended price reductions europe japan manufacturing selling innovative stimulate economic growth number emerging markets result healthcare treatments especially given developments companies faced japan economy contracted work done reshape significant pressure growing sales demand japanese exports impacted geographically rebalance business although new products growth global economic slowdown elsewhere emerging markets nevertheless many factors affect particularly europe eurozone helped partly offset challenges performance success sector economies continued contract business exact impact recession deepened even revised sales world pharmaceutical difficult forecast growth forecasts proved optimistic market worth billion first time since single currency constant exchange rates cer global economic overview launched region failed grow months end september quarter calendar year growth increasing billion difficult market conditions stemming emerging markets weaker previous year share global international financial crisis expected china continued grow sales grew north america continued impact worlds lowest level remained top pharmaceutical economies sales decade according imf market declined europe growth world pharmaceutical markets emerging markets also based imf assessments outlook showed significant regional variation increased share global economic growth economies across globe remained immediate sign year many largest weak governments continued end weak global economy pharmaceutical companies encountered struggle longterm effects improvements budget deficits generic competition significant financial crisis overall growth among many worlds richest number products estimated slowed according nations factors political billion sales lost products international monetary fund imf turbulence within european union lost patent protection experienced instability middle east competition generics likely affect international business environment figure world pharmaceutical market value compound growth geographic region bn total sep sep north america europe emap japan total sales world market top therapeutic classes bn total central nervous system antineoplasticimmunomodulatory cardiovascular alimentary tract metabolic antiinfectives bacterial viral fungal excluding vaccines respiratory data market share market growth rates gsk estimates based recent data independent external sources including ims health values based cer constant exchange rate imf data taken world economic outlook update january gsk annual report strategic review financial review risk governance remuneration financial statements investor information population growth demand medicines vaccines price controls consumer healthcare products expected according united nations revision population projections continue grow significantly faster many countries prices world population peak mature markets pharmaceutical products controlled billion compared billion next years law governments may also influence countries prices control national lifestyle changes seeing declining birth rates particularly healthcare organisations europe japan many populations increase people also bear large part cost supplying regions seen sharp rise living longer partly aided success medicines consumers populations particularly middle medical interventions treating europe governments responding east southern asia preventing diseases previously increasing austerity pressures caused significant mortality infants countries rising populations see figure increasing age healthcare reforms countries economies comes increasing infirmity illness france spain germany experiencing improved economic restricted pricing mandated outlooks imf forecasts lifestyle changes affecting generic substitutions emerging markets grow health risks well people become japan government implemented compared less physically active alter mandatory biannual price review figures respectively consumption food alcohol pharmaceutical products developed markets tobacco growing incidence chronic noncommunicable conditions usa government price governments developing countries type diabetes heart disease controls private sector purchases pressure improve healthcare federal law requires pharmaceutical infrastructure provide basic universal emerging markets increasingly manufacturers pay rebates coverage many made significant people moving away certain medicines eligible commitments however subsistenceagricultural lifestyle find reimbursement several state strong healthcare systems paid work cities growth federal healthcare programmes missing people developing countries disposable incomes expansion rebates increased expanded buy medicines directly result middleclass sections populations affect affordable households emerging markets spend significant large proportion care act aca continuing significantly higher proportion healthcare spending countries government finalising personal income medicines comes directly patient additional details implementing spent richer countries pharma futures aca expansion governments report perspectives emerging insurance programme lowincome markets estimates high americans new health insurance china india marketplaces financial penalty brazil example certain americans choose purchase health insurance scheduled figure estimated change world population millions years pop years pop years pop world population projected increase substantially current levels biggest proportional growth older age group source ims gsk annual report strategic review market continued additionally crossborder trade figure european commission adopted acceleration generics market us fda approvals new molecular entities proposals july new regulation comparative effectiveness research aimed boosting clinical research valuebased care delivery pharmaceutical europe simplifying rules pricing issues importance conducting trials proposals industry part continuing currently review industry healthcare debate usa seeking ensure new legislation expected come effect regulatory pressures create favourable environment rd europe pharmaceuticals vaccines industry highly regulated regional new falsified medicines directive countryspecific laws regulations became effective january important determining whether nature reviews drug discovery february introduced measures prevent entry product successfully developed doinrd falsified medicines legal supply approved usa chain include requirements importation active substances number impact regulatory usa fifth reauthorisation eu third countries noneu member agency requirements increasing prescription drug user fee act pdufa states may present challenges particularly across aspects product passed signing pharmaceutical manufacturers quality safety evaluation law food drug administration benefit risk continues safety innovation act fdasia emerging markets paramount consideration approval law establishes new userfee statutes demand patient access new medicine regulatory generic medicines followon versions new drugs emerging markets grows authorities increasingly focusing biopharmaceuticals commonly referred importance conducting safety medicines biosimilars also equips fda clinical trials countries postapproval phase tools intended accelerate provide data medicines profile regulatory agencies criteria development review innovative local populations new medicines gives agency new evaluating benefit risk also growing number emerging markets authority concerning drug shortages vary widely making challenging requiring studies conducted pharmaceutical companies meet fda approved new molecular incountry assess variation requirements country entities majority ethnosensitivity new medicines representing first market addition evidence highly approval see figure regulated authority ema fda approved new medicine europe initiate review european union eu saw regulatory requirements significant new legislation regulatory markets challenging requirements implementation terms volume pace change revised eu pharmacovigilance legislation consistency guidance brings new measures aimed nevertheless continue take part strengthening safety monitoring regional national regulatory medicines started july initiatives provide opportunities european medicines agency ema scientific regulatory dialogue approved novel medicines industry agencies approvals nine medicines stakeholders aim include broader rare diseases sets patient populations countries medicine development programmes increase global patient access new innovative medicines optimise regulatory approvalsgsk annual report strategic review financial review risk governance remuneration financial statements investor information consumer healthcare life patent countries principal pharmaceutical years filing date however vaccines competitors include abbott consumer healthcare industry long development time new laboratories amgen astrazeneca subject national regulation comparable medicines mean substantial bristolmyers squibb eli lilly johnson prescription medicines amount patent life johnson merck novartis pfizer testing approval manufacturing eroded launch markets roche holdings sanofi takeda labelling marketing products possible lost time high standards technical appraisal consumer healthcare market restored leads variations frequently involve lengthy review become challenging consumers amount patent life available approval process delay demanding better quality better product market product launches value retailers consolidated addition commercial globalised strengthened intellectual property products protected registered negotiation power principle trademarks trademarks major markets competitors markets include trademarks important maintaining colgatepalmolive johnson johnson process discovering brand identity products procter gamble unilever pfizer developing new medicine vaccine may local variations example novartis takes many years cost usa trademark advair covers addition many smaller billion product sold eu seretide companies compete gsk intellectual property effective trademark protection may generally certain markets legal protection intellectual extended long trademark property via patents trademarks used renewing necessary outlook registered designs copyrights enforce trademark rights domain name registrations critical prevent infringements gsks globally diversified sales base ensuring reasonable reward improved rd output provides clear innovation fund rd see pages generic pressures platform growth marking pharmaceutical start series vaccines development process patents expire medicines growth years group medicines subject competition patent protection new active specifically expect deliver core eps generic products effect ingredients available major markets growth cer sales growth particularly acute western markets patents often obtained around cer year based generic products rapidly new drug formulations manufacturing ias revised adjusted eps capture large share market processes medical uses devices p also expect deliver generic manufacturers typically administering products strong cash generation incur significant costs rd education remain committed using free cash emerging markets aligned market development able flow support increasing dividends approach recognising offer products considerably share repurchases returns patentprotected medicines lower prices branded competitors attractive bolton acquisitions pressures apply although may obtain patents significantly vaccines products confident ever products prevent patents exist active gsk well placed succeed challenged ingredients delivery device emerging proinnovation markets expire grant patent inhaled respiratory medicines rd model working mean held valid creating clear longterm enforceable court court competition capacity gsk deliver continued determines patent hold innovation benefit patients invalid noninfringed unenforceable within pharmaceutical industry sustained performance returns protect innovation competition come shareholders risks outlook legal jurisdiction significant litigation companies making patentprotected see risk factors pages concerning patent challenges medicines indications treat summarised note financial similar diseases medicines statements legal proceedings manufacturers making generic copies medicines following patent expiration gsk annual report strategic review deliver strategy designed deliver sustainable growth reduce risk improve longterm financial performance returns shareholders grow grow past five years time reshaped diversified created balanced business us pharmaceuticals product portfolio capable vaccines business reflect global business delivering sustainable sales growth changing market dynamics centred three business prepare launch areas pharmaceuticals vaccines multiple new products europe consumer healthcare restructuring improve provide us significant efficiency focus resources competitive advantages growth opportunities opportunities synergy continues challenging market environment substantially increased investment highergrowth areas emerging markets japan global vaccines consumer healthcare businesses read deliver deliver changed rd broken traditional products organisation better able hierarchical rd business model sustain pipeline products created smaller agile value offer valuable improvements groups scientists treatment patients accountable projects healthcare providers underpinned increased externalisation focus improving research allowing us access rates return rd new areas science share rigorous allocate risk development investment across pharmaceuticals partners also changed vaccines consumer processes make decisions earlier healthcare rd medicines significantly differentiated existing therapies progressed read simplify simplify business continues savings programme operating change shape transforming generated across business operate programme comes end model reduce complexity become continuing examine ways efficient simplify operating model increase efficiencies past four years implemented global restructuring therefore begun programme designed deliver new major change programme significant savings support across manufacturing rd investment priority growth europe deliver savings businesses well offset pressures new programme includes groups margin resulting series technological advances changes shape mix opportunities eliminate business complexities improve competitiveness read gsk annual report strategic review financial review risk governance remuneration financial statements investor information bn financial architecture values behaviours financial architecture designed work towards goals group turnover support delivery execution deliver success groups strategy drive sustainable important achieve growth core earnings per share many ethical issues associated free cash flow order maximise total research development sales returns shareholders manufacture sale products emerging markets relationships healthcare architecture established four key professionals patients regulators financial priorities gsk delivering ethical conduct priority gsk sustainable sales growth improving put interests patients operating leverage improving consumers first driven financial efficiency converting values transparency respect integrity earnings cash patientfocus everything applying framework understand without drive better consistent application values talented decision making across company diverse engaged workforce improve delivery key execute strategy financial objectives earnings per focused supporting employees share growth free cash flow creating culture values generation returned key product filings shareholders reinvested bolton based decision making guides business practices values acquisitions wherever bn attractive returns available backed clear code conduct robust compliance systems training decisions rigorously benchmarked support help employees make new product sales using cash flow return investment right decisions cfroi returns based framework strong policy compliance also improved financial programmes help embed reporting align closely behaviours leadership architecture providing board central executive data insights progress team board active ensuring making businesses corporate governance oversees regions progress informs sound decision making key drivers operational executive management financial efficiency transitioned reporting core basis enabling greater bn visibility underlying performance business annual benefits restructuring days working capital cycle days read read gsk annual report strategic review grow deliversimplify grow diversified global business overview past five years created balanced business product portfolio capable delivering sustainable sales growth centred three business areas pharmaceuticals vaccines consumer healthcare believe offer significant competitive advantage opportunity synergies substantially increased investment highergrowth areas emerging markets japan global vaccines consumer healthcare businesses time reshaped us pharmaceuticals vaccines business reflect changing market dynamics prepare launch multiple new products europe restructuring improve efficiencies focus resources growth opportunities continues challenging environmentgsk annual report strategic review financial review risk governance remuneration financial statements investor information progress reported turnover year flat adjusting disposal noncore otc brands overall strong performances emap growth businesses largely offset declines usa europe total sales emerging markets account business grew year vulnerability generic competition declining sales white pills western markets accounting turnover group turnover bn white pills western markets bn reported growth cer reported growth cer bn turnover major growth areas bn sales emerging markets bn group turnover group turnover bn priorities globally diversified sales base coupled strong rd output provides us platform sustainable future growth continue invest key growth businesses emerging markets consumer healthcare support outlook proinnovation markets like usa japan priority year prepare launch multiple new products pipeline europe focus restructuring pharmaceutical business reduce costs reallocate resources also considering strategic options maximise value portfolio region see financial review see gsk annual report strategic review grow diversified global business us pharmaceuticals vaccines turnover bn fundamentals us respiratory market sales medicines increased business grew business strong despite bn respiratory controller segment returned pressure generics overall prescription volume growth group turnover product discontinuations year followed decline food drug administration remain confident revised class labeling controllers sales advair largest product ability deliver growth increased flovent sales declined pipeline new sales ventolin medicines performance strong performances lovaza lamictal promacta newly launched products votrient arzerra also helped us offset loss patent marketplace exclusivity arixtra argatroban loss avandia sales new us healthcare market continued treatment lupus benlysta contributed operating profit bn change rapidly patients sales million year providers payers sought improved bn care lower costs drive vaccines business turnover flat value along implementation decline flu vaccine sales offset healthcare reform spurred sales pediarix increased consolidation among healthcare boostrix grew organisations providers including year pipeline continued hospitals health maintenance strong momentum several organisations preferred provider products receiving fda approval organisations home health agencies including votrient sarcoma promacta hospices changing way care hepatitis c thrombocytopenia provided paid usa menhibrix vaccine meningitis cy environment decisions infuenza type b raxibacumab purchasing prescribing increasingly anthrax inhalation fabior foam made central point dermatology addition year pharmaceutical industry submitted five medicines fda adapt approach product marketing respiratory medicines breo anoro pharmaceuticals vaccines turnover continue work effectively oncology medicines dabrafenib healthcare providers payers trametinib braf mek growth albiglutide diabetes cer performance respiratory year also significant antivirals throughout year continued completed settlements us central nervous system transform business government broad range long cardiovascular urogenital effectively market sell medicines standing legal cases past several metabolic vaccines provide value antibacterials years taken actions levels customers demand challenging oncology emesis business change procedures healthcare environment vaccines compliance marketing selling dermatology business demonstrated embed new way business rare diseases underlying strength strong operate instilling valuesbased immunoinflammation performance products serving culture within organisation respiratory neuroscience vaccine committed operating business oncology markets overall sales transparency integrity respect although excluding impact focus best interests patients avandia sales flat throughout year continued transform business model operating profit increased billion result continuing also provided million efforts simplify processes worth gsk medicines vaccines produce efficiencies operations uninsured insured patients enrolled patient assistance programmesgsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify europe pharmaceuticals vaccines turnover bn economic climate pharmaceuticals business turnover declined sales volume seretide government austerity bn asthma copd product increased measures continue revenue declined price cuts oncology products votrient group turnover impact performance promacta arzerra performed well maintain sales duodart avodart treat benign prostatic hyperplasia grew determination develop even though duodart business build market access approval france italy opportunity provided gaining approval governments market products flow new products continues challenge pipeline see improvements prolia treatment osteoporosis benlysta lupus launched marketplace almost markets europe operating profit bn economic climate europe vaccines business reported continues pose challenges bn pharmaceutical companies wide turnover declined reflecting austeritydriven price cuts range businesses industries introduction national tenders austerity programmes pressuring several countries governments find new ways tightening healthcare budgets throughout europe sought stringent austerity measures implemented work governments countries affected implementing austerity measures find pricing medicines also patients ways manage patient demand access new treatments healthcare expenditure partnership approach resulted one particular concern interruption supply operation reference pricing countries overall reduction prices set reference charged overdue receivables countries could create additional pressure levels set country support charitable programmes severe austerity measures adopted strengthen healthcare pharmaceuticals vaccines turnover others communities regions growth operate remains important part cer performance business financial support year respiratory european business continued totals million europe antivirals affected austerity measures excluding uk central nervous system overall sales cardiovascular urogenital following review metabolic respond challenging business restructuring european antibacterials climate continued invest business reduce costs improve oncology emesis products reducing operating costs efficiency reallocate resource vaccines compared despite support growth opportunities europe dermatology rare diseases initiatives operating profit fell reduce european cost base immunoinflammation primarily owing loss sales also evaluating strategic options ensure able maximise value current future portfolio gsk annual report strategic review grow diversified global business emap pharmaceuticals vaccines turnover bn despite volatility across developing countries market access dcma unit manages region emerging bn commercial business worlds markets asia pacific poorest countries focuses volume rather profit growth also performed group turnover business continues well dcma unit sales increased perform strongly million growth across vaccines overall emap pharmaceuticals turnover increased improved momentum pharmaceuticals slow first quarter strong growth respiratory combined good marketplace performances number established brands newer oncology portfolio overall market growth emap region slowed somewhat sales innovative brands continue global economic factors played outpace market seretide part increasing price controls avodartduodart avamys gaining operating profit bn funding constraints aggressive market share also seen local competition also contributed number promising product bn however believe business launches across region strong uptake duodart philippines environment region remains prolia brazil russia argentina strong growing populations expanding middle classes higher benlysta treatment lupus spending healthcare approved ten countries confident region continue region including russia taiwan provide significant contribution launched four also preparing growth pharmaceutical industry launch several products within long term latestage pipeline regulatory filings completed relvar performance philippines taiwan brazil strong presence many high classic brands business grew growth emap markets across strong performances augmentin vaccines pharmaceuticals businesses ventolin zeffix made good progress including successful tender wins pharmaceuticals vaccines turnover pharmaceuticals vaccines turnover medicines augmentin ventolin growth growth throughout region saudi arabia russia south korea cer growth strong across three main kazakhstan respiratory pillars business innovative brands antivirals despite quarterly volatility classic brands central nervous system vaccines growth driven vaccines cardiovascular urogenital synflorix rotarix cervarix metabolic regionally saw strong growth latin synflorix proven particularly antibacterials america million successful launch also saw solid oncology emesis china million performance base paediatric vaccines india million partly vaccines business dermatology rare diseases offset effect mandatory price reductions number markets including turkey koreagsk annual report strategic review financial review risk governance remuneration financial statements investor information operating profit grew billion represents substantial broadly line sales growth contribution united nations millennium development goal commitment increase access reduce child mortality medicines across emap region sustaining operating profit growth leastdeveloped countries demonstrated continuing covered dcma unit price gsk expansion flexible pricing medicines developed market initiatives affordability partnerships prices innovative brands vaccines example launched new also reinvest profits lowercost pack four ventolin rotacaps make countries back local lowcost inhaler indonesia healthcare infrastructure provide patients affordable effective treatment rolled across emap markets gsks contracts gavi alliance central strategy increase access vaccines developing countries anticipate programmes resulting partnership vaccinate million children gastrointestinal diarrhoea caused rotavirus coming five years million children pneumococcal disease see information programme yemen committed supply gavi million doses rotarix five years million doses synflorix ten years six new gavieligible countries introduced rotarix two additional countries pakistan madagascar introduced synflorix gsk annual report strategic review grow diversified global business emap pharmaceuticals vaccines continued case study wider access vaccines august government yemen introduced rotavirus vaccines national immunisation programme help prevent thousands childrens deaths severe diarrhoea programme made possible commitment gavi alliance committed supply gavi million doses rotavirus vaccine next five years minimum million doses pneumococcal vaccine next ten years vaccines priced small fraction developed world prices intended reach children worlds poorest countries burden illness often highest partnering gavi vaccines reach children arrangement provides us security around high volume long term supply allowing us operate sustainable business model pictured infant receiving vaccine yemen nemeyfriahslaarimaivaggsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify japan pharmaceuticals vaccines turnover bn despite scheduled benefited revision system compounds formulations government price bn receiving premium revisions pharmaceuticals turnover grew group turnover completion cervical strong growth recently launched products lamictal avodart cancer vaccine catch volibris partly offset impact programme march mandatory biennial price cuts impacted growth approximately japanese business percentage points increasing generic performed strongly competition paxil respiratory portfolio grew million strong contributions adoair sales xyzal offsetting declines marketplace flixonase zyrtec japans pharmaceutical market grew paxil leading cns product faced operating profit bn affected strong challenges newly launched governments scheduled reimbursement antidepressants generic bn price revisions take place every version entering market june two years sales fell paxil together newly introduced paxil cr remains statefunded cervical cancer leader antidepressants market vaccination programme girls hib pneumococcal vaccine approval requip cr infants young children also ministry health labour welfare impact pharmaceutical companies recommended switching patients earnings year regular requip based benefits new formulation offered performance regulatory approvals market japan continues since six approvals encourage innovation coming new approvals business performed strongly granted year include samtirel turnover fell pneumocystis pneumonia paxil cr million largely reflected depression requip cr parkinsons pharmaceuticals vaccines turnover adverse comparison disease votrient soft tissue sarcoma benefited particularly growth botox hyperhydrosis malaron cer strong cervarix sales due hpv malaria new product filings made respiratory vaccination catch programme relvar asthmacopd arzerra antivirals excluding cervarix turnover chronic lymphocytic leukemia central nervous system increased cardiovascular urogenital vaccines business recorded sales metabolic price revision conducted million boosted antibacterials new provisional drug pricing governmentfunded immunisation oncology emesis system provides premiums programmes though completion vaccines patentprotected medicines hpv catchup programme impacted dermatology prices maintained total sales rotarix launched late rare diseases exclusivity period new system contributed sales million means pharmaceutical manufacturers offpatent products suffer larger reduction reimbursement prices compared manufacturers strong innovation portfolios gsk annual report strategic review grow diversified global business japan pharmaceuticals vaccines continued operating profit billion fell case study reflecting loss sales compared japan market rewarding innovation gsk daiichi sankyo co ltd started new vaccines joint venture japan japan market rewards healthcare innovation vaccine co ltd jvc venture significantly grown sales market share country recent gsk stake hold years launched multiple new products commercial rights market six approvals bringing total number regulatory existing vaccines parent approvals since potential approximately companies responsible late launches japan next three years stage development creates significant economies scale development key focus japanese business reduce time lag distribution vaccines submission new medicines usaeu submissions japanese market japanese regulatory authorities previously time frame several years better global collaboration development country continues recover safety studies able reduce matter months earthquake tsunami march employees volunteer team new asthmacopd medicine relvar example filed japan team orange formed following three months first western submission taking global approach catastrophe continued provide approved add established respiratory medicine portfolio help support people affected country areas also worked raise funds scholarship programme targeting students impacted disaster year ended gsk japan designated company year british chamber commerce japangsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify consumer healthcare turnover bn consumer healthcare markets weightloss product alli experienced major interruption business continues bn supplier impacting sales perform strongly particularly smoking reduction cessation group turnover emerging markets products also performed well year gaining share north america europe another contributor marketplace pain management category sales market consumer healthcare category continued benefit products operated two distinct speeds rollout patented optizorb strong growth emerging technology panadol concept brands economies contrasting sharply including panadol europe asia challenging environments western latin america dolex colombia europe north america competition crocin india intense companies sought oral care category led growth outpace market growth developed versus market growth approximately economies improve presence operating profit bn sensodyne became businesss first emerging markets billiondollar brand boosted bn performance global rollout sensodyne repair protect launch sensodyne repair consumer healthcare business protect whitening extra fresh restructured late four large denture care business also registered highvalue categories total wellness strong growth oral care nutrition skin health particularly positive results benefit new structure began expansion emerging markets realised total turnover excluding sales noncore otc nutrition registered global brands increased billion growth horlicks continued grow relatively consistent performance indian subcontinent quarters reflected continued horlicks family nutrition range sold close growth oral care nutrition total million sachets india wellness partly offset small decline maxinutrition range skin health addition took steps acquired continued strong increase global availability growth breakdown turnover brands innovations reached announced review evaluating strategic nearly countries growth options lucozade ribena cer regional basis us sales grew drinks brands primarily total wellness european sales flat marketed established western markets oral care nutrition impacted continuing economic brands iconic review skin health pressures drag supply look best ways ensure interruptions alli year continued growth rest world markets grew skin health business registered india middle east china decline strong performances making strong contributions early wound care bactroban china completed plans good growth lip care zovirax increase stake indian consumer introduction abreva conceal healthcare subsidiary usa offset declines hinds increasing presence latin america oilatum uk important fastgrowing market operating profit billion fell sales total wellness business reflecting disposal noncore fell sales otc brands divested noncore otc brands excluded sales grew within business gastrointestinal products registered growth launch tums freshers usa strong performance eno emerging gsk annual report strategic review grow diversified global business consumer healthcare continued case study reaching rural communities indian business fastestgrowing consumer healthcare business average sales growth past five years business generated revenues million operating across nutrition total wellness oral care categories number leading brands india biggest far horlicks sold close million drink sachets horlicks india horlicks drink evolved iconic household brand range nutritional products including breakfast cereals biscuits instant noodles original trademark product diversified specialised formulations different consumers including junior horlicks womens horlicks mothers horlicks increasing availability horlicks rural markets reaching additional villages addition harnessing popularity strong reputation indian consumers brand working community organisations schools mothers groups local doctors pharmacies mobile vans provide advice education health nutrition remote rural communities population lives network also working local healthcare providers increase communities access key medicines treat diseases greatly worsen blight malnutrition concentrating efforts improving access medicines zentel worm infestations fesovit iron deficiency vitamin mineral supplements treatments respiratory problemsgsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify viiv healthcare turnover bn hivaids business new agreement enables viiv healthcare advance portfolio withstood generic bn effectively efficiently competition number maximising full potential longterm value assets return shionogi group turnover products finishing receives representation viiv year significant filing healthcare board becomes shareholder company marketplace regulatory submissions investigational integrase inhibitor estimated million dolutegravir europe usa people worldwide reported canada completed following receipt living hiv phase iii data comprehensive market hiv medicines highly trial programme naive treatment competitive multiple new market experienced patients fda entrants increasing number granted priority review submission generic competitors usa regulatory files dolutegravir operating profit bn europe scientific progress hiv fixeddose combination epzicom marked new therapies provide kivexa anticipated bn benefits existing medicines efficacy providing comprehensive sustainable tolerability resistance profiles approach improving access hiv performance medicines remains key priority viiv healthcare commitment covers turnover viiv healthcare countries including middleincome billion countries lowincome countries least previous year decline sales developed countries subsaharan anticipated mature product africa offer royaltyfree voluntary portfolio including combivir epivir licences notforprofit pricing ziagen usa experienced generic lowincome leastdeveloped countries competition impact partly subsaharan africa offset strong performances people hiv currently live epzicomkivexa selzentrycelsentri middleincome countries approach sales epzicomkivexa grew casebycase basis taking million sales selzentry account local needs tiered breakdown turnover celsentri million pricing policy based gross domestic growth driven increasing earlyline use product burden epidemic cer usa broader uptake genotypic improve affordability marketed combivir tropism testing europe rapid pipeline hiv medicines covered epivir expansion selzentrycelsentri continued access policy epzicomkivexa lexiva international region first viiv healthcare also spearheaded selzentry line approvals several large markets initiatives address paediatric hiv trizivir including japan argentina australia include collaboration despite fall sales operating profit clinton health access initiative billion flat cer terms chai mylan pharmaceuticals primarily reflecting robust cost control produce tastemasked dispersible changes mix products sold medicine paediatric use resource limited settings significant unrestricted viiv healthcare established gsk educational grants also provided pfizer october viiv five organisations support healthcare shionogi agreed collection paediatric data information viiv healthcare would acquire exclusive research positive global rights codeveloped portfolio action programme positive action investigational integrase inhibitors children fund viiv healthcare also including dolutegravir continued make important progress supporting community response hivaids gsk annual report strategic review grow deliversimplify deliver products value overview changed rd organisation better able sustain pipeline products offer valuable improvements treatment patients healthcare providers increased level externalisation research allowing us access new areas science share risk development partners also changed processes make decisions earlier around pipeline progressions medicines significantly differentiated existing therapies progressed broken traditional hierarchical rd business model created smaller agile groups scientists accountable delivering projects underpinned focus improving rates return rd rigorous allocate investment across pharmaceutical vaccine consumer healthcare rdgsk annual report strategic review financial review risk governance remuneration financial statements investor information progress new vaccines approved flu meningitis meningitishib received two significant new indications existing medicines treating cancer hepatitis also filed six key new products approval regulators including treatments respiratory disease cancer hiv diabetes unprecedented level latestage pipeline delivery company overall return rd investment increasing remain confident reach longterm goal sales new pharmaceuticals vaccines products bn core rd expenditure bn bn bn new product approvals usa estimated rate return rd feb feb target priorities key focus successfully progress six key product filings made although clearly decisions approval assets made regulators increasingly confident ability sustain pipeline delivery expect receive phase iii data assets delivery dataflow next two years priority group also continue drive improvements ways working across rd organisation increasing levels output maintained without increased expenditure gsk annual report strategic review deliver products value investment rd research development primary goal rd develop gsk became first major pipeline products safely pharmaceutical company publish critical ensuring efficiently produce innovative new internal rate return irr rd sustainable business medicines provide improved investment indicate positive value treatments valued realised choices within continue patients payers rd organisation irr provides offer new medicines measurement offering insight people work across manage rd business vaccines consumer rd organisation many based complex methodology based large rd centres uk products help weighs rd costs incurred usa belgium china discover develop late stage people live longer rd expenditure noncore items pipeline projects profits billion representing healthier lives new medicines vaccines total turnover achieve regulatory approval made rd expenditure split three available patients incorporates actual parts proportions devoted predicted sales figures probabilities core rd expenditure three areas business pharmaceuticals success medicines pipeline vaccines consumer healthcare also take account estimate allocate rd investment consistently attributable rd costs estimated profit rationally across three businesses margins capital investment working investment rd based capital requirements see best opportunities stated longterm aim market science rather increasing rate return rd fixed proportion sales overall investment february rd budget remained relatively flat past four years announced irr around pharmaceuticals increase irr vaccines discovery development process calculated february irr consumer healthcare long expensive uncertain figure updated every years especially pharmaceuticals next published figure vaccines rd possible calculation february predict projects succeed estimated rate return rd fail information discussed spending included products launched pages january december rate return rd compounds phases iib iii development process declining rd productivity issue calculation based actual sales pharmaceutical industry forecast sales whole faced past decade adjusted reflect expected result become important failure rates broadly line companies provide greater level standard industry failure rates transparency returns cost base used calculation rd organisations make determine comprises estimate attributable capital investment allocation rd costs actual projected returns generated rd milestone payments appropriate primarily determined commercial estimated working capital requirements success new medicines vaccines factored calculation based achieve regulatory approval historical performance launched confident track deliver longterm goal improve returns around details full product development pipeline made pharmaceutical vaccine assets set pages website performance marketed products discussed detail financial review pages gsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify pharmaceuticals rd successful year significant progress process began rd organisation therapy areas reviewed seek long term need scientifically promising areas course year received investments drug discovery move two new significant indications organisation culture predisposed making pipeline existing medicines promacta reinvest existing areas thrombocytopenia associated lead new medicines result therapy area rebalancing hepatitis c votrient treatment process changed business model valued soft tissue sarcoma addition moving smaller agile submitted six key new medicines patients focused discovery performance units regulators respiratory medicines relvar dpus five scientists pay treatments breo anoro oncology medicines dpu works particular disease dabrafenib trametinib braf pathway responsible discovery mek dolutegravir hiv development potential new albiglutide diabetes medicines early stage clinical highlights two new chemical entities moved trials completion phase lla phase iii development part new model dpus cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid assets terminated phase iii given budgets threeyear existing medicines promacta development listed window complete specific tasks votrient core pharmaceuticals rd business plans dpu identified expenditure billion specific targets investment across cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid decline continue multiple years plans also included treating respiratory disease move towards sustainable replenishment opportunities collaboration cancer hiv diabetes latestage pipeline external organisations large submitted regulators small companies academia people work cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals rd view internal rd expertise gives us strong research identified following research projects early stage discovery basis identifying forming collaborations drug discovery investment review latestage development typically inlicensing optionbased discovering new medicines threeyear mark dpus core pharmaceutical rd investment early stage rd drug discovery reached late early seeks identify biological targets business plans reviewed involved development discovery investment board dib diseases create small identified areas improvement molecules biopharmaceuticals suggested agreed progress targets interact disease targets investment levels membership ultimately leading new medicines dib comprises senior rd sheer scale scientific discoveries commercial management external makes essential highly individuals expertise including selective invest drug life science investment experience discovery discovery resources focus understanding payer perspectives development areas consider likely lead chaired president rd facilities central support significant medical advances overall review dpus last six years positive led number new transformed rd organisation investment allocations discovery become efficient productive research course four new dpus created three closed addition scientists submitted proposals new discovery performance units gsk annual report strategic review deliver products value pharmaceuticals rd continued outcome consistent developing medicines patients portfolio investment board pib intentions dpu structure assesses technical commercial compound advances late dib review retain flexibility investment case project stage development typically phase discovery research investment progress development pib iia undergo much largerscale ensure remain focused cochaired chairman rd studies humans investigate scientific opportunity remains greatest president north america efficacy safety way working pharmaceuticals includes heads future remain flexible time work optimise pharmaceutical region along landscape changes compounds physical properties head global manufacturing formulation produced overall discovery expenditure pib accountable investment efficiently sufficient quantities remained flat approximately decisions funding allocation across manufacturing process million individual project latestage pharma rd investments convert results activities annual expenditure medicines discovery development regulatory file submission total annual rd biopharm rd oncology stiefel rare regulatory agencies expenditure investment decisions diseases emerging markets rd made science medicines development teams mdts allows investment decisions presents compelling case small units six ten people made holistic way ensuring remains need new treatments responsibility compound balance diversity assets differing later stages development risk profile novelty opportunity learned great deal filing regulatory agencies development cost potential first dib review expect assets latestage reimbursed payers deliver assets commit development medicine development typically phase projects reviewed pib certain iib next three years also actively seek opportunities key decision points commit medicine add products pipeline development commit phase iii increase productivity would alliances companies commit file launch funding mean gsk moving towards sustainable latestage assets typically take generally allocated next replenishment latestage pipeline form inlicensing copromotion key decision point typically increase cost arrangements likely two four years ahead pib also aligned existing areas therapy carries annual latestage funding expertise investment review investment projects reviewed adjusted necessary prioritised individual latestage project incurred annual expenditure total annual rd expenditure timeline development stages pharmaceutical research drug discovery preclinical clinical trials regulatory scale post marketing review launch surveillance phase phase ii phase iii approved new medicine number patientssubjects years years years ind submitted nda submitted yrevocsiderp compounds compounds compounds indefinitegsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify case study concentrating development estimated takes nine years take medicine initial research point approved regulators made available patients rd organisation working reduce time two cancer medicines recently submitted regulatory authorities dabrafenib braf inhibitor tramatenib mek inhibitor malignant melanoma shown done submissions regulators took place less seven years time teams selected compounds potential anticancer treatments able developing deep understanding compounds worked could design clinical trials include patients whose tumours specific genetic mutation made susceptible investigational medicines compounds worked tumours genetic mutation collaborated another company develop diagnostic test identify tumours carrying mutation pictured representation melanoma cells noitamina lacidem modnar gsk annual report strategic review deliver products value pharmaceuticals rd continued sales new pharmaceutical products case study launched last years grew represented total opening access trial data pharmaceutical sales governance clinical trials vital part development process new medicines vaccines recognise importance sharing research trials rd governance structure help advance scientific understanding inform medical judgment developed ensure clearer accountabilities product reviews access patientlevel data clinical trials valuable researchers oversight strategic issues want learn existing medicines improve patient care overall budget management across rd number years gsk responded external requests patientlevel data owned rd executive team casebycase basis proactive allowing researchers radex dib pib control investment request anonymised patientlevel data published clinical trials decisions early latestage rd approved terminated medicines enable researchers examine described trial data closely combine data different studies conduct research scientific review board srb governing body accountable researchers able submit requests via dedicated website scientific assessment rd portfolio ensure requests valid scientific basis established support investment decision making fully independent panel oversee requests grant access portfolio investment board pib expanding first company sign srb debate review alltrials campaign calls registration clinical trials disclosure endorsement unified rd view clinical trial results publication clinical study reports detail scientific aspects assets srb design methods results clinical trials form basis submissions establishes view overall scientific regulators promise asset development plan deliver asset cost effectiveness also announced plans make clinical study reports medicines clinical plan opportunities risks publically available gsk clinical study register medicines likely product profile gaps approved discontinued development results evidence missing remains uncertain published put place dedicated team work back time srb view formal rd position post reports approved medicines dating back formation communicated pib gsk starting commonly prescribed patient data clinical study reports removed ensure patient confidentiality two important governance maintained boards rd technology investment board tib makes steps advance long standing commitment openness investment decisions new platform transparency clinical trials already publish summary results whether technologies licensing options perceived positive negative every research trial gsk based collaborations point clinical study register almost clinical trial result summaries entry clinical trials new available site receives average almost visitors month product supply nps board individuals participate research hope might bring advances governing body accountable healthcare new plans acknowledge commitment reflect technical feasibility infrastructure desire ensure contribution lead health gains assessments covering aspects safeguarding confidentiality physical product supply chain developed launched global regulatory board enhance compliance companywide standards make regulatory services efficient agile align capabilities business needs global local levels organisation led chief regulatory officergsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify vaccines rd vaccines rd invested million core often work academia vaccines rd biotech industry identify centred discovering scientists working new vaccine antigens cases developing prophylactic development new vaccines formulation vaccine clinical lots involves mixing antigens gsk therapeutic vaccines year three new vaccines proprietary adjuvant systems approved nimenrix meningitis protect people menhibrix menigitis hib vaccine manufacturers use adjuvants infectious diseases cancers quadrivalent flu vaccine improve specific immune systems response antigens contained chronic disorders addition currently around vaccines innovating vaccines development range area adjuvant systems diseases malaria tuberculosis years cancer currently four vaccine candidates latestage development proprietary adjuvant systems trials zoster malaria mmr usa combine adjuvants give highlights therapeutic vaccine magea appropriate immune response specific antigen expertise allows us november published latest understand combinations cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid results phase iii study antigen adjuvant system help nimenrix menhibrix fluarix adjuvanted malaria vaccine candidate body mobilise effective quadrivalent rtss ongoing seven immunological pathway provide countries africa cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid maximum protection specific malaria vaccine announced rd effort focused diseases targeted populations development new prophylactic candidate vaccines usually therapeutic vaccines combination several antigens discovery research final composition vaccine antigens adjuvant may change discovery development new time preclinical research usually vaccine complex process requiring takes two five years later stage longterm investment typically takes clinical trials usually take another years develop new vaccine years vaccine discovery begins identifying well discovery new vaccines new antigens specific early development projects rd supports structures pathogens viruses bacteria latestage projects inclusion parasites cancer cells new antigens existing vaccines create recognised immune system new generation vaccines produce pathogens yeast bacteria mammalian cells traditionally vaccines used genetically manipulate prevent illness however purified formulated pioneering different approach designed vaccine antigen creates programme bodys immune bodys immune response system fight existing diseases represents new treatment model therapeutic vaccine evaluating immunotherapeutic concept variety tumour types gsk annual report strategic review deliver products value vaccines rd continued governance oversight key decisions rests two bodies vaccine consolidated development commercial board organisation vaccine discovery vdcb vaccine investment development teams simplify board vib vdcb reviews infrastructure focus timely decision research project strategy advises making enhance clarity scientific technical accountability vaccines research commercial feasibility development led project teams vaccine leadership teams board overall view responsible daytoday progress projects early advanced projects including identifying developing vdcbs core members come new products across organisation vdcb recommendation progress project several key decision points submitted vib vaccine development process commit research decide initiate vib final decision full research program commit whether invest project taking candidate development decide account scientific commercial invest resources move clinical perspectives reviewed vdcb development commit early clinical vib evaluates public health benefit development commit phase iii business opportunity development registration launch costs risks project timing overall evolution portfolio vaccines vib also responsible assessing overall fit project vaccines portfolio vaccines research development cycle identify produce preclinical phase phase ii proof phase iii file registration antigens antigens testing concept post marketing surveillance research including immunology preclinical development clinical development including post marketing surveillance transfer process manufacturing years years years yeargsk annual report strategic review financial review risk governance remuneration financial statements investor information consumer healthcare rd innovation timelines investment core consumer partnership healthcare rd million mclaren group nutrition scientists consumer healthcare million developed two bespoke lucozade products significantly people formulations support specific uk usa india china working nutritional needs formula shorter consumer rd intention one drivers lucozade hydration pharmaceuticals satisfying develop innovative categorydefining formulation contains determined products differentiated science mix essential hydration salts needs consumer informed consumer insights carbohydrates proteins support remains central focus optimal performance lucozade race innovation portfolio critical formulation enhances performance element consumer healthcare high temperatures addressing strategy ensuring sustainable flow needs weight management mental new scientificallydifferentiated products focus speed absorption often include new technologies formulations launched formulations well product targeting unique needs athletes line extensions highlights serious sports people involved sales innovative products highintensity endurance exercise cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid launched recent years given importance chinese combinations consumer healthcare global sales market opened rd key contributions coming innovation centre country cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid sensodyne repair protect panadol concentrating developing new innovation products extra advance smoking reduction products fastgrowing market cessation mini lozenges cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid researchers focus innovations meeting needs innovative new products launched specifically developed meet needs chinese consumer market included consumers china cidcidcidtums freshers developed following consumer insights firstofitskind product combines therapeutic benefits calcium carbonate heartburn relief effective breath fresheners cidcid abreva conceal clear nonmedicated patch instantly conceals cold sores met consumer desire address appearance concerns troubling recurring condition designed used abreva cream patented microair technology patch provides protective barrier contaminants eight hours allowing air promote healing cidcidcidhorlicks growth new addition horlicks range contains milk protein micronutrients balanced macronutrient energy profile ingredients important growth formulation developed following research impact nutritional supplementation children including major study testing benefits horlicks gsk annual report strategic review deliver products value late stage pipeline summary full diverse product development pipeline identified projects comprising new chemical entities biological entities vaccines new combinations new indications existing compounds phase iii filed approval recently approved advanced status shown includes approvals approvals usa key medicines filed phase iii assets new first phase iii eu since january since january delivered key data starts since january cidcid fabior acne vulgaris cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcid anoro copd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid usa diabetes asthma cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcid menhibrix nmeningitis cidcid anoro copd diabetes cidcidcidcidcidcidcidcidcidcidcidcidcid cy hinfluenza type rheumatoid arthritis cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid b disease prophylaxis usa melanoma melanoma cidcid nimenrix nmeningitis cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid hiv cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid hiv ac w disease cidcidcidrelvarbreo copd cidcidcidcidcidcidcidcidcidcidcidcidcidcid duchenne prophylaxis eu asthma muscular dystrophy cidcidcidpromacta hepatitis c cidcidcidcidcidcidcidcidcidcidcidcidcid metastatic cidcid patrome ipx induced thrombocytopaenia melanoma parkinsons disease usa cidcidcidcidcidcidcidcidcidcidcidcid fabry disease cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid seasonal influenza cidcid mosquirix malaria prophylaxis usa cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid diabetes prophylaxis anthrax cidcidcidpromacta inhalation usa hepatitis c induced cidcid sorilux scalp psoriasis thrombocytopaenia usa cidcidcidrelvarbreo copd cidcid votrient sarcoma usa asthma eu cidcidcidcidcidcidcidcidcidcidcidcidcid metastatic melanoma cidcid tykerb adjuvant breast medicines phase iii cancer development cidcid votrient sarcoma registration terminated key phase iii filed approval large comparative study compound following successful phase iii trials approval granted versus placebo andor established treatment file product approval begin market medicine vaccine patients establish clinical benefit regulatory authorities full pipeline pages safety website inlicence alliance relationship third partygsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify phase iiiregistration pharmaceuticals vaccines pipeline summary therapeutic area compound indication phase iii filed approved biopharmaceuticals arzerra ofatumumab chronic lymphocytic leukaemia first line therapy use cid relapsed patients arzerra ofatumumab diffuse large b cell lymphoma relapsed patients cid arzerra ofatumumab follicular lymphoma refractory relapsed patients cid benlysta belimumab systemic lupus erythematosus cid benlysta belimumab vasculitis cid mepolizumab severe asthma cid sirukumab rheumatoid arthritis cid albiglutide type diabetes cid raxibacumab inhalation anthrax cid cardiovascular metabolic darapladib atherosclerosis cid immunoinflammation vercirnon crohn 's disease cid infectious diseases relenza iv zanamivir influenza cid neurosciences patrome ipx parkinson 's disease cid oncology trametinib dabrafenib metastatic melanoma adjuvant therapy cid tyverbtykerb lapatinib breast cancer adjuvant therapy cid tyverbtykerb lapatinib gastric cancer cid tyverbtykerb lapatinib head neck squamous cell carcinoma resectable disease cid votrient pazopanib ovarian cancer maintenance therapy cid votrient pazopanib renal cell cancer adjuvant therapy cid dabrafenib metastatic melanoma cid trametinib metastatic melanoma cid trametinib dabrafenib metastatic melanoma cid tyverbtykerb lapatinib metastatic breast cancer combination trastuzumab cid votrient pazopanib sarcoma cid revoladepromacta eltrombopag hepatitis c induced thrombocytopaenia cid respiratory fluticasone furoate asthma cid immunoinflammation relvarbreo copd mortality outcomes cid vilanterol fluticasone furoate umeclidinium copd cid vilanterol copd cid relvarbreo asthma cid vilanterol fluticasone furoate relvarbreo copd cid vilanterol fluticasone furoate anoro umeclidinium vilanterol copd cid paediatric vaccines mmr measles mumps rubella prophylaxis cid mosquirix malaria rtss malaria prophylaxis plasmodium falciparum cid menhibrix hibmencytt neisseria meningitis groups c haemophilus influenzae cid type b disease prophylaxis nimenrix menacwytt neisseria meningitis groups c w disease prophylaxis cid vaccines zoster herpes zoster prevention cid flu pre pandemic prepandemic pandemic influenza prophylaxis cid flu vaccine seasonal influenza prophylaxis cid antigenspecific cancer magea immunotherapeutic treatment melanoma cid immunotherapeutic magea immunotherapeutic treatment nonsmall cell lung cancer cid rare diseases drisapersen duchenne muscular dystrophy cid adenosine deaminase severe combined immune deficiency adascid cid migalastat hcl fabry disease cid dermatology alitretinoin chronic hand eczema cid duac low dose acne vulgaris cid fabior tazarotene foam acne vulgaris cid sorilux scalp psoriasis cid hiv dolutegravir abacavir sulphate hiv infections fixed dose combination cid lamivudine dolutegravir hiv infections cid inlicence alliance relationship third party gsk annual report strategic review grow deliversimplify simplify operating model overview business continues change shape transforming operate reduce complexity become efficient past four years implemented global restructuring programme designed deliver significant savings support investment priority growth businesses well offset pressures groups margin resulting changes shape mix business savings programme generated across business including rd manufacturing centralisation streamlining support functions finance hr programme comes end continuing examine ways simplify operating model increase efficiencies begun new major change programme across manufacturing rd europe deliver savings build capabilities new programme includes series technological advances opportunities eliminate complexities improve competitivenessgsk annual report strategic review financial review risk governance remuneration financial statements investor information progress restructuring programme delivered annual savings billion remains track hit target set billion annual savings costs support functions reduced onefifth since also reduced fixed infrastructure rd footprint increasing productivity output pipeline despite reducing carbon footprint energy use since total carbon footprint excluding raw materials increased compared driven higher inhaler sales however current carbon reduction projects enable us reach interim target cut value chain carbon footprint million tonnes co equivalent major change programme operational excellence annual savings bn anticipated savings bn bn bn working capital days pharmaceuticals rd footprint days priorities new major change programme identified billion additional annual savings across manufacturing rd european pharmaceutical business delivering programme key priority next three years also focused reform supply chain simplify processes reduce inventory cost complexity gsk annual report strategic review simplify operating model reducing cost increasing efficiency continued transformation operating core business services model processes key transform operating business strategy enabling us early created core business model reduce costs standardise streamline important services cbs group centralise aspects business including support functions brought together complexity improve supply chain functions facilities management efficiency hr finance procurement one implementing centralised team allowing us streamline restructuring programme deliver elements standardise processes significant savings support investment intention increase priority growth businesses well productivity free time offset pressures groups margin businesses focus execution resulting changes shape business strategy local markets mix business steady progress restructuring programme implementation cbs platform key element cbs strategy key objective operational creation series regional excellence restructuring programme multifunctional business service centres began release resources bscs improve service delivery three invest growth strategy planned six centres went online date restructuring programme remainder expected delivered approximately billion established mean annual savings remains track need fewer support staff globally deliver billion annual savings providing standard cost effective processes group significant portion savings also standardising generated reinvested processes introduction business areas offer potential enterprisewide resource planning future profitable growth erp system end nine emerging markets vaccines european pharmaceutical markets consumer healthcare similarly enrolled commercial erp system savings rd costs equating turnover reinvested back discovery europe anticipate adding development research markets covering existing operational excellence european markets end year programme coming close also introduced improved forecasting superceded new major planning processes latin change programme focus american markets expected reduction opportunities simplify supply supply chain operating costs reduced chain processes previously announced inventory levels improved forecasting building groups rollout platform across capabilities manufacturing group accelerated rd well restructuring european business supply chain global also saw million manufacturing restructuring charges relating acquisition human genome sciences sites countries hgs total restructuring charges related manufacturing vaccines hgs expected approximately pharmaceuticals consumer million expected healthcare products large part cash cost majority network sites responsibility remaining hgs restructuring charges global manufacturing supply booked gms people involved manufacture supply pharmaceutical consumer healthcare products sites operated vaccines businessgsk annual report strategic review financial review risk governance remuneration financial statements investor information grow deliversimplify key focus within manufacturing case study organisation supply chain restructuring create better endtoend squeezing production times processes reduce costs responsive customer demand manufacturing network lynchpin ability make consumer healthcare distribute products around world also offers important opportunity business established fully integrated make efficiencies work done toothpaste manufacturing plant supply chain first gsk significantly maidenhead uk last year demonstrated greater operating flexibility already apparent allowed business stepbystep analysis process involved changing respond effectively manufacture one product another staff production supply related challenges line identified changes could cut time taken changeover year extending approach saving hours production time per year shaving time freedup pharmaceuticals vaccines production time helping provide manufacturing capacity produce supply chains additional million tubes toothpaste per year inventory reduction programme looking ways share learning create focused improvement standard performance excellence across supply chains manufacturing supply processes helped reduce days inventory outstanding calculated cer basis course year throughout also sought reduce cost simplification product portfolio removing small volume least commercially important packs standardising pack presentation formats set revised target remove packs achieve improvement standardisation period past five years manufacturing organisation restructured rationalised network streamlined operating model improved site performance deliver savings approximately million per annum environmental efficiencies environmental sustainability priority gsk reducing footprint using resources efficiently working others tackle challenges reduce costs build competitiveness create trust business despite reducing carbon energy use since total carbon footprint excluding raw materials increased driven higher inhaler sales trakcorc niai gsk annual report strategic review simplify operating model financial architecture financial architecture gsks financial architecture continue balance cost savings established four key financial priorities continued investment business designed support gsk delivering sustainable sales support preparedness launch execution groups growth improving operating rd pipeline key driver leverage improving financial efficiency future sales growth increasing strategy enhance converting earnings pipeline sales contribution end returns delivers cash applying framework remain confident drive better consistent decision drive improvement core operating shareholders making across company improve margin medium term delivery key financial objectives earnings per share growth free financial efficiency cash flow generation returned shareholders reinvested despite pressure operating bolt acquisitions wherever margin financial efficiencies attractive returns available delivered significant value decisions rigorously benchmarked contributed positive leverage using cfroi returns based framework groups reported earnings per share year sales growth set target reduce basis points net funding costs although reported sales year sales flat delivered year earlier expected adjusting disposal non net funding costs core consumer healthcare brands around despite net debt position reflects continued strong performance growing billion billion growth businesses enabled net interest payments emerging markets helping offset year remain broadly flat pressure western markets especially weaker expected performance also continue develop europe move expect tax strategy number moves deliver sales growth around cer update structure settle outstanding claims allowed us operating leverage reduce core tax rate rate delivered target core operating margin two years earlier expected declined percentage points expect core rate percentage points due expected impact continue focus alignment hgs acquisition remaining tax strategy future business percentage points due primarily implemented number impact maintaining flat sga measures centralise pharmaceutical lower turnover partially mitigated intellectual property product lower rd expenditure remain inventory ownership uk focused managing cost base earnings per share effectively operational excellence programme started significant progress delivered annual savings billion improving financial efficiency also launched new change together reinitiated share programme deliver annual buyback programme enabled us savings billion maintain flat core eps compared cer basis despite decline sales expect deliver core eps growth cer based ias revised adjusted eps pgsk annual report strategic review financial review risk governance remuneration financial statements investor information financial architecture drive improved returns focus returns sales growth eps operating leverage returns shareholders financial efficiency free cash flow cash flow growth cash conversion returns shareholders measurement reporting see significant opportunity free cash flow available invest improved financial enhance cash conversion business return shareholders reporting align closely greater focus cash generation consistent maintaining targeted financial architecture providing capital allocation particular focus credit profile priority cover data insights progress working capital dividend intend free cash flow making businesses made significant progress reduced beyond requirement regions progress working capital cash conversion available share buybacks key drivers operational cycle days bolton acquisitions wherever financial efficiency already made good progress payables attractive returns available transitioned reporting core receivables focused decision allocate basis enabling greater visibility addressing groups inventory cash flow rigorously benchmarked underlying performance business position sustainable secure way using returnsbased framework based details transition core developing endtoend supply cfroi comparisons reporting provided chain joins manufacturing returned billion cash commercial businesses increases shareholders paid billion visibility improve flexibility dividends ordinary dividend responsiveness reducing inventory p per share addition required releasing cash bought back billion shares part reinvest business long term programme started expect deliver continued dividend growth targeting share repurchases billion gsk annual report strategic review simplify operating model identifying managing risk manage risk risk management processes business embedding clear processess board board responsible system directors corporate governance strategy risk management management financial performance practices aauuddiitt rriisskk ccoommmmiitttteeee tthhee bbooaarrdd hhaass ddeelleeggaatteedd rreessppoonnssiibbiilliittyy reviewing approving adequacy effectiveness internal controls operated group audit risk committee corporate executive cet supports ceo team management gsks business activities rriisskk oovveerrssiigghhtt aanndd tthhee ccoouunncciill ooff sseenniioorr eexxeeccuuttiivveess iiss compliance council authorised board assist arc overseeing risk management internal control activities group rocc meets regularly review assess significant risks mitigation plans provide oversight internal controls ensure compliance applicable laws regulations internal policies business units leadership teams rriisskk mmaannaaggeemmeenntt aanndd tthhee rrmmccbbss oovveerrsseeee mmaannaaggeemmeenntt ooff aallll compliance boards risks considered important respective business units including risks designated significant gsk whole gnitroper dna gnirotinom hguorht ytilibatnuocca ytirohtua fo noitageled clear framework cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid identifying managing risk regulations operational strategic cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid level risk identification conditions mitigation processes designed responsive cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid constantly changing environment cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid groups key risks categorised disclosure requirements follows full descriptions cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid specific mitigating activities set treasury investments pages cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid corruption legislation new products cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid sustainability compliance cidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid reimbursementgsk annual report strategic review financial review risk governance remuneration financial statements investor information responsible business made commercial success directly using innovative science linked operating trustworthy create value substantive moves responsible way report approach increase access progress making across biggest contribution make four areas improving health scientific transparency innovation announced cidcidcidhealth innovating address initiatives open innovation currently unmet health needs seek share intellectual improving access products property knowledge external irrespective people live researchers help stimulate rd ability pay controlling areas traditional commercial eliminating diseases affecting approaches met difficulties worlds vulnerable people include cidcidcidour behaviour putting interests cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid patients consumers first driven promising inhibitors tuberculosis values everything tb library compounds backed robust policies strong help stimulate research tb still kills compliance processes million people year cidcidcidour people enabling people cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid st thrive develop individuals tres cantos open lab foundation deliver mission help independent researchers advance cidcidcidour planet growing business projects reducing environmental research projects portfolio atm index impact across value chain cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid highlights approach innovative publicprivate third consecutive report gsk examples progress four areas collaboration launched tackle scored highest biannual access follow additional information antibiotic resistance supported medicines atm index released approach performance published european innovative medicines index prepared access corporate responsibility report initiative imi project medicines foundation provides ranking found website funded joint budget pharmaceutical companies access improving access medicine activities measuring seven technical health products healthcare aspects rd activities pricing schemes patents licensing policies working make medicines access medicines healthcare healthcare products available priority us recognise affordable many people need challenges providing sustainable possible aim access healthcare across world also generating returns need cost barrier people sustain business invest rd developed developing countries continue evolve business flexible approach pricing model address increasing need one way create access build new existing treatments way business increasing overall volume price products flexible products sell offer tiered pricing reflective different healthcare vaccines medicines capped needs developed developing prices uns least developed countries changed way countries ldcs preferential pricing conduct rd open viiv healthcare antiretrovirals ten years ago hivaids ldcs subsaharan africa lowincome countries see corporate responsibility report gsk annual report strategic review simplify operating model responsible business continued developing countries case study market access dcma unit giving children better start created business group dedicated increasing patient access gsk medicines worlds poorest soiltransmitted helminths commonly known intestinal worms affect countries countries invest two billion people worldwide one biggest causes profits made back ill health schoolage children world health organization estimates community programmes strengthen million children risk infection infection worms cause local healthcare infrastructure stomach pain sickness malnutrition well stunting physical growth investment resources like clinics longterm brain development hospitals doctors nurses training membership global coalition pharmaceutical companies programmes increases number nongovernment organisations including bill melinda gates people get muchneeded foundation world bank well governments global health healthcare medicines october organisations committed work together control eliminate ten programme place neglected tropical diseases ldcs business made profit contribution includes donating antiparasitic treatment albendazole help fight intestinal worms schoolage children healthier children reinvestment programme likely attend school get better education giving better delivered partnership chance getting good jobs becoming productive members society three nongovernmental organisations ngos regional expertise work first year donation programme provided albendazole save children west africa treatment million school age children including children amref east southern africa ghana pictured care international asia increasing peoples access medicines also availability medicines products country address increasing registration new existing products across markets using local manufacturing options whenever possible make sure people range countries get medicines need targeting neglected tropical diseases neglected tropical diseases ntds threaten one billion people developing countries gsk united private public partners create london declaration initiative control eliminate ten neglected tropical diseases end decade initial focus extending access medicines five diseases treatments already exist including lymphatic filariasis intestinal worms donated three billionth albendazole tablet fight disfiguring disease snikrep sucramgsk annual report strategic review financial review risk governance remuneration financial statements investor information malaria responsible gsk donated medicines valued employee survey results deaths year mainly among million cost million reflect efforts integrate values children subsaharan africa cash product donations million based culture gsk holistic approach malaria control distributed countries respondents stated understand includes vaccine development promoting humanitarian aid supplies antibiotics constitutes ethical business practices preventive measures bed nets basic medicines oral hygiene items conduct job mosquito control preferential distributed affected agreed work environment pricing antimalarials ldcs conflicts cholera epidemic niger encourages ethical behaviour face published latestage clinical trial floods philippines hurricanes pressures meet business objectives results showing rtss vaccine isaac sandy usa gsk employees access candidate help protect african continue invest programme whistleblowing mechanisms children malaria prevent diarrhoea pneumonia use get advice supporting health wellbeing teaching children importance report suspected cases misconduct communities hand washing programme anonymously required global running years reached confidential reporting line available fund support local programmes million children countries different languages make significant contribution began integrating oral health health wellbeing continue support guiding education school deworming communities contributions support principles business human programme disaster relief medicine donations rights endorsed united nations engagement programmes change behaviour human rights council aim behaviour improve health apply guiding principles across science education help develop deliver success operations supplier health professionals scientists important us achieve relationships engineers future put interests patients sales marketing consumers first driven values launched new global code practices promotion customer giving cidcidcidcidcidcidcidcidcidcidcidcidcidcid interactions last year code covers cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid payments health care professionals samples hospitality grants cidcidcidcidcidcidcidcidcidcidcid donations activities must conform cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ethical medical scientific standards applicable laws ethical conduct regulations industry codes sales marketing employees ethical conduct priority gsk failure uphold high ethical standards trained revised code product inkind erode trust company entered settlement cash products damage reputation us federal government related management result serious financial legal past sales marketing practices time consequences actions triggering revised simplified issues originated different era cash giving type programme code conduct make clear company supported ignored usa taken employees apply gsk values behaviours code available action levels improved languages supported new procedures compliance marketing selling part settlement policy resource centre companys intranet provides information entered corporate integrity support training agreement us department health human services annual business ethics certifications building improvements managers revised existing compliance programmes relaunched health managers asked undertake education training confirming compliance code conduct gsk annual report strategic review simplify operating model responsible business continued working healthcare manufacturing supply performancebased pay bonuses professionals suppliers gsk required adhere sharebased equity plans align employee interests business targets healthcare professionals hcps third party code conduct valuable partners gsk providing us must demonstrate ethical standards invested significantly scientific medical expertise within business development leadership insights patient care work supply chains carried interventions every stage hcps include conducting research indepth environment health safety pipeline senior executives behalf acting advisory audits critical suppliers improve first line leaders consulting capacity providing sustainability supply chain early career development programmes expertise gsk advisory boards strengthen supplier relationships also include graduate schemes internships speaking behalf diseases conducted assessments understand industrial placements apprenticeships therapy areas relevant us believe geographical risks plan esprit global mba programme hcps fairly compensated potential interruptions supply supply employed apprentices clear standards aligned continuity assessed key recruited graduates industry codes practice suppliers another appropriate laws regulations scheduled diverse workforce govern payments continue address problem focus creating inclusive committed publishing payments counterfeit medicines china engaging environment empowers make hcps one added serial numbers products employees continually contribute first companies start resulting significant reduction organisation enables us usa commencing number reports counterfeit achieve strategic business objectives transparency research medicines track trace inclusive environment good technology help us implement business brings together different committed reporting results similar initiatives elsewhere world knowledge perspectives experiences clinical research irrespective working styles enhance whether outcomes perceived people creativity innovation positive negative medicines increase transparency gsk wants employer choice aim attract diverse workforce announced plans enable ability attract retain motivate reflects communities researchers access anonymised patient best people essential achieving operate level data published clinical trials objectives executing strategy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid medicines requests data employment practices designed positions grew reflecting reviewed independent panel help us create right workplace culture goal increase proportion experts evaluate scientific merit employees feel valued senior levels proposal already publish respected empowered inspired summary results every research trial cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk clinical study register recruiting developing emerging markets asia pacific early outlined plans add rewarding people japan regions represent clinical study reports onto register gsk committed supporting total workforce future see employees perform best cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid conduct regular clinicalquality ensure appropriate programmes uk us employees assurance assessments confirm mechanisms place deliver conduct trials upholds standards overall performance individuals meet women management positions conducted assessments development needs including review investigator sites challenging onthejob projects gsk local operating companies mentoring coaching svp vp clinical research organisations carrying derived formal development director manager clinical trials behalf gsk fully training programmes total investigates concerns identified performance development performed investigations planning process means employees ethnic minorities uk usa employees response suspected irregularities taking businessaligned objectives corrective action appropriate behavioural goals reward systems uk promote high performance help usa attract retain best peoplegsk annual report strategic review financial review risk governance remuneration financial statements investor information case study fair play sport proud play important role london olympic paralympic games official laboratory services provider using scientific expertise facilities support integrity games health competing athletes working kings college london provided facilities equipment allowed expert analysts kings independently operate world antidoping agency wada accredited laboratory antidoping tests carried games end olympics every medalist stepped podium half competing athletes tested scienceled organisation well placed provide testing facilities offering one research development sites located minutes north olympic park first time pharmaceutical company involved provision antidoping services olympic paralympic games gsk annual report strategic review simplify operating model responsible business continued committed employment healthy highperforming water policies free discrimination workforce zero harm goal reduce water impact environment tolerate improve quality life across value chain relative harassment discrimination actual employees families reduced water perceived race colour ethnic national piloted groundbreaking consumption operations origin age gender sexual orientation preventative health programme compared recognise gender identity andor expression religion phased globally across gsk water important natural resource belief physical abilitydisability next five years partnership play positive role chronic health conditions genetic employees families managing use sustainably makeup protected characteristics designed reduce personal health begun develop longerterm relevant country risks access set core strategies input several engaging employees preventive health services international organisations also signed un ceo water mandate maintained rate continue aim zero harm initiative designed help companies employees saying proud work employees continue develop develop implement disclose gsk based participation rate risk reduction programmes including sustainable water practices global employee survey upgrades guard equipment machinery dustreduction activities waste volunteering programmes continue manufacturing sites provide employees strong goal zero waste sent sense purpose pulse gives employees employee injury illness rate landfill operations chance join charity non reduced reduced waste generation governmental organisation ngo operations reduced three six month fulltime placements planet waste sent landfill compared gsk orange day allows established inhaler employees commit day time environmental sustainability priority collection service complete cycle local charity either individually gsk focus reduce carbon uk collected part team water waste set ambitious inhalers date recently targets areas working expanded pilot inhaler collection corporate partner london create change use raw service usa five cities olympic games allocated materials use disposal tickets went employees ran products consumers managing impacts global golden ticket competition alongside priority issues carbon asking employees nominate colleagues carbon water waste also manage range demonstrated actions daily goal reduce value chain important environmental issues lives work showing olympic carbon footprint one green chemistry aims values friendship equality integrity carbon footprint replace use hazardous chemicals excellence excluding contribution raw processes materials currently lower environmental impact managing change measure annual basis created green chemistry performance conscious effect increased compared unit put green chemistry theories restructuring employees aim however remain confident practice unit published achieve organisational financial hitting target internal guides help employees make goals without eliminating positions better chemical choices designing cidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid redeploy employees possible developing new products energy operations remain committed consulting changes via number consultation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid forums well discussions resulted rise greenhouse european works council similar gas emissions inhaler use bodies countries national cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid practice jobs lost business global certification carbon change offer compensation trust standard certifies support outplacement line making yearonyear overall local requirements employment reductions emissions associated legislation also offer employees operations transport gsk support resilience training multinational achieved employee assistance programme standard date strategic review financial review risk governance remuneration financial statements investor information gsk annual report financial financial review financial position resources financial review review risk risk factors respiratory growth japan respiratory portfolio continues key aspect business promising pipeline products japan respiratory portfolio grew boosted strong contributions several recently launched products see gsk annual report financial review group performance white pills western markets white pills western markets refers sales tablets simple financial review discusses operating financial injectables excluding biopharmaceuticals vaccines north performance group financial outlook financial america europe resources compare results year primarily results preceding year cer basis review cer growth discuss results core basis total basis order illustrate underlying performance practice growth rates included report constant exchange discuss results terms constant exchange rate cer rates cer unless otherwise stated cer growth discussed growth represents growth calculated exchange rates use number adjusted measures report performance used determine results overseas companies sterling business measures used management remained unchanged used previous year cer planning reporting purposes discussions represents growth constant exchange rates represents presentations investment analysts rating agencies growth actual exchange rates defined measures defined ifrs may restatement comparative information comparable similarly described measures used companies set note financial statements segment information segments turnover operating profit core results reporting disclosed amended reflect changes groups core results exclude following items total results internal management structure together certain changes amortisation impairment intangible assets excluding therapeutic classifications turnover product addition computer software goodwill major restructuring costs charges amortisation impairment intangible assets related including costs following material acquisitions legal charges marketed products reported cost sales rather net insurance recoveries settlement litigation sga comparative information restated accordingly government investigations operating income adjustment increases cost sales decreases royalty income disposals associates products businesses sga million amounts previously reported acquisition accounting adjustments material acquisitions together tax effects items financial review major restructuring costs charged arriving operating profit group turnover business include costs arising operational excellence restructuring programme initiated expanded restructuring costs following acquisitions human restated growth growth cer genome sciences inc august stiefel laboratories inc pharmaceuticals july vaccines reconciliations core results total results presented pharmaceuticals vaccines core results reporting aligns business performance reporting around consumer healthcare underlying trading performance group primary growth drivers removing volatilty inherent many cer represents growth constant exchange rates represents noncore items core results reporting utilised basis growth actual exchange rates internal performance reporting core results presented discussed financial review management believes total group turnover broadly line last year approach provides investors clearer view million decline pharmaceuticals underlying trading performance group management also vaccines turnover partly offset flat reported turnover believes approach make groups results consumer healthcare pharmaceuticals turnover comparable majority peers many use similar primarily result increased pressure austerity measures forms underlying performance reporting discuss results europe vaccines turnover declined reflecting impact although precise calculations may differ financial review lower sales cervarix japan million also presents discusses total results group million following completion hpv vaccination catchup programme excluding cervarix vaccines free cash flow turnover increased reported consumer healthcare turnover flat million excluding noncore otc brands free cash flow net cash inflow operating activities less divested early consumer healthcare turnover grew capital expenditure interest dividends paid noncontrolling interests plus proceeds sale property plant group turnover geographic region equipment dividends received joint ventures associated undertakings free cash flow growth calculated sterling basis reconciliation presented restated growth growth cer usa working capital conversion cycle europe working capital conversion cycle calculated number emap days sales outstanding plus days inventory outstanding less japan days purchases outstanding group sales outside usa europe accounted total turnover reported growth gsk annual report strategic review financial review risk governance remuneration financial statements investor information group turnover segment viiv healthcare turnover declined primarily reflecting generic competition usa combivir epivir offsetting growth generated epzicom selzentry restated growth growth cer consumer healthcare turnover excluding sales noncore pharmaceuticals vaccines otc brands divested early increased usa relatively consistent performance quarters reflected europe continued growth oral care nutrition wellness partly offset emap small decline skin health regional basis us sales grew japan europe sales flat impacted continuing viiv healthcare economic pressures drag alli rest world markets particularly india middle east china continued trading make strong contribution grew reported turnover unallocated consumer healthcare flat million pharmaceuticals vaccines pharmaceuticals turnover consumer healthcare restated growth growth us pharmaceuticals vaccines turnover declined excluding cer respiratory impact avandia pharmaceuticals vaccines sales flat pharmaceuticals turnover fell sales declines avandia antivirals well number older products including arixtra valtrex central nervous system partly offset encouraging performance new cardiovascular urogenital products particularly oncology grew million metabolic sales contribution benlysta improved respiratory sales antibacterials grew turnover also benefited net effect oncology emesis incremental revenue conclusion vesicare dermatology copromotion agreement first quarter vaccines rare diseases sales flat growth sales infanrixpediarix immunoinflammation boostrix offset lower flu vaccines sales adverse pharmaceuticals comparisons hepatitis vaccines rotarix benefited viiv healthcare hiv significant stockpile purchases us centers disease control cdc europe pharmaceuticals vaccines turnover declined respiratory primarily driven impact various ongoing government respiratory sales increased growth usa emap austerity measures including price cuts parallel trade generic japan offset decline europe total sales seretideadvair substitution decline resulted adverse pricing effects grew million ventolin sales increased volume decline pharmaceuticals sales declined million flixotideflovent sales fell million vaccines sales declined despite slight reduction rate xyzal sales almost exclusively made japan doubled decline fourth quarter underlying economic environment million continued challenging usa sales advair million compared emap pharmaceuticals vaccines turnover increased estimated underlying growth year volume strong growth latin america million china decline offset positive impact price mix million india million flovent sales declined million compared estimated partly offset effect mandatory price reductions underlying growth volume increase partly offset number markets including turkey korea pharmaceuticals negative impact price mix ventolin grew turnover increased improved momentum slow first million estimated underlying growth quarter strong growth respiratory combined good driven mostly volume performances number established brands newer oncology portfolio vaccines business recorded strong european respiratory sales reflecting impact performance expected uneven delivery across quarters ongoing austerity measures seretide sales reflecting phasing tender sales particular concentration million price cuts offset volume growth towards end year approximately japan pharmaceuticals vaccines turnover fell reflecting emap respiratory sales grew growth across adverse comparison strong cervarix sales despite products portfolio seretide grew million material contribution third phase programme strong growth china latin america offsetting impact benefiting first quarter catchup programme price reductions principally turkey ventolin sales increased complete excluding cervarix japan pharmaceuticals vaccines million turnover increased pharmaceuticals turnover grew strong growth recently launched products lamictal antivirals avodart volibris partly offset impact mandatory decline antivirals sales largely resulted generic biennial price cuts impacted growth approximately four competition valtrex million percentage points increasing generic competition paxil respiratory portfolio grew driven strong performance xyzal offsetting declines flixonase zyrtec adoair seretide grew million vaccines rotarix launched fourth quarter contributed sales million gsk annual report financial review central nervous system cns dermatology declines seroxatpaxil sales million requip sales declined million primarily result decline sales million primarily result generic usa million suffered competition partially offset growth impact generic competition evoclin extina duac european lamictal million sales million benefited acquisition toctino second half year emap sales grew usa lamictal franchise increased million million reflecting strong growth promoted brands strong growth lamictal xr approximately us dermovate bactroban franchise offset impact generic competition immediate release twice day formulation generic competition rare diseases lamictal xr began first quarter japan sales lamictal ir grew million part due sales volibris grew million led strong performance recently launched bipolar indication japan mepron sales increased million primarily result favourable adjustment us accruals returns cardiovascular urogenital rebates recorded fourth quarter flolan sales fell million largely result biennial price reduction sales category flat net benefit conclusion japan generic competition europe vesicare copromotion agreement combined growth sales avodart lovaza offset impact generic immunoinflammation competition arixtra coreg august acquired human genome sciences inc hgs avodart franchise grew million growth driven time recorded sales benlysta prior acquisition strong contributions recent launches combination usa recorded turnover share gross profit product duodartjalyn europe avodart japan copromotion agreement hgs reported benlysta turnover usa decline avodart sales part due impact million million arose usa total labelling changes implemented availability inmarket sales benlysta usa year million generic competitor class partially offset growth jalyn combined sales fell viiv healthcare hiv lovaza grew million primarily reflecting benefit viiv healthcare sales declined usa improved pricing lovaza continues hold broadly flat market share europe emap sales growth epzicom market declined approximately compared kivexa million selzentry economic pressures resulted fewer doctor visits million offset decline reduced testing asymptomatic conditions mature portfolio primarily result generic competition high triglycerides usa combivir epivir metabolic vaccines turnover decline metabolic product sales continued reflect loss growth growth sales avandia impact declining sales bonviva cer europe following change deal structure total vaccines sales antibacterials performance vaccines business improved towards end year significant increase tender sales fourth antibacterials sales grew emap primarily augmentin quarter overall decline sales primarily attributable offset impact austerity measures adverse comparison strong cervarix sales europe encouraged pharmacylevel generic substitution benefited hpv vaccination catchup programme japan generic competition europe usa complete cervarix sales declined million oncology emesis excluding cervarix vaccines sales increased three new products votrient million promacta infanrixpediarix sales increased million primarily million arzerra million reflecting strong tender orders emap growth usa continued grow strongly usa europe emap tykerb benefited competitor supply shortage tyverb also grew million growth usa rotarix sales grew million strong sales growth emap japan offsetting small decline europe hycamtin throughout emap well initial launch sales japan usa europe argatroban usa adversely affected despite market share gains sales declined primarily due generic competition comparison strong sales benefited usa votrient million benefited large stockpile purchase cdc launch new indication use advanced softtissue sarcoma synflorix sales increased million largely reflecting sales promacta grew million reflecting continued strong growth emap continued effect longerterm use data added label boostrix sales increased million largely driven usa product continues benefit expanded indication use adults oldergsk annual report strategic review financial review risk governance remuneration financial statements investor information sales hepatitis vaccines fell million declines consumer healthcare turnover mature markets partly result reduced government funding offset growth emap restated growth growth fluarixflulaval sales million primarily cer result decline usa reflected reduction total wellness number doses sold approximately million doses compared oral care approximately million doses sales grew nutrition europe emap skin health previously announced japanese vaccines joint venture gsk daiichi sankyo co ltd started operations july jv holds development commercial rights existing restated growth growth preventative vaccines parent companies sell vaccines cer jv agreed upon price reflected turnover usa second half reduced approximately europe million change structure companies row equal stake joint venture share profits equally sales new pharmaceutical vaccine launches consumer healthcare turnover flat year excluding noncore otc brands divested early turnover growth growth increased reflecting strong growth rest world cer arzerra markets sales usa excluding noncore otc brands grew year europe flat benlysta duodartjalyn total wellness lamictal xr total wellness sales million nimenrix excluding noncore otc brands divested early potigatrobalt category delivered growth despite number supply prolia interruptions gastrointestinal health including tums eno led promacta category growth pain management including panadol also requip xl registered strong growth driven growth emerging synflorix markets smoking reduction cessation respiratory treximet health categories delivered growth sales alli declined volibris result supply interruption resolved votrient late third quarter dermatology oral care new products launched last five years oral care sales grew million sensodyne sensitivity inclusive total sales new products acid erosion strongest performing brand sales million grew year represented million strong results denture care products also pharmaceuticals vaccines turnover helped offset decline aquafresh sales nimenrix approved european medicines agency april nutrition active immunization invasive meningococcal disease nutrition sales grew family nutrition horlicks grew due caused neisseria meningitides serogroups ac w strong growth india maxinutrition adult nutrition business launches underway several countries throughout europe delivered sales growth year strong emerging market including uk germany netherlands growth lucozade offset declines europe menhibrix combination vaccine help prevent meningococcal serogroups c hib disease approved fda skin health june october advisory committee skin health sales declined million strong bactroban immunization practices centers disease control growth china solid results lip care including abreva prevention voted limited recommendation immunisation offset decline sales hinds mexico infants increased risk meningococcal disease product yet available regional performance fluarix quadrivalent first fourstrain intramuscular influenza growth rest world markets excluding noncore vaccine help prevent disease caused seasonal influenza otc products divested early broadly based approved fda december use adults strong growth across categories europe overall growth children three years older launch fluarix quadrivalent oral care wellness brands almost entirely offset expected time influenza season loss alli sales due supply issue usa growth oral care gastrointestinal health smoking reduction cessation brands also significantly offset decline alli sales result supply interruption gsk annual report financial review core results table analyses group rd expenditure categories use core reporting basis manage performance group definition core results set review groups total results set pages restated reconciliation total results core results presented discovery development growth facilities central support functions restated pharmaceuticals rd turnover turnover cer vaccines rd turnover consumer healthcare rd cost sales core rd selling general administration amortisation impairment research intangible assets development major restructuring royalty income total rd core operating profit proportion pharmaceuticals rd investment made latestage portfolio continues grow total net finance costs pharmaceuticals rd costs share tax profits associates joint core rd expenditure declined million ventures turnover compared million turnover core profit tax ongoing cost management including oneoff benefits taxation beneficial phasing effects funded additional hgs costs core profit tax royalty income core profit attributable shareholders royalty income million compared million core earnings per share p p operating profit cost sales core operating profit million decrease cer core cost sales increased turnover terms turnover decline cer operating margin primarily reflected impact lower sales lower volumes declined percentage points compared adverse regional product mix partially offset ongoing cost months december percentage points management oneoff royalty pension adjustments due expected impact hgs acquisition remaining selling general administration percentage points arose flat sga lower turnover partially mitigated lower rd expenditure operating profit also core sga costs percentage sales compared benefited number oneoff items recognised reflecting flat costs turnover decline cost sales sga rd including favourable adjustments investments growth businesses new product launches well totalling million related capping future pensionable additional hgs costs funded ongoing cost management salary increases change basis future discretionary oneoff benefits pension increases rpi cpi certain legacy plans advertising promotion decreased selling distribution flat general administration increased core operating profit business research development growth margin restated margin remain focused delivering improved return cer investment rd sales contribution reduced attrition cost pharmaceuticals reduction important drivers improving internal rate vaccines return rd expenditure determined percentage sales pharmaceuticals instead capital allocated using strict returns based criteria vaccines consumer healthcare operations pharmaceuticals rd broadly split discovery activities completion phase iia trials development work phase iib onwards corporate unallocated costs core operating profit gsk annual report strategic review financial review risk governance remuneration financial statements investor information share tax profits associates joint ventures core operating profit segment growth share tax profits associates million restated million principally arose groups holdings turnover turnover cer aspen pharmacare pharmaceuticals vaccines profit taxation usa taking account net finance costs profit disposal interest europe associates share profits associates profit emap taxation million compared million japan cer decline decline sterling terms viiv healthcare pharmaceutical rd taxation trading tax core profit amounted million represented unallocated effective core tax rate meeting target pharmaceuticals core rate two years ahead expectations gsk pharmaceuticals targeting core tax rate around full year vaccines consumer healthcare gsk continues believe made adequate provision liabilities likely arise periods open yet corporate agreed tax authorities ultimate liability matters may unallocated costs vary amounts provided dependent upon core operating profit outcome agreements relevant tax authorities litigation earnings per share decline pharmaceuticals vaccines core operating margin primarily reflects changing regional mix businesses core earnings per share pence flat cer terms towards lower margin markets decline consumer healthcare actual rates currency impact reflected core operating margin primarily reflects decline sales following strengthening sterling euro number disposal noncore otc brands year currencies partially offset weakening sterling us dollar japanese yen net finance costs dividend finance income board declared four interim dividends resulting dividend interest income year pence pence increase ordinary dividends fair value movements board also declared supplemental interim dividend pence per share related disposal certain noncore otc brands north america see note dividends finance expense interest expense revision ias employee benefits unwinding discounts liabilities remeasurements fair value movements ias revised implemented gsk january main effect expected returns pension finance expense scheme assets longer recognised income statement expected returns replaced income calculated using despite increase net debt billion net finance discount rate used measure pension obligations expense year broadly similar million discount rate based market rates high quality corporate reflecting benefits strategy improve funding profile bonds consequence pension scheme costs higher group ias revised reporting results restated retrospectively effect change target reduce average effective annual net funding ratio results would reduce core operating profit year approximately basis points around approximately million core eps approximately p achieved oneyear earlier planned p estimated core operating profit net debt increased billion twelve months primarily reduced approximately million core eps due payments billion settle groups significant approximately p change ongoing us federal government investigations within existing provisions billion cash cost acquisition hgs balance well groups strong cash generation proceeds disposal consumer healthcare otc brands enabled financing share repurchases billion increased dividend payments billion gsk annual report financial review core results reconciliation december acquisition core intangible intangible major legal operating adjust total results amortisation impairment restructuring charges income ments results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions core results reconciliation december acquisition total core intangible intangible major legal operating adjust results results amortisation impairment restructuring charges income ments restated turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal interests associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic review financial review risk governance remuneration financial statements investor information total results operating profit growth total operating profit million decrease cer restated terms turnover decline cer operating margin turnover turnover cer decreased percentage points compared turnover months december percentage points cost sales due expected impact hgs acquisition remaining selling general percentage points arose growth sga lower administration turnover partially mitigated lower rd expenditure higher research operating income operating profit also benefited development number oneoff items recognised cost sales royalty income sga rd including favourable adjustments totalling operating income million related capping future pensionable salary increases change basis future discretionary pension operating profit increases rpi cpi certain legacy plans net finance costs profit disposal operating profit level noncore charges totalled interest associates million year million share tax intangible asset amortisation million profits associates million included million related amortisation joint ventures benlysta intangible asset acquired part hgs acquisition profit taxation intangible asset impairment charges million taxation million included impairments horizant alli total profit viiv healthcare compound lersivirine totalling million major taxation year restructuring charges million million included total profit attributable million related acquisition hgs charges shareholders arising operational excellence programme earnings per share p legal charges million million various earnings per ads us federal government investigations resolved q within existing pretax provision tax cost cost sales approximately million lower provided result credit cost sales increased turnover recorded noncore tax charge q however due primarily reflected impact lower sales higher intangible evolving state litigation environment gsk utilised tax asset impairments lower volumes higher restructuring costs benefit arising recording offsetting additional pretax provision adverse regional product mix partially offset ongoing cost approximately million equating tax cost management oneoff royalty pension adjustments million related matters recorded noncore legal charge sga q net effect selling general administration movements total earnings neutral legal charges million principally related provisions existing product sga costs percentage sales compared liability antitrust matters reflecting increase costs turnover decline investments growth businesses new product operating income million million launches higher legal restructuring charges well additional included profit disposal noncore otc brands hgs costs partly offset ongoing cost management million noncash gains million arising oneoff benefits settlement preexisting collaborations part hgs shionogiviiv healthcare joint venture acquisitions acquisition advertising promotion decreased selling distribution accounting adjustments million nil relate decreased general administration increased acquisition hgs acquisition accounting related adjustments primarily reflecting increased legal costs year related acquisition reported noncore items research development net finance costs rd expenditure declined million turnover compared million turnover ongoing cost management including oneoff benefits lower restructuring finance income beneficial phasing effects offset additional interest finance income hgs costs higher intangible asset impairments fair value movements operating income finance expense operating income million million interest expense included profit disposal noncore otc brands million noncash gains million arising unwinding discounts liabilities settlement preexisting collaborations part hgs remeasurements fair value movements viiv healthcareshionogi joint venture acquisitions finance expense despite increase net debt billion net finance expense year broadly similar million reflecting benefits strategy improve funding profile group gsk annual report financial review profit disposal interest associates critical accounting policies pretax profit disposal interest associates nil consolidated financial statements prepared accordance compared million reflecting disposal ifrs adopted use european union also remaining shares quest diagnostics ifrs issued iasb following accounting policies approved board described note financial share tax profits associates joint ventures statements accounting principles policies required make estimates assumptions affect amounts share tax profits associates million assets liabilities revenue expenses reported financial million principally arose groups holdings statements actual amounts results could differ aspen pharmacare estimates profit taxation critical accounting policies information taking account net finance costs profit disposal interest judgements estimates made given note financial associates share profits associates profit statements key accounting judgements estimates taxation million compared million relevant detailed notes financial statements indicated cer decline decline sterling terms relate following areas cidcid turnover taxation cidcid taxation note cidcid legal disputes notes uk corporation tax uk statutory rate cidcid property plant equipment note less double taxation relief cidcid goodwill note overseas taxation cidcid intangible assets note current taxation cidcid pensions postemployment benefits note deferred taxation taxation total profits information judgements estimates made areas given note financial statements key accounting charge taxation total profits amounted million judgements estimates represented effective tax rate groups balance sheet december included tax payable turnover liability million tax recoverable asset million respect turnover accounting policy largest business within tax charge noncore items charge us pharmaceuticals vaccines us market million comprising predominantly deferred tax hence complex arrangements rebates discounts allowances noncash relating centralisation pharmaceutical intellectual following briefly describes nature arrangements property product inventory ownership uk existence us pharmaceuticals vaccines business restructuring trading arrangements increased investment uk reflects terms gsk agreed discussions cidcid arrangements certain indirect customers whereby various tax authorities facilitated introduction customer able buy products wholesalers reduced uk patent box rules particular agreed enter prices chargeback represents difference bilateral advance pricing agreement internal revenue invoice price wholesaler indirect customers service usa hm revenue customs uk contractual discounted price accruals estimating chargebacks give us considerable certainty future tax affairs calculated based terms agreement historical restructuring simplify business internal trading experience product growth rates arrangements substantially decreasing administrative complexity cidcid customer rebates offered key managed care group deliver supply chain working capital efficiencies purchasing organisations gpo direct indirect noncore noncash tax charges totalling approximately customers arrangements require customer achieve million next two years arising unwinding certain performance targets relating value product deferred profit inventory existing inventory produced prior purchased formulary status predetermined market shares restructuring leaves supply chain relative competitors accrual customer rebates continue believe made adequate provision estimated based specific terms agreement liabilities likely arise periods open historical experience product growth rates yet agreed tax authorities ultimate liability matters cidcid us medicaid programme stateadministered programme may vary amounts provided dependent upon providing assistance certain poor vulnerable patients outcome agreements relevant tax authorities litigation medicaid drug rebate program established reduce state federal expenditure prescription drugs earnings per share patient affordable care act became law total earnings per share p year compared participate providing rebates states accruals p noncore charges totalled p p medicaid rebates calculated based specific terms noncore items included tax charge million p arising relevant regulations patient affordable care act centralisation pharmaceutical intellectual property product inventory ownership uk transactions completed resulted number significant noncash accounting entries however largely offset othergsk annual report strategic review financial review risk governance remuneration financial statements investor information cidcid cash discounts offered customers encourage prompt legal disputes payment accrued time invoicing respect accounting policy legal disputes adjusted subsequently reflect actual experience following briefly describes process determine cidcid record accrual estimated sales returns applying level provision necessary historical experience customer returns amounts invoiced accordance requirements ias provisions together market related information stock levels contingent liabilities contingent assets provide wholesalers anticipated price increases competitor activity anticipated settlement costs outflow resources reconciliation gross turnover net turnover us considered probable reliable estimate may made pharmaceuticals vaccines business follows likely outcome dispute legal expenses arising claims group may become involved significant legal proceedings respect possible margin margin make reliable estimate expected financial effect restated restated could result ultimate resolution proceedings gross turnover cases appropriate disclosure cases would included annual report provision would made market driven segments government mandated position could change time therefore state programs assurance losses result outcome legal proceedings exceed material amount amount cash discounts provisions reported groups financial statements customer returns prior year adjustments like many pharmaceutical companies faced items various complex product liability antitrust patent litigation total deductions well investigations operations conducted various net turnover governmental regulatory agencies throughout year general counsel group head groups legal market driven segments consist primarily managed care function senior vice president head global medicare plans gsk negotiates contract pricing litigation group responsible litigation honoured via rebates chargebacks mandated segments consist government investigations routinely brief chief executive primarily medicaid federal government programs officer chief financial officer board directors receive government mandated pricing via rebates chargebacks significant litigation pending group governmental investigations group total balance sheet accruals rebates discounts allowances returns us pharmaceuticals vaccines business meetings appropriate detail status significant december december follows litigation governmental investigations review matters number claims notified us information potential claims yet notified assessment validity claims progress december december made settling claims recent settlement levels potential reimbursement insurers chargebacks meetings also include assessment whether managed care medicare part sufficient information available us able make reliable gpo rebates estimate potential outcomes disputes often external us government state programmes counsel assisting us various litigation matters investigations cash discounts also assist briefing board senior management customer returns following discussions matters possible make reliable estimate amount provision total may required level provision legal disputes reviewed adjusted appropriate monthly process operated monitor inventory levels wholesalers abnormal movements process uses gross sales volumes prescription volumes based third party data sources information received key wholesalers aim maintain inventories consistent level year year based pattern consumption basis us pharmaceuticals vaccines inventory levels wholesalers distribution channels december estimated amount approximately one month turnover calculation uses third party information accuracy totally verified believed sufficiently reliable purpose gsk annual report financial review financial position resources property plant equipment business sciencebased technologyintensive highly regulated governmental authorities allocate significant financial resources renewal maintenance property plant assets equipment minimise risks interruption production noncurrent assets achieve compliance regulatory standards number property plant equipment processes use chemicals hazardous materials goodwill total cost property plant equipment december intangible assets million net book value million investments associates joint ventures land buildings represented million plant investments equipment million assets construction million deferred tax assets invested million new renewal property plant derivative financial instruments equipment mainly related large number projects noncurrent assets renewal improvement expansion facilities various total noncurrent assets worldwide sites property mainly held freehold new investment financed liquid resources december current assets capital contractual commitments future expenditure million inventories operating lease commitments million believe current tax recoverable facilities adequate current needs trade receivables observe stringent procedures use specialist skills manage derivative financial instruments environmental risks activities environmental issues liquid investments sometimes dating operations modified discontinued cash cash equivalents reported environmental sustainability assets held sale note financial statements legal proceedings total current assets total assets goodwill liabilities goodwill increased year million december million increase primarily reflects current liabilities goodwill arising acquisition hgs million partly shortterm borrowings offset weakening overseas currencies trade payables derivative financial instruments intangible assets current tax payable intangible assets include cost intangibles acquired shortterm provisions third parties computer software net book value total current liabilities intangible assets december million noncurrent liabilities million increase reflected assets acquired acquisition hgs million longterm borrowings acquisition global rights shionogi viiv healthcare deferred tax liabilities llc joint venture assets million partly offset pensions postemployment benefits amortisation impairment existing intangibles provisions derivative financial instruments investments noncurrent liabilities held investments including associates joint ventures total noncurrent liabilities carrying value december million total liabilities million market value december net assets million million largest investments associate aspen pharmacare holdings limited equity book value december million share capital million investment theravance inc share premium account book value december million retained earnings million investments include equity stakes reserves companies group research collaborations shareholders equity provide access biotechnology developments potential interest noncontrolling interests interests companies arise business divestments total equity gsk annual report strategic review financial review risk governance remuneration financial statements investor information derivative financial instruments assets net debt noncurrent current derivative financial instruments held fair value million million majority amount relates interest rate swaps cash cash equivalents foreign exchange contracts designated accounting hedges liquid investments borrowings repayable within one year inventories borrowings repayable one year inventory million increased million net debt year increase reflects impact acquisition hgs net debt increased million reflected acquisition together higher vaccine stocks partly offset initiatives hgs million net cash acquired together reduce manufacturing cycle times reduce stockholding days legal settlements year million included efficient use inventory throughout supply chain previously announced payments us government trade receivables billion billion settlement certain investigations groups strong cash generation together proceeds trade receivables million decreased disposal consumer healthcare otc brands also reflecting specific actions taken reduce overdue enabled financing share repurchases billion receivables part initiative reduce working capital increased dividend payments billion derivative financial instruments liabilities movements net debt held current noncurrent derivative financial instruments held fair value million million relating primarily foreign exchange contracts represent hedges intercompany loans deposits external debt legal net debt beginning year provisions designated accounting hedges decrease cash bank overdrafts cash inflow liquid investments trade payables net increase longterm loans trade payables amounting million net repayment ofincrease shortterm loans increased million reflecting amount debt subsidiary undertakings acquired payable noncontrolling shareholders gsk consumer exchange movements healthcare ltd india offer purchase additional movements shares also benefits working capital initiatives net debt end year provisions total equity carried deferred tax provisions shortterm december total equity decreased noncurrent provisions million december million december million decrease arose million respect estimated future liabilities principally share repurchases year million million related legal disputes provision made legal disputes summary movements equity set indemnified disposal liabilities employee related liabilities costs restructuring programmes extent balance sheet date legal constructive obligation existed could total equity beginning year reliably estimated total comprehensive income year pensions postemployment benefits dividends shareholders shares issued account pension postemployment arrangements accordance ias deficits net changes noncontrolling interests surpluses allowing deferred taxation million forward contract relating noncontrolling million pension arrangements million interest million unfunded postemployment liabilities shares purchased cancelled held treasury shares pension liabilities decreased following increase asset consideration received shares transferred values uk deficit reduction contributions million million oneoff adjustments uk esop trusts pension obligations made year partly offset reductions shares acquired esop trusts rates used discount uk pension liabilities sharebased incentive plans us pension liabilities tax sharebased incentive plans distributions noncontrolling interests december uk scheme purchased insurance contract guarantee payment specified pensioner liabilities total equity end year contract valued million december changes noncontrolling interests year primarily arise acquisitions shionogiviiv healthcare joint venture shares gsk consumer healthcare ltd groups consumer healthcare subsidiary india gsk annual report financial review share purchases commitments respect loans future interest payable loans disclosed taking account effect employee share ownership plan esop trusts acquired derivatives million shares glaxosmithkline plc million shares held trusts satisfy future exercises options entered number research collaborations awards group share option award schemes develop new compounds pharmaceutical companies proportion shares held trusts respect awards terms arrangements include upfront fees equity rules scheme require us satisfy exercises investments loans commitments fund specified levels market purchases rather issue new shares shares research addition often agree make payments held trusts matched options awards granted future milestones achieved december esop trusts held million agreements relate compounds early million gsk shares future exercise share options stages development milestone payments continue share awards carrying value million number years compounds move successfully million deducted reserves market development process generally closer product value shares million million marketing approval greater possibility success amounts shown within intangible assets represent commenced new longterm share buyback maximum would paid milestones achieved programme million shares repurchased cost include billion relates externalised projects million see note share capital currently discovery portfolio number new commitments made targetting repurchases billion licensing agreements including arrangements exact amount timing future purchases whether angiochem inc five prime therapuetics inc md anderson shares held treasury shares cancelled cancer centre morphotek inc determined company dependent market conditions factors december held million reached agreement trustees uk shares treasury shares million shares cost pension schemes make additional contributions five million million deducted year period eliminate pension deficit identified retained earnings december actuarial funding valuation table includes commitment excludes normal ongoing annual shares purchased period january funding requirement uk approximately million february information pension obligations see note financial statements pensions postemployment commitments contingent liabilities benefits financial commitments summarised note financial statements commitments contingent liabilities contingent liabilities obligations respect short longterm debt set following table sets contingent liabilities comprising note financial statements contingent liabilities discounted bills performance guarantees letters credit note financial statements net debt items arising normal course business amounts provided pensions postretirement benefits expected expire set note financial statements pensions postemployment benefits amounts provided restructuring total yr yrs yrs yrs programmes legal environmental disputes set guarantees note financial statements provisions contingent liabilities contractual obligations commitments total following table sets contractual obligations normal course business provided various commitments december fall due payment indemnification guarantees respect business disposals legal disputes subsequently arisen total yr yrs yrs yrs provision made outflow resources considered probable reliable estimate made likely outcome loans dispute included note financial interest loans statements provisions finance lease obligations finance lease charges provide outcome tax legal disputes outflow resources considered probable reliable operating lease estimate outflow may made december commitments disputes provision made intangible assets possible make reliable estimate potential outflow property plant equipment funds might required settle disputes possibility investments outflow remote purchase commitments ultimate liability matters may vary significantly pensions amounts provided dependent upon outcome commitments litigation proceedings negotiations relevant tax total authorities discussed risk factors pages notes financial statements taxation legal proceedingsgsk annual report strategic review financial review risk governance remuneration financial statements investor information cash generation conversion reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow shown summary consolidated cash flow set reconciliation free cash flow net cash inflow operating activities net cash outflow investing activities net cash inflow operating activities net cash outflow financing activities purchase property plant equipment decrease cash bank overdrafts purchase intangible assets disposal property plant equipment exchange adjustments interest paid cash bank overdrafts beginning year interest received cash bank overdrafts end year dividends received joint ventures cash bank overdrafts end year associated undertakings comprise distributions noncontrolling interests cash cash equivalents free cash flow overdrafts investment appraisal formal process assessing potential investment net cash inflow operating activities taxation paid proposals order ensure decisions aligned overall million decrease million sterling terms strategy process includes assessment cash flow return compared reflected impact reduced investment cfroi well net present value npv operating profit phasing tax payments internal rate return irr timeline project net cash outflow investing activities million long term also consider impact earnings credit million higher primarily reflected profile relevant acquisition hgs sale noncore otc brands discount rate used perform financial analyses decided year partly offset proceeds disposal internally allow determination extent investments shareholding quest diagnostics inc cover cost capital specific investments discount rate net cash outflow financing activities million may adjusted take account country risk weightings primarily reflected net increase external borrowing million offset repurchase shares dividends capital expenditure financial investment shareholders totalling million cash payments tangible intangible fixed assets amounted million million disposals realised free cash flow million million cash payments acquire free cash flow amount cash generated business equity investments million million made meeting obligations interest tax dividends paid year sales equity investments realised million noncontrolling interests capital expenditure property million plant equipment intangible assets future cash flow expect future operating cash flow sufficient fund free cash flow operating debt service costs satisfy normal levels free cash flow growth capital expenditure meet obligations existing licensing free cash flow adversely impacted legal settlements agreements meet expenditure arising major million million free cash flow excluding legal restructuring programmes precise timing uncertain settlements million million outlined note financial statements major restructuring together million disposal noncore costs meet routine outflows including tax otc brands enabled group pay dividends shareholders dividends subject risk factors discussed pages billion spend billion repurchasing shares may time time additional demands finance acquisitions share repurchases access commitment continue use free cash flow support sources liquidity short longterm capital markets increasing dividends undertake share repurchases returns banks financial institutions addition cash attractive reinvest business including bolton acquisitions flow operations needs working capital restated working capital percentage turnover working capital conversion cycle days working capital reduced million compared reduction million working capital conversion cycle reduced eight days reflecting improvements conversion receivables payables inventory partly offset acquisition hgs added three days conversion cycle gsk annual report financial review maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper bank borrowings leases payment policies capital management group companies responsible monitoring managing financial strategy supports groups strategic priorities working capital terms sales collections supplier regularly reviewed board manage capital structure payments reflect local commercial practice group appropriate mix debt equity order optimise returns shareholders whilst maintaining credit ratings uk company uk subsidiaries policies provide us flexibility access debt capital markets ensure suppliers paid time particular attractive terms financial architecture designed drive uk companies seek growth earnings per share cash generation order cidcid settle terms payment suppliers agreeing maximise returns groups strategy free cash flow terms transaction generate deployed deliver returns shareholders reinvested business depending returns cidcid ensure suppliers made aware agreed terms attractive continue apply strict financial returnsbased payment criteria cash flow return investment order allocate cidcid abide terms payment capital assess investment opportunities policy permits arrangements accelerated payment small capital structure group consists net debt suppliers billion see note net debt shareholders equity billion see consolidated statement changes equity payment performance total capital including provided noncontrolling interests billion billion december average number days payable outstanding represented trade payables parent company details see note financial statements financial nil nil respect company uk instruments related disclosures subsidiaries aggregate days days liquidity treasury policies december cash liquid investments held gsk reports sterling pays dividends sterling profits follows role corporate treasury monitor manage external internal funding requirements financial risks support strategic objectives gsk operates global basis primarily bank balances deposits subsidiary companies manage capital ensure subsidiaries able operate going concerns us treasury treasury repo optimise returns shareholders appropriate balance money market funds debt equity treasury activities governed policies corporate debt instruments procedures approved board directors recently government securities july treasury management group tmg meeting chaired chief financial officer takes place monthly basis review treasury activities members receive management information relating treasury activitiesgsk annual report strategic review financial review risk governance remuneration financial statements investor information net debt billion december table interest rate risk management summarises cash gross debt effects hedging gsks objective reduce effective net interest cost rebalance mix debt fixed floating interest rates time policy interest rate risk management limits amount cash liquid investments floating interest payments prescribed percentage gross debt fixed operating profit floating use series interest rate swaps redenominate one noninterest bearing bonds floating interest rates duration swaps net debt matches duration principal instrument interest rate gsks policy borrow centrally order meet anticipated derivative instruments accounted fair value hedges funding requirements cash flow forecast funding relevant liability requirements monitored tmg monthly basis foreign exchange risk management strategy diversify liquidity sources using range facilities maintain broad access funding markets foreign currency transaction exposures arising internal external trade flows hedged exposure overseas december gsk billion cash cash equivalents operating subsidiaries transaction risk minimised matching liquid investments billion borrowings repayable local currency income local currency costs purpose within one year gsk also access shortterm finance internal trading transactions matched centrally manage us billion commercial paper programme billion intercompany payment terms reduce foreign currency risk billion issue programme december foreign currency cash flows hedged selectively gsk billion five year committed medium term management corporate treasury tmg possible facilities billion day committed facilities manage cash surpluses borrowing requirements facilities put place september consider subsidiary companies centrally using forward contracts hedge level committed facilities adequate given current liquidity future repayments back originating currency requirements order reduce foreign currency translation exposure seek european medium term note programme billion denominate borrowings currencies principal assets december billion notes issue cash flows primarily denominated us dollars euros programme also us shelf registration statement sterling certain borrowings swapped currencies december billion billion notes required issue programme gsks longterm borrowings mature dates borrowings denominated swapped foreign currencies match investments overseas group assets may treated gsks longterm credit ratings remained unchanged since hedge relevant assets forward contracts major february currently gsk rated stable outlook currencies also used reduce exposure investment standard poors stable outlook moodys investors overseas group assets tmg reviews ratio borrowings service moodys shortterm credit ratings p assets major currencies monthly standard poors moodys respectively counterparty risk management treasury operations gsk sets global counterparty limits gsks banking objective treasury activity manage posttax net cost investment counterparties based longterm credit ratings income financial operations benefit earnings use moodys standard poors corporate treasurys usage variety financial instruments finance operations limits monitored daily corporate compliance officer derivative financial instruments manage market risks cco operates independently corporate treasury operations derivatives principally comprising forward foreign breach limits would reported cfo immediately currency contracts interest rate currency swaps used cco also monitors credit rating counterparties swap borrowings liquid assets currencies required changes ratings occur notifies corporate treasury group purposes manage exposure financial risks changes made investment levels authority limits changes foreign exchange interest rates appropriate addition report relationship banks corporate treasury operate profit centre credit ratings presented annually tmg approval hold issue derivatives speculative purposes treasury reviewed regularly policies specifically prohibit activity transactions financial instruments undertaken manage risks arising underlying business activities speculation gsk annual report financial review financial review pharmaceuticals turnover therapeutic area accordance us sec disclosure requirements following growth growth cer discussion compares results year december respiratory results year december antivirals following introduction core measures report central nervous system performance group changes reflect new reporting cardiovascular urogenital structure group see financial review metabolic restated consistent basis antibacterials growth rates included financial review constant oncology emesis exchange rates cer unless otherwise stated cer growth dermatology discussed rare diseases immunoinflammation group turnover division pharmaceuticals growth growth viiv healthcare hiv cer pharmaceuticals vaccines respiratory pharmaceuticals respiratory sales increased billion reflecting strong vaccines performances japan emerging markets asia pacific consumer healthcare seretideadvair sales flat growth japan asia pacific offset small declines usa europe addition ventolin grew million avamysveramyst sales group turnover geographic region million growth growth usa sales advair billion cer line estimated underlying growth year volume usa decline partly offset positive impact price mix europe flovent grew million ventolin grew emap million japan europe respiratory sales seretide sales billion impact price reductions european governments offset volume increases group turnover segment emerging markets respiratory sales grew growth many products portfolio seretide sales flat growth growth million volume growth offset continuing cer impact price cuts particularly russia turkey pharmaceuticals vaccines antivirals usa europe antivirals decreased billion sales growth emap impacted lower sales relenza million compared significant sales related pandemic flu japan addition valtrex sales continued decline result generic viiv healthcare competition usa europe million trading sales zeffix grew million strong growth unallocated emerging markets offset small declines pharmaceuticals markets vaccines consumer healthcare central nervous system cns cns sales decreased billion performance primarily pharmaceuticals turnover therapeutic area impacted decline seroxatpaxil sales million partially offset lamictal sales growth turnover declined billion growth cardiovascular million benefiting growth japan product urogenital respiratory dermatology antibacterials hiv sales doubled million continuing strong oncology emesis offset declines metabolic performance lamictal xr usa antivirals central nervous systemgsk annual report strategic review financial review risk governance remuneration financial statements investor information cardiovascular urogenital selzentry sales growth primarily driven increase market share usa sales million cardiovascular urogenital sales increased billion europe sales million primarily driven avodart franchise million launches new combination product duodartjalyn decline mature portfolio including combivir usa europe avodart japan lovaza declined million primarily driven decline million arixtra declined million result western markets result newer treatment options start generic competition usa third quarter vaccines turnover metabolic growth growth metabolic sales decreased billion primarily reflecting cer loss sales avandia addition sales boniva vaccines sales negatively impacted termination copromotion vaccines agreements certain european countries loss flu pandemic vaccine sales year resulted antibacterials decline reported vaccines sales billion excluding effect flu pandemic vaccine sales underlying sales grew antibacterial sales grew billion growth reflecting growth cervarix synflorix rotarix partly category led sales augmentin emerging markets offset lower sales hepatitis franchise infanrix million category held back austerity price cuts impact changes pharmacopeia china mild flu season northern hemisphere oncology emesis consumer healthcare turnover oncology emesis sales increased billion reflecting growth strong growth new products votrient promactarevolade cer arzerra together doubled million partly total wellness offset generic competition older products oral care ongoing launches promactarevolade continued throughout nutrition sales outside usa grew million skin health million sales usa grew million strong performances new oncology products partly consumer healthcare sales grew billion compared offset impact generic competition usa hycamtin estimated market growth markets compete continued decline zofran net impact acquisitions disposals significant fell million excluding otc brands targeted divestment consumer healthcare sales grew approximately disposal north dermatology american otc brands completed january dermatology sales grew billion growth emerging total wellness markets benefiting ongoing launches stiefel products new markets offset impact price cuts europe total wellness sales increased billion strong growth generic competition evoclin usa several subcategories offset decline alli panadol franchise registered growth gastrointestinal care rare diseases core brands tums eno respectively sales grew billion majority growth oral care coming volibris sales doubled million oral care sales increased billion led sensodyne immunoinflammation continued benefit successful launch repair benlysta launched year usa germany protect ongoing geographic expansion pronamel acid recorded turnover million erosion business viiv healthcare hiv nutrition viiv healthcare sales grew billion usa europe nutrition grew billion led strong growth horlicks emerging markets rest world combined inclusion maxinutrition february growth primarily driven epzicomkivexa million nutrition growth excluding maxinutrition selzentry million partly offset decline skin health mature portfolio million epzicomkivexa sales growth driven strong performance skin health sales declined billion usa europe usa sales epzicom million reflecting relatively equal mix volume price growth volume growth europe benefited improved positioning regional local guidelines kivexa continued grow japan mexico number developing markets asia pacific gsk annual report financial review core results net finance costs definition core results set reconciliation total results core results presented finance income interest income growth fair value movements turnover turnover cer turnover finance expense cost sales interest expense selling general unwinding discounts liabilities administration remeasurements fair value movements research finance expense development royalty income core operating profit net finance expense fell slightly million million net finance costs reflected relatively stable levels net debt groups share tax strong cash generation funded share repurchases billion profits associates increased dividend payments joint ventures share tax profits associates joint ventures core profit tax taxation share tax profits associates million core profit tax million arose principally groups holding core profit attributable aspen pharmacare decline reflected disposal shareholders share quest diagnostics february core earnings per sharep p profit taxation cost sales taking account net finance costs share profits associates core profit taxation million compared core cost sales increased turnover million cer decline decline sterling terms reflected impact reduction higher margin sales pandemic related products avandia valtrex together taxation effect regional mix impact us healthcare reform european austerity price cuts adverse impacts partially tax core profit amounted million represented offset lower inventory writeoffs greater savings effective core tax rate operational excellence programme gsk continues believe made adequate provision selling general administration liabilities likely arise periods open yet agreed tax authorities ultimate liability matters core sga costs decreased turnover may vary amounts provided dependent upon compared reflected impact outcome agreements relevant tax authorities litigation reduction sales pandemic related products avandia valtrex us healthcare reform levy million earnings per share continuing investment growth businesses new product core earnings per share pence cer terms launches partly offset ongoing cost savings actual rates currency impact reflected advertising promotion declined selling distribution strengthening sterling us dollar partially offset declined general administration increased weakening sterling japanese yen research development dividend core rd expenditure increased million board declared four interim dividends resulting dividend turnover compared million year pence pence increase pence per turnover increase reflected investment latestage share board also declared supplemental interim pipeline partly offset efficiency savings dividend pence per share related disposal certain noncore otc brands north america completed core operating profit january paid time fourth interim dividend see note dividends core operating profit million decrease cer terms gsk annual report strategic review financial review risk governance remuneration financial statements investor information core results reconciliation december total core intangible intangible major legal operating results results amortisation impairment restructuring charges income restated turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal interests associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions core results reconciliation december total core intangible intangible major legal operating results results amortisation impairment restructuring charges income restated turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal interests associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report financial review total results rd expenditure decreased million turnover compared million turnover growth reflecting lower restructuring costs efficiency savings lower restated restated intangible asset impairments partly offset increased investment turnover turnover cer latestage pipeline turnover cost sales operating income selling general operating income million million administration primarily comprising profits asset disposals million research million partly offset equity investment impairments development million million restructuring costs royalty income million nil associated proposed divestment operating noncore consumer healthcare brands income operating profit operating profit net finance cost operating profit million increase profit disposal cer sterling terms compared excluding interest associates legal costs million million operating profit share tax million increase cer terms sterling profits associates terms principally reflecting decline turnover lower cost joint ventures sales lower rd expenditure higher operating income profit taxation noncore items comprised intangible asset amortisation taxation million million intangible asset impairment profit taxation million million major restructuring costs year million million legal costs million total profit attributable million operating income million shareholders million earnings per share p earnings per ads us net finance costs cost sales finance income cost sales increased turnover interest finance income reflected impact reduction higher margin sales fair value movements pandemic related products avandia valtrex together effect regional mix impact us healthcare reform european austerity price cuts adverse impacts partially finance expense offset lower restructuring costs lower inventory writeoffs interest expense greater savings operational excellence programme unwinding discounts liabilities selling general administration remeasurements fair value movements finance expense sga costs decreased turnover compared legal costs million million primarily arose additional charges year net finance expense fell slightly million million product liability cases regarding paxil poligrip products reflected relatively stable levels net debt groups various government investigations reflect best strong cash generation funded share repurchases billion estimates additional amounts expected necessary increased dividend payments profit disposal interest resolve disputes excluding legal costs sga costs associates turnover percentage points lower profit disposal interest associates reflected lower restructuring charges ongoing cost savings including operational excellence programme partly offset pretax profit disposal interests associates impact reduction sales pandemic related million million tax primarily reflecting products avandia valtrex us healthcare reform levy disposal remaining shares quest diagnostics million continuing investment growth businesses new product launches share tax profits associates joint ventures advertising promotion declined selling distribution share tax profits associates million declined general administration excluding legal million arose principally groups holding increased collectively items accounted aspen pharmacare decline reflected disposal decline sga legal costs shares quest diagnostics february research development profit taxation remain focused delivering improved return taking account net finance costs profit disposal interest investment rd sales contribution reduced attrition cost associates share profits associates total profit reduction important drivers improving internal rate taxation million compared million return rd expenditure determined percentage sales increase cer sterling terms reflected instead capital allocated using strict returns based criteria impact lower legal charges gsk annual report strategic review financial review risk governance remuneration financial statements investor information taxation inventories inventory million increased million year increase reflects higher vaccine stocks partly offset uk corporation tax uk statutory rate initiatives reduce manufacturing cycle times reduce less double taxation relief stockholding days trade receivables overseas taxation current taxation trade receivables million decreased deferred taxation reflecting specific actions taken reduce overdue taxation total profits receivables part initiative reduce working capital charge taxation total profits amounted million derivative financial instruments liabilities represented effective tax rate held current noncurrent derivative financial instruments gsk continues believe made adequate provision held fair value million million relating liabilities likely arise periods open primarily foreign exchange contracts represent hedges yet agreed tax authorities ultimate liability matters intercompany loans deposits legal provisions may vary amounts provided dependent upon designated accounting hedges outcome agreements relevant tax authorities litigation trade payables earnings per share trade payables amounting million total earnings per share pence year compared increased reflecting working capital initiatives extend pence noncore charges totalled pence supplier terms towards day term objective pence included legal charges million pence million pence year provisions financial position resources carried deferred tax provisions shortterm noncurrent provisions million december property plant equipment million respect estimated future liabilities million million related legal total cost property plant equipment disputes provision made legal december million net book value disputes indemnified disposal liabilities employee related liabilities million land buildings represented costs restructuring programmes extent million plant equipment million assets balance sheet date legal constructive obligation existed construction million invested million could reliably estimated new renewal property plant equipment december capital contractual commitments future expenditure net debt million operating lease commitments million net debt increased million million free cash goodwill flow asset disposal proceeds largely funded dividends shareholders share repurchases goodwill increased year million december million increase primarily total equity reflects goodwill arising acquisition maxinutrition december total equity decreased group holdings limited million partly offset weakening million december million decrease arose overseas currencies principally share repurchases year intangible assets cash flow intangible assets include cost intangibles acquired net cash inflow operating activities taxation paid third parties computer software net book value million decrease million sterling terms intangible assets december million compared million decrease reflected amortisation impairment existing intangibles partly offset additions net cash outflow investing activities million million business combinations additions million lower primarily reflected proceeds disposal shareholding quest diagnostics investments inc lower purchases intangible assets year held investments including associates joint ventures million million carrying value december million capital expenditure financial investment million market value december million million cash payments tangible intangible fixed assets amounted million million disposals realised derivative financial instruments assets million million cash payments acquire equity noncurrent current derivative financial instruments investments million million made held fair value million million majority year sales equity investments realised million amount relates interest rate swaps foreign exchange million contracts designated accounting hedges gsk annual report risk factors principal risk factors uncertainties risks uncertainties relevant groups business financial condition results operations may affect groups performance ability achieve objectives factors among group believes could cause actual results differ materially expected historical results risks uncertainties may affect groups performance ability achieve objectives currently known group deemed immaterial group reviews assesses significant risks regular basis implemented oversight programme help ensure system internal controls place system includes policies procedures communication training programmes supervision monitoring processes escalating issues appropriate level senior management system helps facilitate groups ability respond appropriately risks achieve group objectives helps ensure compliance applicable laws regulations internal policies addition groups audit assurance function responsible independently assessing adequacy effectiveness management significant risks reporting outcomes business management risk oversight compliance council audit risk committee necessary groups management risks discussed pages corporate governance principal risks uncertainties might affect groups business identified united kingdom regulations require discussion mitigating activities company takes address risks uncertainties however possible group implement controls respond risks may face complete assurance provided steps group taken address certain risks including listed mitigating activities include manage risks effectively principal risk factors uncertainties listed order significance delivering commercially successful new products mitigating activities include risk description risk rd deliver commercially group changed pharmaceuticals vaccines rd organisation recent years attempt deliver large successful new products diverse latestage pipeline discovery organisation structure group operates highly competitive markets sustain flow innovative new medicines vaccines pharmaceuticals vaccines businesses faces competition group evolved traditional hierarchical proprietary products large international manufacturers pharmaceuticals vaccines rd business model rd producers generic pharmaceuticals pharmaceuticals business model based smaller units attempt encourage vaccines businesses also face increasing competition greater entrepreneurialism accountability scientists manufacturers emerging markets lower cost manufacturing group believes create environment base group significant product innovations technical conducive development commercially viable new products advances intensification price competition competitors development additional uses existing products may materially adversely affect groups financial results addition group plans continue collaborating partners group always predict timing impact competitive academia biotechnology companies pharmaceutical products potential impact sales groups products companies group believes improve ability light competitive environment group operates develop competitive products decrease amount time continued development commercially viable new products well takes group also increasing consultation patients development additional uses existing products critical payers ensure medicines develops provide improvements groups ability replace sales older products decline healthcare systems value reward upon expiration exclusive rights increase overall sales group reviews product development external developing new pharmaceutical vaccine products costly collaborations series formal governance committees lengthy uncertain process new product candidate fail committees progressively evaluate scientific stage development process one late financial considerations product well potential stage product candidates could fail receive regulatory approval benefitsrisks associated continued development new product candidates may appear promising development assets committees include rd executives well medical significant investment group economic human scientific commercial specialists relevant therapy resources may fail reach market may limited business areas commercial success could example result efficacy safety concerns inability obtain necessary regulatory protecting intellectual property rights approvals difficulty manufacturing excessive manufacturing costs erosion patent coverage result lengthy development risk description risks failing secure protect period infringement patents intellectual property rights intellectual property rights others inability differentiate product adequately competes failure obtain effective intellectual property protection furthermore health authorities increased focus safety products product differentiation assessing benefitrisk balance innovator pharmaceutical vaccine consumer healthcare drugs made difficult pharmaceutical vaccine company group seeks obtain appropriate intellectual property products gain regulatory approval also increasing pressure protection products ability obtain enforce patents healthcare budgets result financial crisis increase proprietary rights regard products critical average age population developed markets groups business strategy success increase absolute population developing markets payers number markets group operates intellectual therefore increasingly demanded greater incremental benefit property laws patent offices still developing pharmaceutical vaccine products agreeing markets may unwilling extend intellectual property protection reimburse drug manufacturers prices manufacturers consider innovative products fashion similar markets appropriate failure develop commercially successful products developed regions eu japan usa enforce develop additional uses existing products previously granted intellectual property rights reasons could materially adversely affect groups financial resultsgsk annual report strategic review financial review risk governance remuneration financial statements investor information groups inability obtain enforce effective intellectual regulations outlining requirements establishing biosimilars property protection products certain markets could interchangeable products well operation complicated material adverse result groups financial results patent litigation provisions yet proposed fda although fda currently implementing biosimilar pathway countries group operates patent without regulations based statute guidance protection data exclusivity may significantly weaker documents europe european medicines agency ema usa eu developing countries reduced finalised guidelines similar biological medicinal products containing threatened reduce effective patent protection pharmaceutical monoclonal antibodies mabs new regulations establishing products generally particular therapeutic areas facilitate biosimilars interchangeable products could allow earlier early competition within markets generic manufacturers competition certain groups products loss patent protection including reducing scope patent rights compulsory licensing government forces loss patent data exclusivity protection manufacturer license patents competitor could materially groups products could material adverse impact sales adversely affect groups financial results markets groups products absence adequate patent data exclusivity protection could limit opportunity rely markets future sales growth mitigating activities include groups products group supported global patents organisation within legal group whose focus seek ensure protect expiry intellectual property rights protection intellectual property rights group beginning groups products competitive products competition continuing global patents group sought generic manufacturers implement improvements certain timedriven processes pharmaceutical vaccine products usually protected controls order better manage ability obtain maintain copied generic manufacturers period exclusivity patent protection groups key assets minimize risk provided issued patent related intellectual property rights invalidity unenforceability patents processes relate regulatory data protection orphan drug status following implementing new review process designed help expiry intellectual property rights protection generic obtaining maintaining appropriate patent protection key manufacturer may produce generic version product assets identifying opportunities obtaining patent term group faces intense competition manufacturers generic extensions ensuring timely payment required renewal fees pharmaceutical products major markets introduction ensuring appropriate listing patents orange book generic products particularly usa group enhanced processes seek ensure key patent applications highest turnover margins typically leads dramatic loss reviewed senior management prior worldwide filing sales reduces groups revenues margins proprietary prior grant senior management approval obtained products group pharmaceutical vaccine products prior listing patents orange book initiation million annual global sales certain abbreviated new drug application anda litigation addition products generic competition usa markets group initiated post approval patent review process europe ensure ongoing review quality patents grant timing impact entry usa major markets global patents group maintains internal litigation processes europe followon product seretideadvair contains designed ensure successful enforcement defence patents active ingredients uncertain us patent compositions goal maintaining exclusive rights market major containing combination active substances seretideadvair products expired group notified acceptance us food drug administration fda global patents group monitors new developments patent law application followon product refers seretideadvair major markets group operates seek ensure contains active ingredients able predict appropriate protection groups assets group sometimes may occur followon product may acting trade associations works local governments enter us market seek secure effective balanced intellectual property protection designed meet needs patients payers supporting generic drug manufacturers also exhibited readiness market longterm investment innovation generic versions many groups important products prior expiration groups patents efforts may ensuring product quality involve challenges validity enforceability group patent assertions generic product infringe groups risk description risk patient consumer result patents group successful defending attack failure gsk contractors suppliers comply patents maintaining exclusive rights market one good manufacturing practice regulations commercial major products particularly usa europe groups manufacturing inadequate governance quality financial results would adversely affected expiration dates product development patents groups major products description litigation settlements may affect dates generic versions patients consumers healthcare professionals trust quality groups products may introduced set pages products point use failure ensure product quality legal proceedings involving patent challenges set enterprise risk applicable across group note financial statements legal proceedings failure ensure product quality could far reaching implications group may also experience impact sales one terms health patients customers reputation products due expiry loss patent protection product regulatory legal financial consequences group marketed competitor similar product class treatment similar disease condition availability generic products similar product class one groups products competes could material adverse impact sales groups products gsk annual report risk factors product quality may influenced many factors including materials services provided thirdparty suppliers necessary product process understanding consistency manufacturing commercial production products including specialty components compliance current good manufacturing practice chemicals commodities components necessary manufacture cgmp accuracy labelling reliability security supply packaging many groups pharmaceutical vaccine chain embodiment overarching quality culture consumer healthcare products thirdparty services internal external environment continues evolve new procured example services provided clinical research products new markets new legislation introduced particular organisations support development key products attention currently focused global supply eu important operation groups businesses although new falsified medicines directive focused security supply group undertakes business continuity planning single sourcing usa passage food drug administration safety certain components bulk active materials finished products innovation act fdasia focus attention reducing current services creates risk failure supply event regulatory levels drug shortages marketplace new cgmp legislation noncompliance physical disruption manufacturing sites introduced many emerging markets including china failure small number singlesource thirdparty suppliers brazil inspection front pharmaceutical inspectors service providers fulfil contractual obligations timely manner increasingly looking global application corrective actions result regulatory noncompliance physical disruption beyond original site inspection manufacturing sites may result delays service interruptions may materially adversely affect groups financial results mitigating activities include mitigating activities include group adopted single quality management system qms defines corporate quality standards systems business supply chain model designed help ensure supply quality units associated pharmaceuticals consumer healthcare security groups products globally group closely products vaccines rd investigational materials qms monitors delivery products intent ensuring broad scope covering end end supply chain starting customers medicines products need materials distributed product applicable throughout safety stocks backup supply arrangements high revenue complete life cycle products rd mature commercial critical products place help mitigate risk addition supply standing manufacturing external suppliers also routinely qms periodically updated based experience new regulation monitored order identify manage supply base risks improved scientific understanding seek ensure operations practical dependencies single sources critical items comply cgmp requirements globally supports delivery removed consistent reliable products large network quality compliance professionals aligned securing adequate pricing reimbursement business unit provide oversight assist delivery risk description risk group may fail secure quality performance operational compliance management adequate pricingreimbursement products existing oversight activities accomplished hierarchy quality council meetings staff trained seek assure regimes pricing laws regulations become standards well expected behaviours based groups unfavourable values followed pharmaceutical vaccine products subject price controls groups chief product quality officer oversees activities pressures restrictions many markets around world gsk quality council serves forum escalate emerging governments intervene directly setting prices addition risks share experiences handling quality issues business markets major purchasers pharmaceutical vaccine units ensure learnings assessed deployed across products whether governmental agencies private health care group providers economic power exert substantial pressure prices terms access formularies difficult economic group implemented riskbased approach assessing conditions particularly major markets europe could increase managing thirdparty suppliers provide materials used pricing pressures groups pharmaceutical vaccine finished products contract manufacturers making group products products group accurately predict whether existing audited help assure expected standards met controls pressures restrictions increase whether new maintaining product supply controls pressures restrictions introduced measures may materially adversely affect groups ability introduce risk description risk interruption product supply new products profitably financial results manufacture pharmaceutical vaccine products usa group highest margins constituent materials requires compliance good manufacturing sales country direct government price controls practice regulations groups manufacturing sites subject private sector purchases federal law requires pharmaceutical review approval fda regulatory agencies manufacturers pay prescribed rebates certain drugs compliance failure groups manufacturing facilities eligible reimbursement several state federal healthcare suppliers key services materials could lead product recalls programmes primarily medicare medicaid pricing pressures seizures interruption production delays approval new likely increase us governments share national health products revoking license operate pending resolution spending continues increase manufacturing issues example noncompliance cgmp additionally due passage comprehensive health care reform requirements us supply could ultimately result severe us governments role providing subsidising health circumstances fines disgorgement profits interruption insurance expected significantly expand indicates supply incurring fines disgorgement impacting growing role leverage government bring bear significant products markets could materially adversely affect groups rebate liability respect us federal programs groups financial resultsgsk annual report strategic review financial review risk governance remuneration financial statements investor information part ongoing deficit reduction discussions usa compliance relevant laws regulations obama administration recently suggested pharmaceutical manufacturers required offer federally mandated rebates risk description risks arising noncompliance government drugs people elderly disabled laws regulations affecting group qualify medicare medicaid known dual group operates global basis must comply eligibles individuals currently receive drug benefits broad range laws regulatory controls development medicare part manufacturers medicare part rebates manufacturing testing approval distribution marketing many negotiated health plans typically lower federally pharmaceutical vaccine consumer healthcare products mandated medicaid rebates legislation passes requiring affect cost product development also time manufacturers pay mandated medicaid level rebates dual required reach market uncertainty successfully eligibles would significant additional rebate liability group operates globally complex legal regulatory pharmaceutical companies group environments often vary among jurisdictions recent years number states also proposed rules regulations change governmental implemented various schemes control pharmacy budget interpretation rules regulations evolve potential drugs used lowincome senior citizens programmes exists conduct group called question including increasing rebate liability pharmaceutical companies importation countries bulk purchases drugs historically stringent regulatory requirements developed markets however recent years emerging markets given possible expansion medicaid us health care increasing regulatory expectations based reform law economic pressures state government national interpretations us eu standards stricter regulatory budgets pricing pressures groups pharmaceutical vaccine controls heighten risk changes product profile withdrawal products likely increase trends may materially regulators basis postapproval concerns product adversely affect groups financial results safety could reduce revenues result product recalls mitigating activities include product liability lawsuits also greater regulatory scrutiny especially usa advertising promotion particular groups effort improve reimbursement evidence directtoconsumer advertising development assets designed help defend future innovation clearly demonstrating value medicines vaccines furthermore interaction exchange information provide patients providers payers using relevant comparators group external communities order advance scientific meaningful endpoints targeted patient populations help medical understanding may may perceived support appropriate price levels formulary access promotional intent regulators potentially resulting loss credibility authorities prescribers patients group communicates governments reinforce interpretation could result regulatory action government awareness value medicines also works national investigation could farreaching effects including industry associations reinforce messages addition impacting product liability actions regulatory pathway assets group monitors global economic environment identify areas significant fines exclusion government programs even potential pricing pressure group continue explore individual criminal liability different pricing models innovative products support modest pricing older products provides opportunity additionally development postapproval adverse event new products reimbursed rewards companies invest profile product product class may materially adversely rd meet unmet patient needs affect groups financial results given sustained shift witnessed european reimbursement group also subject laws usa eu pricing environment group plans initiate jurisdictions regulating export products certain countries restructuring european pharmaceuticals business reduce instance iran subject wideranging sanctions laws costs improve efficiencies reallocate resources support usa eu jurisdictions group exported identified growth opportunities markets group certain pharmaceutical vaccine products pharmaceuticals reduces european cost base group also evaluating vaccines businesses certain healthcare products including strategic options ensure development new capabilities overthe countermedicines medical devices consumer ability maximise value groups current future healthcare business iran via sales nonus entities three portfolio region initiative expected progress privately held iranian distributors us law requires specific disclosure additional restructuring supports strategy change certain dealings iran including transactions dealings shape business deliver sustainable longterm growth governmentowned entities entities sanctioned activities short term also help offset pressure related terrorism proliferation weapons mass destruction group seeing margin structure resulting changes believe iranian distributors fall within business mix relevant categories group also business via nonus entities jurisdictions targeted sanctions laws including cuba selected developed markets group engaged new syria sudan failure comply laws could expose reimbursement approaches medicines group group civil criminal penalties including fines prosecution agrees outcomesbased risksharing arrangements payers imposition export economic sanctions group policy advocacy perspective group works reputational damage could materially adversely trade associations help support government adoption policies affect groups financial results fair balanced transparent unfairly impact innovative pharmaceutical companies gsk annual report risk factors mitigating activities include changing global political economic conditions groups internal control framework designed help ensure risk description risk exposure various external political adhere legal regulatory requirements significant economic conditions well natural disaster work accomplished strengthen groups compliance may impact groups performance ability achieve programme group continuously evaluates enhances based objectives changes healthcare marketplace changes groups commercial model guidance governmental agencies many worlds largest economies including major markets requirements set corporate integrity agreement cia group operates financial institutions recently entered group subject faced extreme financial difficulty including decline asset prices liquidity problems limited availability credit addition group implemented numerous mechanisms support group operates across wide range markets markets compliance legal regulatory requirements following potential encounter natural disasters could impact represent examples mechanisms business operations groups chief regulatory officer oversees activities economic uncertainty continued particularly regulatory governance board includes promoting compliance europe uncertain long effects last whether regulatory requirements companywide standards making economic financial trends worsen improve austerity regulatory services efficient agile aligning measures certain countries europe increased pressures regulatory capabilities business needs global local levels payers countries force healthcare companies medical governance executive committee accountable group decrease price products debt crisis chief medical officer oversees system principles policies given rise concerns countries may able pay accountabilities help ensure group applies generally products current economic conditions may also adversely affect recognized principles good medical science integrity ethics ability distributors customers suppliers service discovery development marketing products includes providers pay products otherwise buy necessary reinforcing groups commitment respecting clear distinction inventory raw materials perform obligations scientific engagement one hand product agreements group could disrupt operations promotion negatively impact business cash flow distributors customers suppliers service providers may group implemented abovecountry medical governance unable pay bills timely manner may even become risk management framework covers relevant group activities insolvent could also negatively impact business results supports development implementation appropriate operations risks may elevated respect management controls applicable policies focus ensuring interactions third parties substantial operations countries patient safety additional mitigating activities related current economic conditions severe particularly medical governance framework please see potential litigation third parties exposed risk business government investigations risk factor interactions directly fiscallychallenged government payers regards sales marketing activities group defined continued economic weakness uncertainty could materially communicated expectations pharmaceutical marketing adversely affect groups revenues results operations promotional activities global code practice code sets financial condition groups businesses including pharmaceuticals minimum group standard activities requires activities vaccines consumer healthcare may particularly sensitive comply applicable laws regulations industry codes effect declines consumer government spending addition pharmaceutical consumer healthcare business units renewed declines asset prices may result lower return copy review process used review materials help assure groups financial investments may cause value groups materials accurate fairly portray products including investments pension plans decrease requiring group ensuring offlabel claims made respect groups increase funding pension plans see note counter products legal group member certain financial statements pensions postemployment benefits us pharmaceutical consumer healthcare committees advises discussion investment strategy general pension appropriate policies help mitigate risk usa working overview business compliance groups legal also undertakes periodic group control changes inflation interest rates assessment current sales promotional activities foreign currency exchange rates controls economic regards economic sanctions risk group factors affecting businesses possibility political unrest implemented global policy procedure reflects groups legal regulatory changes nationalisation jurisdictions commitment strict adherence applicable sanctions export group operates control laws relevant business global policy requires business unit global support function perform appropriate risk mitigating activities include assessments following review business iran group extent groups portfolio geographic footprint assist ceased sales products consumer healthcare business mitigating exposure specific localised risk certain intends supply products high medicalpublic health degree external uncertainties carefully considered need determined using criteria set world health developing strategy reviewing performance organization pharmaceuticals vaccines businesses group continued conscious commercial decision maintain supply countries funding problems within agreed limits total receivables group designated cross business team specifically evaluate european economic risk team developed response plans different european economic events attempt ensure preparedness aim reducing potential impact group eventsgsk annual report strategic review financial review risk governance remuneration financial statements investor information several mitigating steps also taken attempt reduce compliance financial reporting disclosure groups financial exposure certain key countries including requirements exercising additional caution counterparty exposures taking prudent balance sheet measures relation high risk countries risk description risk associated financial reporting proactively managing shortterm liquidity positions disclosure changes accounting standards additional mitigating activities related european prices pressures new revised accounting standards rules interpretations issued please see government payers pricing risk factor time time international accounting standards board group formal crisis continuity management strategy could result changes recognition income expense global policy procedure managed centrally may materially adversely affect groups financial results strategy requires documentation crisis continuity plans international financial reporting standards changes periodic review plans crisis continuity management market valuation certain financial instruments required team assists critical crisis preparedness response efforts globally reflected groups reported results gains losses incorporates lessons learned global strategy actually realised could significant impact managing alliances acquisitions income statement given period accounting deferred taxation intercompany inventory may give rise volatility risk description risks alliances acquisitions depending upon group entity owns inventory part groups strategy diversify new product areas regulators regularly review financial statements listed markets group grown expects continue companies compliance accounting regulatory grow part acquisitions business alliances requirements group believes complies intense competition alliance acquisition candidates appropriate regulatory requirements concerning financial pharmaceutical industry group may unable statements disclosures however companies make deals acceptable terms acquiring forming experienced investigations potential noncompliance alliances companies group may assume significant debt accounting disclosure requirements resulted become subject unknown contingent liabilities fail realise restatements previously reported results sometimes significant benefits expected transactions example penalties investigation required restatement could pharmaceutical biotech companies including group materially adversely affect groups financial results may consider acquiring involved patent disputes product mitigating activities include liability litigation government investigations legal proceedings whose outcome subject considerable uncertainty group maintains control environment designed identify assumption debt unknown contingent liabilities material errors management periodically tests design failure realise expected benefits may materially adversely operating effectiveness key financial reporting controls affect groups financial results provides management assurance controls operated effectively key financial reporting disclosure processes process integrating companies group may acquire may result disruption ongoing business effort integrating group keeps date latest developments financial organisations different locations among things reporting requirements working external auditor differing systems corporate cultures may divert attention advisors ensure adherence relevant reporting resources result loss key employees adverse requirements consequences may materially adversely affect shared accountability financial results across group groups financial results financial results reviewed signed regions reviewed corporate controller chief financial mitigating activities include officer cfo allows corporate controller group engages significant due diligence prior alliance cfo assess evolution business time acquisition assess operational financial reputational evaluate performance plan significant judgments reviewed risk may result alliance acquisition diligence confirmed senior management includes documentary review discussions employees compliance tax law managing treasury representatives collaborator companies group employees key roles diligence required complete training prior investments working transactions risk description risk groups business models major transactions entered group reviewed various tax law practice change time groups management boards throughout group including instance existing tax policies operating models longer technology investment board product management board appropriate significant losses arise treasury corporate executive team board investments contractual arrangements group enters include groups effective tax rate driven rates tax jurisdictions provisions reduce eliminate groups financial exposure higher lower applied uk particular transaction addition many jurisdictions uk belgium usa integration acquired companies managed groups currently offer regimes encourage innovation new scientific corporate strategy group pursuant specific standards working endeavours providing tax incentives example rd tax credits responsible management business affected lower tax rates income derived patents acquisition integration team appointed company acquisition seek ensure smooth integration minimise disruption business integration team attempts ensure group attains maximum value may generated deal whilst ensuring key risks managed timely manner gsk annual report risk factors furthermore given scale international nature groups compliance antibribery corruption business intragroup transfer pricing inherent tax risk legislation international businesses changes tax laws application respect matters transfer pricing foreign risk description risk failing create corporate dividends controlled companies rd tax credits taxation environment opposed corruption failing instil intellectual property restriction tax relief allowed business practices prevent corruption comply interest intragroup debt could impact groups effective tax anticorruption legislation rate materially adversely affect financial results groups extensive increasingly international operations may tax charge included financial statements groups give rise possible claims bribery corruption group best estimate tax liability time audits tax operates number markets corruption risk authorities concluded degree uncertainty regarding identified high groups transparency international failure final tax liability period groups policy submit comply applicable legislation us foreign corrupt tax returns within statutory time limits engage tax practices act uk bribery act similar legislation authorities ensure groups tax affairs current countries could expose group senior officers civil possible differences interpretation tax criminal sanction legislation regulation resolved quickly possible exceptional cases matters settled agreement could potentially include fines prosecution debarment tax authorities group may resolve disputes public procurement reputational damage could formal appeals proceedings example october materially adversely affect groups financial results supreme court canada delivered decision appeal mitigating activities include respect groups transfer pricing discussed note financial statements taxation group like international group implemented global antibriberyanticorruption businesses also subject range duties taxes abac programme programme includes global abac policy incurs similar types risk ongoing training detailed requirements respect thirdparty group deals high value transactions frequent basis due diligence contracting oversight addition programme may result increased risk financial loss due strengthened controls interactions government officials mismanagement cash entering high risk positions hedge entering business development transactions transactions could materially adversely affect operational performance reviewed groups abac oversight groups financial results committee dedicated abac team responsible driving implementation mitigating activities include programme design execution abac audit group monitors government debate tax policy key strategy methodology supported extended team jurisdictions deal proactively potential future changes functional experts within legal group compliance audit tax law assurance abac team provides continued support business ongoing training communication guidance tax risk managed set policies procedures ensure community experts meet provide timely guidance consistency compliance tax legislation group engages business issues escalated abac programme advisors legal counsel review tax legislation applicability continues evolve response external environment ongoing group group attempted mitigate risk benchmarking internal stakeholder feedback aggressive audits date possible tax affairs working real time tax authorities possible potential litigation group undertaken number projects move risk description risk substantial adverse outcome centralised simplified intellectual property ownership trading litigation government investigations model new model centralises pharmaceutical intellectual property uk reducing complexity intercompany note financial statements legal proceedings contains arrangements enabling us drive bilateral advance discussion material proceedings governmental investigations pricing agreements apas future uk currently involving group proven could give rise civil jurisdictions group operates apas give greater certainty andor criminal liabilities unfavourable resolution similar application transfer pricing direct tax affairs future proceedings investigations may material adverse hence reduce risks group faces effect groups financial condition results operations example group entered settlement treasury department act profit centre agreement us federal government resulting payment group reduces incentive take risks order increase us billion group group made provisions returns department strives minimise risk centralise related legal proceedings investigations financial transactions reduced earnings treasury risk managed detailed set treasury policies future group may also make additional significant reviewed approved board annual basis group provisions related legal proceedings investigations proactively monitors treasury activities intent identifying would reduce earnings many cases group believes exceptions policy practice plaintiff bar claim damages amounts bear reasonable relationship underlying harm allegedly caused groups products actions accordingly may potentially misleading group quantify based amount damages claimed potential exposure claims proceedings investigations type described note financial statements legal proceedingsgsk annual report strategic review financial review risk governance remuneration financial statements investor information recent insurance loss experience including pharmaceutical product group reached agreement resolve certain federal liability exposures increased cost reduced capacity state governmental investigations pricing marketing insurers provide coverage pharmaceutical companies reimbursement prescription drug products detailed note generally including group financial statements legal proceedings additional related state investigations initiated basis product liability litigation factual claims could result restitution civil litigation behalf preclinical clinical trials conducted development state governments could also result related proceedings potential pharmaceutical vaccine consumer healthcare initiated group behalf consumers private products determine safety efficacy products payers proceedings may result trebling damages awarded use humans following approval regulatory authorities fines respect violation law conduct group notwithstanding efforts group makes determine could result additional investigations future us federal safety products regulated clinical trials unanticipated state governments similar civil litigation side effects may become evident drugs vaccines consequences could materially adversely affect groups widely introduced marketplace financial results instances thirdparties may perform analyses published mitigating activities include clinical trial results although necessarily accurate meaningful may raise questions regarding safety group attempts mitigate risks inherent drug pharmaceutical vaccine consumer healthcare products may development conscientious approaches product publicised media may result product liability claims development distribution focus patient safety group currently defendant substantial number product overriding priority include accurate documentation liability lawsuits including class actions involve significant claims exercise careful medical governance damages related groups pharmaceutical consumer group constructed system medical governance help healthcare products litigation particularly us inherently ensure safety efficacy drugs vaccines consumer unpredictable class actions sweep together persons products produces groups chief medical officer cmo prescribed groups products inflate potential liability responsible medical governance group global force numbers claims pain suffering punitive policy policy safeguarding human subjects group damages frequently asserted product liability actions clinical trials patients take group products paramount allowed represent potentially open ended exposure thus importance cmo authoritative role evaluating could materially adversely affect groups financial results addressing matters human safety global safety board cases group may voluntarily cease marketing product gsb comprising senior physicians representatives supportive face declining sales based concerns efficacy safety functions well lawyer leads legal support even absence regulatory action pharmaceuticals rd integral component system gsb reviews investigational marketed products within antitrust litigation pharmaceuticals rd portfolio subsidiary boards accountable usa become increasingly common patent gsb also legal delegates perform similar reviews infringement actions prompt claims antitrust laws consumer healthcare products vaccines violated prosecution patent litigation involving defence patent claims direct addition medical governance framework within group indirect purchasers payers typically filed class actions described group uses several mechanisms foster relief sought may include treble damages restitution claims early resolution new disputes arise reduce number similarly antitrust claims may brought government entities disputes actually proceed litigation private parties following settlement patent litigation alleging group formalised processes proactive riskdispute settlements anticompetitive violation antitrust management programme aims drive standardised laws usa europe regulatory authorities continued practice early resolution disputes consistent use across challenge anticompetitive socalled reverse payment settlements organisation establishes specific vocabulary identity innovator branded generic drug manufacturers concept early analysis resolution thereby accelerating us supreme court currently reviewing legality desired culture shift legal group also routinely trains settlement agreements group may also subject groups employees strategies attempt minimize groups antitrust litigation involving competition claims unrelated patent litigation exposure infringement prosecution successful antitrust claim private party government entity group could materially response execution cia group implemented adversely affect groups financial results enterprise steering committee ensure oversight governance cia compliance additionally group appointed senior sales marketing litigation executive within usbased compliance group whose role group operates globally complex legal regulatory provide assurance senior management board environments often vary among jurisdictions failure group complying obligations cia comply applicable laws rules regulations jurisdictions may result civil criminal legal proceedings brought group continues evaluate commercial practices group governmental entities federal state ensure compliance cia also find opportunities levels private plaintiffs rules regulations change limit eliminate commercial activities may effectively align governmental interpretation rules regulations commercial strategy values andor may result evolve conduct group may called question unnecessary risks example group implemented system evaluating compensating sales professionals usa usa example group settled number federal quality interactions healthcare professionals state investigations marketing certain products including element customer evaluation rather entered cia federal government relating achieving individual sales targets groups marketing promotion products usa gsk annual report risk factors managing environmental health safety mitigating activities include sustainability compliance group regularly engages credit risk monitoring activities relating wholesalers including review periodic financial risk description risk ineffectively managing environment information credit ratings develops monitors group internal health safety sustainability ehss objectives risk ratings establishes periodically reviews credit limits requirements protecting information environmental laws various jurisdictions impose actual potential obligations group remediate contaminated sites risk description risk exposing business critical sensitive group also identified potentially responsible party data due inadequate data governance information us comprehensive environmental response compensation systems security liability act number sites remediation costs relating groups use ownership sites group relies critical sensitive data corporate failure manage properly environmental risks could result strategic plans personally identifiable information trade secrets additional remedial costs may materially adversely affect intellectual property drive planning operations security groups financial results see note financial statements type data exposed escalating external threats legal proceedings discussion environmental related increasing sophistication changing goal disruption proceedings group involved group routinely financially politically motivated accrues amounts related liabilities matters failure implement appropriate safeguards adequately protect impact risk risk occur could lead significant unauthorised unintentional access acquisition use harm people environment communities modification loss disclosure critical sensitive data may group operates failure meet stakeholder expectations adversely impact groups ability maintain patent rights regulatory requirements competitive advantages may result legal noncompliance resulting fines penalties inability sell product mitigating activities include particular market management ehss risk fundamental groups performance mitigating activities include reputation group committed appropriately managing ehss risk embedded importance mission help group assesses changes risk environment people feel better live longer briefings government agencies subscription commercial threat intelligence services security information sharing group operates rigorous procedures seek eliminate hazards companies industry beyond practicable protect employees health wellbeing right culture essential starting point employment groups policies controls information protection practices designed create work place culture regularly reviewed employees routinely trained group group employees feel valued respected empowered inspired dedicated information security expertise resources achieve goals response changing external risk environment group implemented global programme increase business groups continuing efforts improve environmental sustainability awareness information protection requirements define reduced groups water consumption hazardous waste minimum information security expectations thirdparty energy consumption group actively manages environmental agreements implement additional technical controls protect data remediation obligations ensure practices environmentally improve security event monitoring sustainable compliant group also subject various laws govern processing groups ehss performance results shared public personally identifiable information pll ensure compliance year corporate responsibility report crossborder transfer requirements pll group submitted application binding corporate rules bcrs concentration sales wholesalers review uk information commissioners office groups bcrs would simplify internal processing pll human risk description risk groups sale products resource research activities creating one global standard small number wholesalers usa similar pharmaceutical vaccine companies group sells products small number wholesalers addition hospitals pharmacies physicians groups sales three largest wholesalers amounted approximately groups us pharmaceuticals vaccines turnover december group trade receivables due three wholesalers totalling million december million group exposed concentration credit risk respect wholesalers one affected financial difficulty could materially adversely affect groups financial resultsgsk annual report strategic review financial review risk governance remuneration financial statements investor information governance board corporate executive team chairmans letter board report shareholders remuneration committee reports remuneration committee chairmans letter total remuneration pay performance remuneration policy directors emoluments total remuneration directors senior management widening access vaccines agreement gavi alliance supplying vaccines low prices help millions children developing countries arrangement based sustainable longterm supply commitment see sppihw mot gsk annual report trakcorc niai governance remuneration board board responsible longterm success company corporate governance strategy risk management financial performance diversity experience international experience number directors experience scientific global finance usa industry europe emap composition tenure executive nonexecutives nonexecutive years years years male board considers nonexecutive female directors independent accordance uk corporate governance code sir christopher gent skills experience sir christopher many years experience leading global businesses chairman track record delivering outstanding performance highly nationality british competitive industries appointed managing director vodafone plc became chief executive officer appointment date retirement june chairman january external appointments sir christopher nonexecutive director ferrari spa senior adviser committee membership bain co member british airways international business chairman nominations advisory board sir christopher formerly member kpmgs corporate responsibility chairmans advisory group nonexecutive director lehman committees member brothers holdings inc remuneration finance committees sir andrew witty skills experience sir andrew joined gsk worked uk south africa chief executive officer usa singapore various senior roles appointed nationality british president gsk europe joined gsks corporate executive team appointed ceo may appointment date january chief singapore sir andrew board member singapore executive officer may economic development board singapore land authority awarded public service medal government committee membership singapore august also awarded public service star member finance committee new year honours list awarded knighthood services economy uk pharmaceutical industry currently member prime ministers business advisory group board member insead business school january external appointments sir andrew currently lead nonexecutive board member department business innovation skills also president european federation pharmaceutical industries associations chancellor university nottinghamgsk annual report strategic review financial review risk governance remuneration financial statements investor information simon dingemans skills experience prior joining gsk simon years experience investment chief financial officer banking sg warburg goldman sachs time advised nationality british broad range large corporates across number industry sectors including pharmaceuticals consumer healthcare simon advised gsk appointment date decade appointment closely involved january chief number gsks key strategic projects including establishment financial officer april viiv healthcare committee membership external appointments member finance committee simon member corporate development council national theatre dr moncef slaoui skills experience moncef joined gsk vaccines engineered development chairman global rd robust vaccines pipeline led worldwide business development vaccines pharmaceutical products appointment lead rd nationality moroccan given overall responsibility gsks oncology business belgian american gsk vaccines global franchises phd molecular biology immunology universit libre de bruxelles appointment date published scientific papers presentations prior may joining gsk moncef professor immunology university committee membership mons belgium member finance committee external appointments moncef member phrma biotechnology industry organization boards usa member advisory committee director national institutes health also adviser qatar foundation moncef advised us presidents council advisors science technology member board agency science technology research astar january sir robert wilson skills experience sir robert long distinguished career industry mainly senior independent rio tinto became chief executive officer nonexecutive director executive chairman retirement october nationality british sir robert became nonexecutive chairman bg group plc january may also chairman economist appointment date group nonexecutive director november bp diageo boots committee membership stand senior independent nonexecutive director member nominations audit member audit risk committee may risk finance committees external appointments sir robert senior adviser morgan stanley chairman accenture global mining executive council professor sir roy skills experience anderson professor sir roy worldrenowned medical scientist advanced knowledge infectious disease epidemiology currently professor independent infectious disease faculty medicine imperial college london nonexecutive director fellow member policy advisory board royal society scientific expert fellow academy medical sciences royal statistical society honorary fellow institute actuaries nationality british foreign associate member institute medicine us national appointment date academy sciences french academy sciences professor october sir roy brings scientific expertise board audit risk committees deliberations committee membership member audit risk stand member audit risk committee nominations finance may committees external appointments professor sir roy member international advisory board hakluyt co ltd trustee natural history museum london gsk annual report governance remuneration board continued lynn elsenhans skills experience lynn wealth experience running global business independent significant knowledge global markets gsk operates nonexecutive director served chair president chief executive officer sunoco inc nationality american prior joining sunoco president chief executive officer lynn worked royal dutch shell joined appointment date held number senior roles including executive july vice president global manufacturing committee membership external appointments member corporate lynn nonexecutive director baker hughes inc director responsibility finance texas medical center director first tee greater committees houston also trustee united way greater houston trustee rice university judy lewent skills experience judy extensive knowledge global pharmaceutical industry independent corporate finance joined merck co nonexecutive director served chief financial officer retired nationality american accordance uk corporate governance code board determined judy recent relevant financial experience appointment date board also agreed appropriate qualifications april background audit committee financial expert defined committee membership us sarbanesoxley act chairman audit risk external appointments committee member judy director thermo fisher scientific inc motorola solutions remuneration finance inc also trustee rockefeller family trust chairperson committees audit committee rockefeller financial services life member massachusetts institute technology corporation member american academy arts sciences judy nonexecutive director purdue pharma inc napp pharmaceutical holdings limited certain mundipharma international limited companies past nonexecutive director motorola inc dell inc quaker oats company trakcorc niai dr stephanie burns skills experience stephanie recognised global business leader served independent chairman president ceo dow corning corporation nonexecutive director retirement end strong scientific background nationality american phd organic chemistry organosilican speciality staunch advocate science education appointment date february external appointments stephanie appointed nonexecutive director corning inc committee membership january sits us presidents export council member corporate stephanie also officer society chemical industry responsibility finance america section past honorary president committees effect ukbased parent society may member remuneration committee stacey cartwright skills experience stacey chartered accountant extensive experience global independent consumer businesses corporate finance executive vice nonexecutive director president chief financial officer burberry group plc prior joining nationality british burberry group plc stacey held role chief financial officer egg plc worked appointment date various financerelated positions granada group plc april accordance uk corporate governance code board committee membership determined stacey recent relevant financial experience member audit risk board also agreed appropriate qualifications finance committees background audit committee financial expert defined us sarbanesoxley act sir crispin davis skills experience sir crispin industry expertise food beverage sector independent previously focused industrial consumer restructurings global nonexecutive director businesses sectors served chief executive officer reed nationality british elsevier plc september march appointment date sir crispin served chief executive officer aegis group plc july worked guinness group plc served group managing director united distillers member committee membership board earlier career sir crispin served years proctor member nominations gamble president north american food division finance committees previously chairman director starbev netherlands bv retire board agm may external appointments sir crispin adviser cvc capital partners also serves councils oxford university national trustgsk annual report strategic review financial review risk governance remuneration financial statements investor information sir deryck maughan skills experience sir deryck wealth international corporate investment banking independent experience previously served chairman chief executive nonexecutive director officer citigroup international salomon brothers inc served nationality british vice chairman new york stock exchange appointment date take sir robert wilson senior independent june nonexecutive director may committee membership external appointments member audit risk sir deryck senior adviser former partner kohlberg nominations remuneration kravis roberts co nonexecutive director blackrock inc finance committees thomson reuters well serving board directors lincoln center trustee new york university langone medical center dr daniel podolsky skills experience daniel worldrenowned researcher advanced knowledge independent underlying mechanisms disease new therapies gastrointestinal nonexecutive director disorders formerly mallinckrodt professor medicine chief scientific expert gastroenterology massachusetts general hospital harvard medical school previously served chief academic officer nationality american partners healthcare system daniels current responsibilities leading appointment date large academic medical centre give relevant insight healthcare july delivery daniel brings scientific expertise board audit committee membership risk committees deliberations member audit risk external appointments corporate responsibility daniel president university texas southwestern medical finance committees center holds philip obryan montgomery jr md distinguished presidential chair academic administration doris bryan wildenthal distinguished chair medical science member institute medicine us national academy sciences member board southwestern medical foundation director antibe therapeutics inc tom de swaan skills experience tom long distinguished career european banking independent industry member managing board chief nonexecutive director financial officer abn amro tom held various executive positions nationality dutch dutch central bank nonexecutive director financial services authority appointment date january accordance uk corporate governance code board determined tom recent relevant financial experience committee membership board also agreed appropriate qualifications chairman remuneration background audit committee financial expert defined committee member us sarbanesoxley act audit risk nominations finance committees external appointments tom chairman supervisory board vanlanschot bankiers vice chairman board directors zurich insurance group nonexecutive director kpmgs public interest committee also vice chairman supervisory board chairman audit committee royal ahold member supervisory board royal dsm jing ulrich skills experience since jing managing director chairwoman global independent markets china jp morgan current role acts adviser nonexecutive director worlds largest asset management firms multinational companies nationality american also advises chinese institutions making investments overseas appointment date jing worked deutsche bank managing july director head greater china equities previously held financial positions specialising asia pacific region clsa committee membership emerging markets investors corporation educated harvard member finance committee stanford universities effect may member audit risk external appointments committee jing independent director ermenegildo zegna spa hans wijers skills experience hans broad range business economic political experience independent served chief executive officer chairman akzo nobel nonexecutive director nv hans long distinguished career nationality dutch academia public service strategy consulting served senior vice president boston consulting group appointment date effect april external appointments hans nonexecutive director chairman designate heineken committee membership nv also deputy chairman nonexecutive director royal dutch member finance committee shell also chairman supervisory board afc ajax gsk annual report governance remuneration corporate executive team corporate executive team supports chief executive officer management business activities sppihw mot dna trakcorc niai sir andrew witty simon bicknell deirdre connelly roger connor chief executive officer senior vice president president north america president global governance ethics pharmaceuticals manufacturing supply see board assurance deirdre joined gsk president north roger connor president global simon appointed senior vice america pharmaceuticals february manufacturing supply gms president governance ethics working eli lilly appointed role january assurance january company years held working year president responsible risk management variety positions including sales designate gms compliance strategic auditing professional general manager roger joined gsk simon joined company secretariat puerto rico senior vice president astrazeneca worked became deputy company human resources recently number roles within finance secretary glaxo wellcome president us operations manufacturing strategy including appointed company secretary native san juan deirdre received gsk sites cork ireland ware glaxosmithkline plc may bachelors degree economics uk prior role gms combined position role marketing lycoming college roger vice president office corporate compliance officer pennsylvania graduated ceo corporate strategy current appointment harvard universitys advanced february gaining law degree simon management programme holds degree mechanical qualified barrister january appointed manufacturing engineering member middle temple harvard university public health policy queens university belfast council masters manufacturing leadership deirdre also member board cambridge university also directors macys inc us chartered accountant department store chain simon dingemans marc dunoyer abbas hussain bill louv chief financial officer head rare diseases unit president europe emap senior vice president core chairman gsk japan business services see board abbas appointed president europe marc appointed lead new emap september joined bill appointed create lead rare diseases business rd company president emerging core business services cbs april commercialisation february markets asia pacific june cbs intergrates shared also served chairman gsk previously abbas spent years elililly services global support functions japan since january held positions including previously chief information previously representative director president europe vice officer president pharmaceuticals japan president europe specific bill joined company vice marc joined company hoechst responsibility western european president medical data sciences marion roussel midsize countries africa middle east held number increasingly senior president pharmaceuticals japan areacommonwealth independent roles rd january may states central eastern europe bill bachelor science degree also president pharmaceuticals asia regions also held positions sales biology college william pacific japan may marketing across australasia india mary master science doctor july abbas appointed viiv healthcare philosophy degrees statistics marc mba hautes ltd board october university florida etudes commerciales bachelor aspen board december law degree paris university also board member singapore also qualified junior cpa france dukenus governing board audit risk committee board born madras india abbas degree medicinal chemistry pharmacology loughborough university strategic review financial review risk governance remuneration financial statements investor information gsk annual report david redfern dr moncef slaoui claire thomas phil thomson chief strategy officer chairman global rd senior vice president senior vice president global vaccines human resources communications david appointed chief strategy officer may responsible see board claire appointed senior vice phil appointed senior vice proactive exploration new president human resources president global communications business opportunities strategic may responsible august responsibility planning leadership gsks environmental sustainability media relations investor relations dermatology business addition strategy previously senior corporate responsibility internal current role appointed vice president human resources communications product chairman board viiv pharmaceuticals international communications healthcare ltd april claire joined company phil joined glaxo wellcome previously senior vice president appointed senior vice president commercial trainee moving northern europe responsibility human resources pharmaceuticals pharmaceutical brand marketing managing gsks pharmaceutical europe successfully product communications businesses region prior led hr function merger became director media relations senior vice president central prior joining company worked glaxo wellcome plc eastern europe david joined ford motor company holding took position director company held series various positions investor relations gsk finance roles becoming finance returned corporate media director european business claire bachelor science degree relations vice president economics management industrial relations university phil earned degree english david bachelor science degree wales claire honoured history durham university bristol university uk outstanding european woman chartered accountant achievement dan troy patrick vallance emma walmsley christophe weber senior vice president president pharmaceuticals president consumer president vaccines general counsel rd healthcare worldwide christophe appointed president dan joined company senior patrick appointed president emma assumed role president vaccines april vice president general counsel pharmaceuticals rd january consumer healthcare worldwide named president designate september prior appointment senior october joining gsk vaccines january prior previously partner vice president medicines discovery may president consumer senior vice president washington law firm sidley austin development healthcare europe regional director asia pacific llp represented mainly patrick joined company emmas leadership business responsible gsk operations pharmaceutical companies trade head drug discovery focused new strategic direction become asia pacific associations matters related organisation science first best fast moving consumer joined company us food drug administration best chance leading healthcare company driven science held increasingly senior commercial fda government regulations new medicines created small values combining best positions including general manager dan formerly chief counsel multidisciplinary teams called discovery gsks scientific knowledge companys swiss subsidiary fda served primary performance units speed marketing excellence chairman ceo liaison white house prior joining gsk patrick clinical fast moving consumer goods world gsk france us department health human academic university college london prior joining gsk emma worked christophe started career services patrick member board loreal years australia working rhnepoulenc dan graduate cornell agency science technology held variety marketing general rorer pharmaceuticals doctor universitys school industrial research astar director management roles paris london pharmacy pharmacokinetics holds labor relations earned law genome research limited also new york master pharmaceutical marketing degree columbia university member international scientific based shanghai general manager master finance degree school law advisory board cambridge consumer products loreal china statistics institute medical research degree classics modern languages oxford university gsk annual report corporate governance dear shareholder chairman board committed gsk seeking operate highest standards corporate governance believe governance structure underpins ability deliver strategy grow diversified business deliver products value simplify operating model following pages outline approach governance structure corporate governance report modified year report begins overview summarises key highlights future actions thereafter disclosures seek mirror structure financial reporting councils uk corporate governance code several statutory disclosures appeared within report past consolidated shareholder information section annual report pages wish draw attention following key areas addressed board year board refreshment diversity last year discussed boards review composition changes initiated result pleased report proactive refreshment board led important changes composition james murdoch larry culp stood board may september respectively sir crispin davis stand reelection agm may places pleased welcome lynn elsenhans jing ulrich joined board july hans wijers join board april appointments close two significant gaps boards composition identified external evaluation board namely global ceo experience knowledge experience emerging markets also pleased sir robert wilson agreed stand reelection shareholders one year steps board agm given significant knowledge experience gsk provide period continuity new nonexecutive directors settle roles also taken opportunity refresh composition board committees details set nominations committee report pages although view diversity widest sense board level specifically look diversity geographical background ethnicity gender types experience pleased board refreshment programme increased gender diversity recruitment lynn jing taken cadre women board places gsk firmly upper quartile ftse terms female board representation also pleased report continue good representation women management positions actively encourage programmes gsk womens leadership initiative help increase pipeline women senior levels organisation corporate reporting fully support department business innovation skills bis efforts improve narrative remuneration reporting far seek raise bar reporting view reflected submissions consultations conducted new proposals addition fully engaged representing companys views developing initiatives including participating member financial lab project run jointly financial reporting council frc bis develop example best practice formats remuneration disclosures corporate integrity agreement finally board conjunction audit risk committee cet fully involved overseeing conclusion settlements us federal government broad range longstanding legal cases implementation corporate integrity agreement cia signed us department health human services requirements cia built governance structures board completed first training programme cia would operate continue receive ongoing training year board also apprised compliance cia quarterly basis details cia implications gsk found pages commend following report shareholders sir christopher gent chairman march gsk annual report strategic review financial review risk governance remuneration financial statements investor information board report shareholders oversight stewardship future actions board board pleased report full compliance requirements uk corporate governance code board responsible longterm success gsk accountable shareholders ensuring group appropriately managed governed delivers gsks strategy grow deliver simplify board programme board met six times board member attended scheduled board meetings exception judy lewent unable attend one meeting due personal circumstances conveyed views comments chairman matters discussed shared directors meeting board agendas shaped create time strategic discussion debate including deep dive reviews key issues business ensure focused consideration strategic priorities agendas board meetings included following business month strategy board oversight governance risk oversight january review expansion operational excellence review financial results review external review risk restructuring programme outlook board evaluation report internal controls review notice agm secretarys report process reappointment auditors march review respiratory strategy annual global manufacturing secretarys report review business development projects supply gms us deep dive future animals research pharma business reviews may annual european operations preparation agm vaccines business reviews secretarys report july review long range forecast annual rd review secretarys report corporate integrity review changes finance strategy review capital licensing agreement training review funding tax strategies proposals review talent leadership development strategy october review output annual board annual business reviews review projects corporate integrity cet strategy meeting consumer healthcare emerging transactions approved agreement training deep dive working capital markets japan board secretarys report december review approval plan review investor activity update tax gms rd strategies ir strategy secretarys report board performance board identified certain actions central increasing ability add value performance board actions set actions progressachievement external landscape increase consideration major external influences gsks relative board programme expanded include consideration major strengths weaknesses help expand boards knowledge influences gsk increase understanding knowledge individual non board visited india october part board cet strategy executive director board site visits meeting specific site visits individual directors arranged groups sites stevenage wavre research triangle park rtp zebulon ensure nonexecutive directors continue engage formally directors offered full access senior executive meetings enjoyed informally company attending meeting gsks executives learn business culture management demonstrate board embedding boards visit india provided opportunity appreciate risk culture risk awareness within emerging markets management embedded business emerging risks captured emerging risks captured ii board contribution composition board plan composition next five six years nominations committee focused longterm recruitment non optimise effectiveness executive directors close two significant gaps identified boards current composition board pleased welcome two new nonexecutive directors lynn global ceo experience knowledge experience emerging elsenhans jing ulrich add ceo emerging markets experience markets boards deliberations actions set full gsks annual report discusses externally facilitated evaluation boards activities dr tracy long gsk annual report corporate governance board report shareholders oversight stewardship future actions continued agms key highlights glance agm held may qeii conference centre london agm held may qeii conference centre london cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid capital board cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid least votes cast favour standing reelection cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid favour commitment role cidcidhighest votes favour reelect number directors cidcidlowest votes favour reduce notice general meeting strategic focus board cet strategy meeting delhi india emerging markets provide significant growth opportunity gsk turnover region grew accounts group turnover board chose hold annual strategy review meeting india gave board joined cet opportunity firsthand view groups local business future potential board cet also pleased able meet highly respected government business figures gain insight countrys political economic outlook induction programmes lynn elsenhans jing ulrich individually designed facilitated chairman company secretary ii purpose orientate familiarise lynn jing appointed board strategy grow deliver simplify industry organisation governance arrangements iii customised take account respective experience different geographical backgrounds business perspectives together committees would serve key elements onetoone induction briefing sessions site visits undertaken set contactactivity induction content executive directors gsks strategic financial rd priorities cet members wide spectrum gsk operations including pharmaceuticals vaccines consumer healthcare businesses strategic development investor relations global communications corporate responsibilty senior executives focused number core functions finance tax treasury audit assurance risk management investor relations company secretary legal regulatory duties uk listed company director corporate governance practices within gsk site visits tours gms rd vaccines sites rtp zebulon wavre investor meetings meetings investors requested induction training programmes lynn jing continued focus internal management meeting attendance operational site visits order give good perspective management operates provide opportunities meet key talent deepen understanding key business issues board performance action points agreed action points arising board evaluation review facilitated senior independent nonexecutive director sir robert wilson progress disclosed gsks annual report set external landscape board members keen supplement understanding external landscape teachins range topics various therapeutic areas design phase iii trials pricing biopharmaceuticals pharmacogenomics emerging technology rd ii oversight strategy board wished spend time business unit strategy competitor analysis pricing regimes acquisition strategy emerging issues iii board composition nominations committee tasked identifying suitable candidates replace board members due retire next yearsgsk annual report strategic review financial review risk governance remuneration financial statements investor information leadership effectiveness senior independent director sir robert wilson senior independent director sid board since may role act sounding board sir board met six times member attending christopher trusted intermediary directors follows also available additional point contact shareholders responsibilities include evaluation performance number number chairman request chairman evaluating board meetings held whilst meetings committees collaboration committee chairmen board member attended years evaluation conducted internally sir christopher gent sid also works chairman process sir andrew witty selection new chairman appropriate chairs simon dingemans nominations committee agreeing recommendation dr moncef slaoui board chairmans successor professor sir roy anderson sir robert maintains understanding issues concerns dr stephanie burns major shareholders meetings reports stacey cartwright investor relations team sir crispin davis lynn elsenhans sir deryck maughan succeed sir robert sid effect end agm may judy lewent sir deryck maughan ceo dr daniel podolsky tom de swaan sir andrew responsible management business developing groups strategic direction consideration jing ulrich approval board implementing agreed strategy sir robert wilson assisted members cet meets least times larry culp year often required james murdoch short biographies members cet given addition scheduled meetings board also met quorate basis corporate executive team pages four occasions l ynn elsenhans jing ulrich appointed nonexecutive directors company secretary effect july larry culp resigned board september company secretary victoria whyte solicitor fellow james murdoch retired board may institute chartered secretaries administrators victoria formerly deputy secretary secretary remuneration chairman committee acted secretary board boards committees since appointment company secretary sir christophers role chairman lead manage january business board provide direction focus ensuring clear structure effective operation victoria supports chairman designing induction new board committees sets agenda board directors delivery corporate governance agenda discussions promote effective constructive debate particular planning agendas annual cycle board support sound decisionmaking process ensuring board committee meetings ensuring information made receives accurate timely clear information particular available board members timely basis advises companys performance directors board procedures corporate governance matters arranges nonexecutive directors attend internal sir christopher works closely sir andrew witty ensure management meetings make visits business operations strategies actions agreed board effectively enhance knowledge understanding business implemented provides support advice sir andrew respecting executive responsibility managing group victoria responded various consultations division responsibilities chairman ceo evolving global governance reporting agenda behalf agreed board set governance section group also engaged shareholders ensure fully website understood gsks governance remuneration arrangements sir christopher responsible performance group shareholders leads discussions development relations nonexecutive directors nonexecutive directors provide strong independent element board well placed constructively challenge support management shape proposals strategy succession planning bring independent judgement breadth skills experience gained senior levels international business operations academia gsk annual report corporate governance corporate governance framework board coherent corporate governance framework clearly defined responsibilities accountabilities designed safeguard enhance longterm shareholder value provide robust platform realise groups strategy internal control risk management arrangements described pages integral part gsks governance framework board chairman executive directors independent nonexecutive directors audit risk remuneration nominations chief executive committee committee committee officer corporate administration corporate responsibility finance corporate executive transactions committee committee team committee board committees order board operate effectively give full consideration key matters board committees established summary role board committee set table full terms reference committee available website reports membership work undertaken audit risk remuneration nominations corporate responsibility committees given pages corporate corporate administration audit risk remuneration nominations responsibility finance transactions reviews reviews reviews reviews reviews reviews recommends recommends approves approves financial internal external issues reporting processes board structure size potential annual report matters connection integrity overall executive composition serious impact upon form f administration financial statements remuneration policy board gsks business convening groups system internal appointment agm preliminary business certain controls identification board members board oversight quarterly results corporate transactions appropriate fees management committees reputation announcements chairman risks external cet management approves internal audit determines processes monitors certain major licensing terms service succession capital transactions proposes remuneration board cet changes appointment executive directors groups investment external auditors members instrument cet counterparty limits responsible reviews initiating audit approves tender selection remuneration external auditors report remuneration oversight workgsk annual report strategic review financial review risk governance remuneration financial statements investor information board induction business awareness training may announced aspiration increase female representation board least able induction programmes lynn elsenhans jing ulrich report annual report encouraging progress presented illustrate typical induction format made towards target directors new director women stage part continued refreshment ensure nonexecutive directors develop maintain board lynn elsenhans jing ulrich appointed new greater insight understanding business invited nonexecutive directors july taking cadre women attend internal management meetings including meetings board pleased delivered early cet research development executive product aspiration exceeded target set executive scientific review board portfolio investment places gsk firmly upper quartile ftse terms board commercial accountability board risk oversight female board representation compliance council also meet employees informally time allocation visits groups operations receptions held around board meetings nonexecutive director letter appointment board kept uptodate legal regulatory governance sets terms conditions directorship matters regular papers company secretary sir christopher nonexecutive directors expected presentations internal external advisers devote time necessary proper performance year board briefed various developments duties precise timings given vary year year narrative reporting executive remuneration risk management depending companys activities directors expected board diversity impact uk eu reviews audit attend board meetings additional meetings required market market abuse insider trading shareholder engagement also expected attend meetings committees developments corporate governance reporting members part two audit risk committee including publication september update meetings open directors furtherance risk uk corporate governance code responsibilities strategy sessions make visits board undertook specific training cia going operational sites addition board members invited attend forward board committed refresher training least one cet meeting year may attend certain research year new board member part development executive operational meetings induction programme receive comprehensive training cia board chairmans evaluation sir christopher also meets director annually board carries evaluation performance onetoone basis discuss ongoing training performance committees every year facilitated development requirements externally every third year progress board board composition outcomes evaluation externally facilitated dr tracy long reported action points arising seek build effective complementary board whose evaluation board sid sir robert wilson capability appropriate scale complexity strategic disclosed positioning business process board appointments led nominations committee described pages board entered period change two non executive directors departing two new appointments board believes continues function well well mindful need balance composition board chaired culture open inclusive relations committees refresh progressively time executive directors nonexecutive directors constructive draw upon experience longer serving directors mutually respectful nonexecutive directors tapping new external perspectives insights notably high level confidence executive directors recent appointees bring boards deliberations importantly domineering personalities board nonexecutive directors drawn wide range industries engagement dialogue constructive backgrounds including pharmaceutical healthcare medical gsk unusual welcoming nonexecutive directors attend research academia retail financial services key internal management meetings appreciated appropriate experience complex organisations global reach nonexecutive directors time may give board considerable experience pharmaceutical industry different character peers offers nonexecutive recent appointees bring new approach group directors opportunity witness management interaction boards discussions culture firsthand see issues debated reviewed much greater depth normally possible context board diversity relatively rigid board agenda committed diversity boardroom board balanced gender diversified similarly committed equal opportunities employees internationally levels organisation diversity inclusiveness workforce promoted throughout gsk terms improvement board felt wanted continue focus forward strategy wished spend believe key requirement effective board time business unit strategy competitor analysis pricing regimes comprises range balance skills experience knowledge acquisition strategy emerging issues gender independence individuals prepared challenge well work team needs backed diversity personal attributes including character intellect sound judgement honesty courage gsk annual report corporate governance board keen continue supplement understanding accountability business industry voluntary teachins range topics including specific therapeutic areas design phase iii internal control framework trials pricing biopharmaceuticals pharmacogenomics emerging technology rd board recognises responsibility present balanced understandable assessment groups position prospects chairmen board committees undertook separate evaluations committees outcome board accountability reviewing approving reported discussed respective committee adequacy effectiveness internal controls operated board summary conclusions review included group including financial operational compliance controls respective committee report risk management board delegated responsibility review audit risk committee committee nonexecutive directors led sir robert met separately receives regular reporting aligned assurance programme without sir christopher present discuss performance considered leadership performance overall contribution responsibility management cet high standard implement board policies risk control cet responsible identifying approving monitoring enforcing key policies addition sir christopher met nonexecutive directors go heart group conducts business independently executive directors internal control framework includes central direction resource relations shareholders allocation oversight risk management key activities rd manufacturing marketing sales legal human resources work engage effectively shareholders regular information systems financial practice part communications agm investor relations activities framework financial planning system annual budget approved board results operating units announce financial results quarterly basis annual reported monthly compared budget forecasts results included annual report shareholders receive prepared regularly year annual summary leaflet advises annual report notice annual general meeting available established procedures place identify consolidate website reporting entities control activities include policies practices covering appropriate authorisation approval transactions sir andrew simon dingemans give live presentations application financial reporting standards reviews institutional investors analysts media full year significant judgments financial performance results also available via webcast teleconference first second third quarter results hold webcast extensive financial regulatory operational controls procedures teleconferences audience results available risk activities reviewed groups internal auditors website responsibility risk management control clearly delegated local business units supported regional management investor relations department offices london structure principles designed provide environment philadelphia acts focal point communications investors central leadership coupled local operating autonomy sir andrew simon sir christopher maintain continuous framework exercise accountability control within dialogue institutional shareholders performance plans group objectives programme regular meetings year held individual meetings investors importance attached clear principles procedures designed also hosted approximately group meetings achieve appropriate accountability control group policy investors potential investors risk management legal compliance mandates business units establish processes managing monitoring victoria whyte acts focal point communications risks significant businesses group corporate governance matters also small central corporate responsibility cr team coordinates strategy business units majority global support functions policy development reporting specifically respect cr prepare reports annually collaboration global ethics team communicates socially responsible investors compliance see summarising risk management activities stakeholders reports reviewed relevant risk management compliance board rmcb operation subsequently sir christopher also meets regularly institutional shareholders reported risk oversight compliance council rocc hear views discuss issues mutual importance committee communicates views members board sid nonexecutive directors available meet shareholders remuneration committee chairman chairman head human resources company secretary hold annual meetings major shareholders discuss executive remuneration governance matters briefing process place managed sir christopher nonexecutive directors focus sector specific issues general shareholder preferencesgsk annual report strategic review financial review risk governance remuneration financial statements investor information risk oversight compliance council global approach ensure core compliance elements proactively evaluated common global expectations rocc council senior executives authorised board regardless business area region risk raising assist committee overseeing risk management visibility best practices across compliance programmes internal control activities group membership comprises several cet members company secretary global standard operating procedure approved global heads departments internal control risk management ethics compliance human resources legal business assurance audit compliance responsibilities rocc leaders harmonise coordination conduct tracking reporting chaired head governance ethics assurance communication internal investigations related actual alleged potential infractions laws regulations gsk policy rocc meets regular basis review assess significant code conduct wrongdoing risks mitigation plans provide oversight internal controls ensure compliance applicable laws regulations support new procedure practical guide undertaking internal policies rocc responding group risk investigations implemented significant training programme management legal compliance policy provided business conducted improve technical forensic investigative units framework risk management upward reporting abilities central investigations team additionally new significant risks business unit assigns individual responsibility investigations governance board formed enable management risks inherent business unit analysis trends root cause analyses make enterprise emerging risks mitigation planning identification recommendations executive management remedial individual overall gsk responsibility mandatory enterprisewide action risk management compliance boards global product quality office rmcbs established major business units global product quality office gpqo oversees activities membership often comprises members senior executive gsk quality council gsk qc serves forum team respective business unit augmented specialists escalate emerging risks share experiences handling quality issues appropriate rmcbs oversee management ensure learnings assessed deployed across risks considered important respective business organisation appropriate included reviews units including risks designated significant mitigations regulatory inspections major investigations relating gsk whole thus increasing number risks external suppliers harmonisation company recall procedures actively managed across group gsk qc representation executive quality councils gms vaccines rd together members audit business unit corporate function must periodically review assurance legal rd supply chain leaders provides significant risks facing businesses review generally insight rocc committee product quality matters includes identifying operational risks legal compliance risks risks achievement strategic goals objectives gpqo oversight responsibility developing common reviews scheduled least annually embedded quality standards systems across gsk ongoing within aligned annual planning process ensure review gsks quality management system ensure significant risks identified changes management content reflective detailed requirements direction external environment manufacture pharmaceuticals consumer healthcare products vaccines investigative clinical trials materials providing global ethics compliance applicable appropriate content quality activities commercial local operating companies rocc rmcbs assisted global ethics compliance responsible supporting development audit assurance implementation practices facilitate employees compliance laws group policy audit assurance responsibility independently assessing adequacy effectiveness management significant global ethics compliance provides assistance help employees risk areas reporting outcomes committee line meet high ethical standards comply applicable laws agreed assurance plan internal audit group comprises seven regulations corporate responsibility thrust global principal teams focused following areas ethics compliances efforts promotion ethical behaviour corporate responsibility accordance values due cidcid commercial financial internal audit diligence prevent detect misconduct noncompliance cidcid information technology internal audit laws regulations effective compliance systems cidcid manufacturing internal audit including environment health global ethics compliance led head governance safety sustainability ethics assurance cet member reports directly ceo direct reporting line committee cidcid rd internal audit provides mechanism bypassing executive management cidcid assurance excellence operations need ever arise also chairs rocc provides summary reports roccs activities groups cidcid antibribery corruption significant risks cet committee regular basis cidcid risk management global ethics compliance completed review internal audit activity conducted single organisation global strategy order ensure consistency across business leadership head audit assurance dual units local operating companies compliance strategies committee reporting line head governance ethics developed agreed ensure global alignment inherent risks assurance committee chairman gsk annual report corporate governance audit assurance undertakes continuous process risk monitoring risk effectiveness controls assessment contributes evolution audit strategies internal control framework framework compilation delivery audit schedule approach operation whole year continues operate allows audit assurance respond expeditiously changes date approval report framework assists business risk environment ensure audit identification evaluation management significant risks strategies fitforpurpose internal audit universe audit required uk corporate governance code uk code programmes managed using lead audit group principle designed manage rather eliminate risk achieving business unit aligned audit group business objectives framework provides reasonable coordination management key communications programmes absolute assurance material misstatement loss reviewed approved collectively assurance leadership team schedule endorsed committee committee receives reports areas significant risk group related internal controls following consideration issues control deficiencies identified audit reports received via assurance framework engagements internal audit recommends processes committee reports annually board effectiveness improvement business unit management develops corrective action controls plans address causes noncompliance gaps internal controls plans tracked completion results reported areas business necessary take risks executive management committee achieve satisfactory return shareholders investment rd acquiring new products businesses assurance reporting committee conjunction full board considered assurance reporting committee follows structured reviewed nature extent risks risks programme integrating reporting business units audit associated achieving companys strategic objectives assurance cases objective apply expertise prudent business units global support functions required present management rather elimination risk boards review reports annually rocc committee detailing risk focuses company subsidiaries extend management compliance approach providing assessment material associated undertakings joint ventures status internal controls key risks highlighting investments although considers risk companys significant compliance issues management must oversee risks participation activities considered important respective business units board committee reviewed assessment including risks designated significant group risks internal control framework operates gsk information regarding controls place manage risks considered effectiveness system internal controls provided assure committee risks adequately operation group year covered report managed within internal control framework date approval board process followed addition business unit reporting significant compliance issues board reviewing system internal controls accords internal audit results investigations escalated guidance internal control issued turnbull committee rocc committee earliest opportunity accordance provisions uk code provide board responsible determining nature antibribery corruption extent significant risks willing take achieving antibribery corruption programme abac part strategic objectives board provides oversight ensure response risk bribery corruption builds gsk maintains sound risk management internal control systems values existing standards form comprehensive practical remuneration approach compliance complex risk area programme overseen abac team provide advisory support routine audits risk ensure programmes independence remuneration report describes level regularly audited external firm specialises components remuneration directors set risk area details abac programme available pages website risk management risk management programme extends beyond legal regulatory issues considers overall strategy changes external environment furthermore risk management principles embedded within management practices part business strategy objective setting process head audit assurance acts global risk officer support director risk management risk management responsible maintaining gsks risk management framework supporting business identifying key risks management risks owned business support compliance business partners details risks affecting group see risk cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid legal proceedingsgsk annual report strategic review financial review risk governance remuneration financial statements investor information reports audit risk nominations corporate membership responsibility committees describing activities membership committee together appointment committees year set dates attendance meetings set audit risk committee report attendance full meetings members committee member since judy lewent chairman january april professor sir roy anderson may stacey cartwright april sir deryck maughan january dr daniel podolsky january tom de swaan chairman dear shareholder september december january would like thank predecessor tom de swaan strong sir robert wilson december leadership committee course last six years tom continues serve member committee committees meetings split two parts value wise counsel cidcid part one deals fundamental aspects internal continuing effects uncertain global political economic financial control considers standing items receiving environment make even important maintain sharp focus reports external auditors gsks audit assurance robustness companys internal control compliance team models year global ethics compliance concluded review global strategy led establishment one cidcid furtherance risk responsibilities entire board invited attend part two committees meetings usually compliance single consistent global compliance framework considers developments external risk environment independent business one compliance champion receives legal updates business unit corporate function gsks values seek foster valuesbased decision making across reports reports outcome strategic risk evaluations groups business units local operating companies topical issues committees agenda included usual addition six scheduled meetings committee also met review financial results controls business operations quorate basis five occasions across world management risk well focusing consideration new emerging risks meeting proactive attendees committee meetings include approach taken identification discussion emerging risks regular attends attendee attendee required gsk entered corporate integrity agreement cia chairman cid us department health human services relation ceo cid past sales marketing practices cia company cfo cid building improvements existing compliance programmes chairman global rd vaccines cid committee supported board overseeing general counsel cid scrutinising implementation improvements receipt quarterly cia compliance updates also receives annual financial controller cid training cia compliance obligations head governance ethics assurance cid head audit assurance cid line groups strategy expand deeper company secretary secretary emerging markets members committee visited groups committee cid indian operations delhi pleased opportunity meet locally based executives visit chief medical officer part two cid committee members able gain deeper understanding chief product quality officer cid distinctive business cultural dynamics emerging external auditors cid market learn firsthand risk management embedded main responsibilities operations india role new chair increase understanding cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid group meeting senior executives gsks operations committees oversight role requires address regularly discuss issues brought committee relationships management internal external management also intend continue toms work making auditors understand monitor reporting relationships committee visible groups employees deepen tiers accountability knowledge internal control assurance framework committee receives regular reports members cet working cet members connecting network senior managers covering key risk management compliance compliance officers activities group including covering rd manufacturing sales marketing corporate functions details reporting framework committee set pages judy lewent accountability audit risk committee chairman gsk annual report corporate governance committee also reviews quarterly results group external auditors prepared management considers reports key committee primary responsibility oversight accounting issues external auditors includes deciding whether seek committee reviews terms reference annual basis retender audit making recommendation shareholders revised december reflect corporate appointment reappointment removal external governance best practice developments auditors assessing annual basis qualifications expertise resources independence effectiveness committee worked structured programme previous audit process activities standing items committee required consider meeting together matters timed effectiveness external auditors coincide key events annual financial reporting cycle evaluating effectiveness audit process prior making external auditors reported critical accounting policies recommendation reappointment external auditors significant judgements practices used committee reviews effectiveness performance group alternative accounting treatments criteria agrees conjunction management discussed management beginning years audit resultant conclusion material written part process committee considers feedback communications management prior years external audit gathered client satisfaction restrictions access information survey facilitated auditors client service review team cfo reported financial performance independent engagement team undertook audit group technical financial accounting work survey seeks feedback financial management matters team corporate business unit level reviewed feedback provided committee satisfied effectiveness general counsel reported material litigation external audit process recommend reappointment auditors forthcoming agm company secretary reported corporate governance securities disclosure practices details current criteria judging effectiveness external auditors set heads audit majority heads groups assurance reported audit scope annual coverage cidcid deliver smoothrunning thorough efficiently executed audit groups compliance audit resources results audits audit groups conducted year cidcid provide accurate uptodate knowledge technical issues timely basis company secretary reported matters affected quality cidcid serve industry resource communicating best practice chair timely disclosure financial material industry trends reporting disclosure information board public markets committee shareholders enabled committee cidcid adhere independence policies including gsks policies review clarity completeness isa uki sec requirements disclosures published annual financial statements interim reports quarterly cidcid deliver focused consistent audit approach globally preliminary results announcements reflects local risks materiality formal announcements relating financial cidcid liaise gsks audit assurance function avoid duplication performance prior approval board work head audit reported progress gsks global cidcid provide consistency advice levels assurance assurance plan review assurance significant risk throughout group fee review see sarbanesoxley act agreeing audit fee proposed external auditors reviewed management committee considers cost qualifications audit risk committee members comparisons ensure fair appropriate gsk details members financial accounting scientific experience contractual obligations restrict committees cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid capacity recommend particular firm external auditor group committee independence qualifications committee management internal auditors full board work together ensure quality companys corporate making assessment committee considers papers accounting financial reporting committee serves detail relevant uk legislative regulatory professional primary link board external internal requirements relating external auditors evaluates reports auditors facilitates necessary independence external auditors compliance management encourages external internal auditors requirements safeguards established communicate freely regularly committee internal quality control procedures committee met collectively separately consideration also given committee need include external auditors head audit assurance risk withdrawal external auditors market head governance ethics assurance without members risk evaluation planning management present judy lewent tom de swaan also members remuneration committee allows provide input committees review groups performance oversight risk factors relevant remuneration mattersgsk annual report strategic review financial review risk governance remuneration financial statements investor information audit partner rotation possible accounting firms engaged undertake nonaudit services external auditors required rotate audit engagement partner every five years current audit partner commenced cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid position audit gsks financial statements concluded robust review process committee together involvement ceo cfo select replacement committee approved appointment new audit engagement partner effect financial year commencing january audit firm tendering pricewaterhousecoopers llp remained place auditors since groups inception december audit contract put tender period performance reviewed annually committee since time part review implications end current audit partners five year term committee considered appropriateness putting place tender audit assurance services process included assessing frcs recent guidance services including tax regulatory compliance subject level change currently underway inside treasuryrelated services group improvements auditors services including fee levels proposed auditors review concluded tender companys interests time committee code conduct reporting lines consequently approved appointment new audit partner however committee agreed issue reviewed also number well established policies including code regularly part annual appointment process conduct available website confidential reporting lines reporting investigation unlawful nonaudit services conduct waivers code conduct made sarbanesoxley act prohibits engagement committee evaluation external auditors provision certain services legal actuarial internal audit outsourcing financial information committees annual evaluation carried systems design external auditors permitted committee chairman concluded committee continued provide nonaudit services committee ensures auditor operate effectively particular committees agendas objectivity independence safeguarded policy requiring thought comprehensive helpful presentations preapproval committee services total fees area business rolling basis addressed risk audit nonaudit work exceed audit fee except concerns committee felt provided solid framework special circumstances would clear advantage within could continue operate effectively fulfil role companys auditors undertaking additional work terms enhancements committees deliberations services may include audit auditrelated tax services committee members felt would helpful find additional time preapproval detailed particular service categories apply greater focus particular issues pipeline risk service subject specific budget vaccines clinical practices local regulatory requirements provision nonaudit services agreed business assurance reports could simplified clear focus key risks management guidelines set groups policy engaging presentations committee focused risk external auditors provide nonaudit services include cidcid ascertaining skills experience external auditors make suitable supplier nonaudit services cidcid ensuring adequate safeguards place objectivity independence group audit threatened compromised cidcid ensuring fee levels exceed annual audit fee external auditors management report regularly committee regarding extent services provided accordance preapproval fees services performed committee may also preapprove additional services casebycase basis fees paid companys auditor cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid financial statements operating profit gsk annual report corporate governance nominations committee report fulfilment specific observations made recent external evaluation board committee search process new nonexecutive directors replace retiring nonexecutive directors gave priority candidates global ceo experience andor knowledge experience emerging markets egon zhender mwm specialise recruitment high calibre executives nonexecutive directors engaged ensure widest possible pools nonexecutive candidates available select egon zhender good sir christopher gent understanding gsks business also assists identification nominations committee chairman talented individuals fill executive roles group dossier potential nonexecutive appointees considered membership committee candidates shortlisted interview membership nominations committee committee merit objective criteria assessing relevant together appointment dates attendance meetings qualifications time commitments set interviewing suitable candidates committee pleased recommend board lynn elsenhans jing ulrich attendance full meetings potential nonexecutive directors appointed members committee member since board effect july board considered sir christopher gent appointments together appointment chairman since hans wijers join board april achieved january december aim appointing candidates either deep knowledge emerging markets experience running global company professor sir roy anderson october sir crispin davis july currently intended sir christopher step sir deryck maughan july chairman end committee therefore tom de swaan october commenced search successor sir robert wilson cidcidcidcidcidcidcidcidcidcidcidcidcid board committee changes larry culp cidcidcidcidcidcidcidcidcidcidcidcidcid committees proactive approach refreshment larry culp resigned board september board resulted orderly changes composition addition four scheduled meetings committee met board committees changes detailed quorate basis two occasions james murdoch stand reelection agm may attendees committee meetings may include larry culp decided step board september almost nine years service sir crispin davis regular attends stand reelection agm nine years service attendee attendee required given number recent appointments two long chief executive officer cid standing board members stepped board head human resources cid may sir robert wilson agreed stand reelection company secretary secretary shareholders one year stepping committee cid board agm sir robert significant knowledge appropriate external advisers cid gsks business affairs provide continuity new board members settle roles board confirmed sir robert continues demonstrate characteristics main responsibilities independence carrying role sir robert succeeded cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid sir deryck maughan senior independent nonexecutive director effect closure agm may work committee tom de swaan succeeded sir crispin davis chairman appointment new nonexecutive directors remuneration committee judy lewent succeeded tom de swaan chairman audit risk committee january committees particular area focus tom member remuneration committee search new nonexecutive directors refresh board since may continue member audit advance planned retirements longserving board members risk committee following judys appointment judy member audit risk committee since april recruiting nonexecutive directors committee evaluates particular skills knowledge independence experience tom de swaan professor sir roy anderson appointed diversity including gender would benefit balance nominations committee lynn elsenhans appointed board appropriately appointment corporate responsibility committee effect october judy lewent appointed member search process broad selection criteria generally used remuneration committee january dr stephanie focus achieving balance continental european burns appointment remuneration committee take effect uk us emerging markets experience board may finally jing ulrich appointed join individuals expertise capabilities developed various audit risk committee effect may sectors specialities date professor sir roy anderson step audit risk committeegsk annual report strategic review financial review risk governance remuneration financial statements investor information cet succession corporate responsibility committee report terms executive succession planning committee also recommended appointment christophe weber roger connor cet may september president vaccines president designate global manufacturing supply gms respectively christophe weber joined company held increasingly senior commercial positions including chairman ceo gsk france senior vice president regional director asia pacific appointed president designate vaccines january subsequently assumed role president sir christopher gent vaccines may corporate responsibility committee chairman cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid membership worked number roles within finance manufacturing strategy appointed site director gms site barnard membership corporate responsibility committee committee together appointment dates attendance cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid strategy february assisted ceo various meetings set projects ensure orderly succession gms roger attendance appointed president designate gms effect january full meetings assumed role president gms january members committee member since advance david pulmans retirement gsk sir christopher gent committee evaluation chairman january december annual evaluation committees effectiveness dr stephanie burns december undertaken chairman responses shared lynn elsenhans october committee concluded committee continued dr daniel podolsky july operate effectively committee successfully addressed james murdoch may actions previous years review appointment lynn elsenhans jing ulrich mapped optimum james murdoch retired board may composition board future committees next challenge select suitable candidates roles identified attendees committee meetings may include regular attends attendee attendee required chief executive officer cid chairman global rd vaccines cid general counsel cid head governance ethics assurance cid head global communications cid head global corporate responsibility cid company secretary secretary committee cid executives cid main responsibilities main responsibilities corporate responsibility committee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid committee rolling agenda receives reports members cet senior managers ensure progress meeting gsks corporate responsibility cr principles reviewed committee annually reviews progress following five cr principles cidcid access medicines cidcid standards ethical conduct cidcid research innovation cidcid employment practices cidcid community investment gsks cr principles discussed least every two years committee also reviews approves corporate responsibility report gsk annual report corporate governance work committee work committee committee focused attention several issues committee move review progress gsks including corporate responsibility cr commitments across four core themes reflect important issues responsible gsks cr principles committees area focus sustainable business growth access medicines rd investment including diseases cidcid health innovating address currently unmet health developing world open innovation needs improving access products irrespective strategy people live ability pay controlling eliminating new business models performance diseases affecting worlds vulnerable people including developing countries cidcid behaviour putting interest patients consumers middleincome countries viiv first driven values everything backed healthcare robust policies strong compliance processes developing health systems future developing world cidcid people enabling people thrive develop individuals deliver mission access challenges performance europe usa cidcid planet growing business reducing environmental impact across value chain standards ethical patient first incentive compensation conduct programme selling competency model committee evaluation embedding ethical values annual evaluation committees views effectiveness organisation undertaken chairman responses shared reinforcing valuesbased decision making committee concluded committee continued business operate effectively part review agreed research innovation replacement refinement reduction terms reference committee programme would updated use animals research development reflect four core themes cr addition meeting would added committees annual programme conduct public disclosure clinical research transparency detailed data behind trial results scientific engagement ensuring distinction scientific dialogue promotional activity business enhancing assessment safety effectiveness medicines employment practices organisational change employee relations human rights inclusion diversity leadership employee development employee health safety wellbeing community investment reinvestment profits made least developed countries back healthcare infrastructure pulse volunteering programme social impacts supply supplier standards working practices chain diversity energy water waste reduction programmes gms environmental performance suppliers product formats including sustainable packaging reducing inhaler propellant childresistant packaginggsk annual report strategic review financial review risk governance remuneration financial statements investor information remuneration report dear shareholder chairman gsks remuneration committee committee pleased present remuneration report seeking approval agm may behalf committee want thank predecessor sir crispin davis strong leadership committee last three half years developing current executive remuneration structure feel current structure strikes good balance motivating retaining executives time incentivising deliver longterm sustainable returns shareholders executive remuneration economic remuneration environments continued evolve accordingly made number adjustments certain aspects executive remuneration arrangements ensure remain appropriate gsk longterm interests shareholders onwards capped increases pensionable earnings within legacy uk defined benefit pension schemes per annum participants including executives limit gsks overall future liabilities schemes response undertakings within corporate integrity agreement cia us federal government strengthened deferral mechanism clawback ability executives senior us staff details set annual report given current external environment committee decided would appropriate award executive directors salary increases increases line average salary increases uk us employees across business year committee reviewed competitiveness executives pay result review committee decided would appropriate increase maximum reward opportunity cfo simon dingemans performance share plan psp base salary position total remuneration competitively uk peers also reflects increased experience role bring psp opportunity line predecessor performance executive annual bonus awards values earned longterm incentive lti plans lower reflected challenging operating environment particularly europe outlook group significantly worsened year despite management delivered strong sales performance emerging markets consumer healthcare adjusting disposal noncore otc brands growth businesses addition delivery cost financial efficiencies helped group maintain core eps constant exchange rates return billion shareholders committee also recognised continued strong output rd six key new products filed regulators since january unprecedented level productivity group agenda course committee continue keep structure remuneration arrangements review prepare new executive remuneration reporting requirements introduced uk continue committed regular dialogue shareholders hold annual meetings gsks largest investors later listen feedback remuneration policy tom de swaan remuneration committee chairman march gsk annual report remuneration report total remuneration value earned base salary benefits annual bonus longterm total incentive remuneration awards pay performance total remuneration current executive directors set table dr moncef slaoui sir andrew witty simon dingemans chairman ceo cfo global rd vaccines total total total total total total salary benefits pay performance annual bonus including amount deferred see value earned lti awards deferred annual bonus plan na na na na na performance share plan na na share option plan na na sharesave na na total remuneration number number number shares shares ads deferral annual bonus amount deferred number shares ads purchased maximum matching award full details elements total remuneration given following pages report details pay performance details base salary pages annual bonus pages benefits pages investment bonus deferred annual bonus plan see table pages value earned lti awards deferred annual bonus plan pages performance share plan pages share option plan pages sharesave pages notes performance periods dr moncef slaouis simon dingemans first awards deferred annual bonus plan dabp end december december respectively earliest periods remuneration recorded dabp therefore year ending december dr moncef slaoui year ending december simon dingemans performance period simon dingemans first award performance share plan ends december earliest period remuneration recorded simon dingemans plan therefore year ending december matching award subject performance targets maximum number shares ads shown matching award include dividends reinvested performance period details pensions accrued date executive directors given pages gsk annual report strategic review financial review risk governance remuneration financial statements investor information pay performance annual bonus annual bonus based following performance targets executive director financial performance personal performance sir andrew witty core group operating profit core group profit simon dingemans individual objectives interest tax dr moncef slaoui rd performance vaccines performance performance targets financial core group operating profit core group profit interest tax performance presented challenging operating environment austerity measures europe including price cuts generic substitution despite stretch targets set year committee levels achieved core group operating profit core group profit interest tax threshold target reflects strong sales growth emerging markets asia pacific japan excluding adverse comparison cervarix prior year consumer healthcare business adjusting disposal noncore otc brands well effective cost control financial efficiencies rd vaccines performance targets year around pipeline growth value exceeded since january six new products filed approval phase iii data expected new assets next two years including nine new drugsvaccines next three years potential launch new assets gsk track deliver target longterm rate return rd spend table sets matters committee considered respect individual objectives set executive director personal ceo performance sir andrew showed strong leadership resilience challenging operating environment conditions europe deteriorated secure flat year year sales excluding disposals counter otc products growth across emerging markets asia pacific japan excluding cervarix consumer healthcare business adjusting disposal noncore otc brands positive cash generation operations disposal noncore otc products enabled billion returned shareholders dividends billion shares repurchased billion ongoing us federal government investigations us department health human services concluded signing corporate integrity agreement sir andrew strengthened core business acquisitions investments completing three significant transactions hgs shionogi theravance increase gsks share key future growth assets year sir andrew also continued advance groups leadership position corporate responsibility issues including action increase transparency clinical research improve access medicines gsk ranked first position prestigious access medicines index sir andrew recommended appointments successors two key corporate executive team roles board subsequently approved appointment roger connor new president global manufacturing supply christophe weber new president vaccines cfo one simon dingemans main objectives implement groupwide cost control financial efficiencies delivered contributing significantly towards overall performance enabling gsk maintain core earnings per share constant currency basis also achieved reductions effective core tax rate meeting targeted rate two years ahead expectations simon drove continued delivery operational excellence restructuring programme delivered approximately billion annual savings remains track deliver billion annual savings also made good progress towards improving groups funding profile net finance expenses year broadly similar million despite increase net debt billion chairman global rd vaccines dr moncef slaoui led rd vaccines successful year rd exceeded pipeline development value targets year detailed also designed implemented effect january new integrated way working rd parts business create strong global product launch capability gsks pipeline new medicines moncef also worked closely christophe weber transitioned successfully new role president vaccines gsk annual report remuneration report pay performance continued value earned longterm incentive awards deferred annual bonus plan structure award granted sir andrew witty performance level achieved three years ended december set award vesting performance measure award performance achieved maximum award relative tsr gsks tsr rank position th comparator group pharmaceutical years companies gsk companies total vested respect performance share plan structures awards granted executives performance levels achieved three four year periods ended december set award vesting performance measure award performance achieved maximum award relative tsr gsks tsr rank position th comparator group pharmaceutical years companies gsk companies total vested respect total vested respect total vested award award vesting adjusted free cash adjusted free cash flow three years billion included flow adjustments number material distorting items including legal settlements favourable exchange rate movements special pension contributions relative tsr gsks tsr rank position th comparator group pharmaceutical years companies gsk companies total vested respect relative tsr performance maintained line three years gsks tsr years rank position would th using revised pharmaceutical comparator december group gsk nine companies set would threshold vesting level set revised vesting schedule potential total vesting award share option plan share option plan awards granted executives split two elements dependent performance three year period ended december performance four year period ended december vesting performance measure award performance achieved maximum award comparison gsks annualised eps growth threshold vesting level growth compound annual rpi plus increase eps increase rpi years total vested respect total vested respect total vested award gsk annual report strategic review financial review risk governance remuneration financial statements investor information remuneration policy table summarises committee sets remuneration members cet executives key elements remuneration including requirement hold minimum levels shares gsk principal pension arrangements committee reviews total remuneration executive executives comparable committee sets companies focus local rather global comparisons committee aims ensure total remuneration remuneration levels competitive set reference median appropriate comparator group balance fixed elements pay performance carefully considered overall packages weighted heavily towards latter fixed pay base salary salaries reviewed annually data relevant comparator groups influenced cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid benefits principally healthcare car personal financial advice life assurance relevant cash lieu money purchase pension contribution secondment travel expenses pay performance safeguards clawback mechanism incorporated annual bonus award process existing mechanism risk extended terms cia committee retains discretion reduce grant vesting management levels performance awards appropriate annual bonus target maximum bonus targets opportunities executive cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid directors follows financial targets core groupbusiness unit operating profit core target maximum group profit interest tax agreed board committee salary salary ceo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cfo chairman global rd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid vaccines cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid deferred annual individuals must invest cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid bonus plan may invest total four equally weighted performance measures dabp bonus earned cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid deferred bonuses may matched cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid oneforone subject performance cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid criteria relative tsr performance performance share awards vests threshold rising stretching performance exceeding share plan executive directors follows set threshold specified margin psp comparator group comprising gsk nine pharmaceutical salary companies vesting threshold rising vesting upper ceo quartile performance cfo chairman global rd vaccines share ownership align interests executives shareholders executives required build maintain significant requirements holdings shares gsk cidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pensions uk executives gsk operates defined contribution plan uk executives participating defined contribution plan benefit company contributions base salary plus matched contributions base salary certain executives members legacy final salary plans closed new entrants since increases pensionable earnings limited per annum limit applies employees including executives legacy final salary plans uk us executives gsk operates cash balance pension plan us plan us retirement savings plan rsp k savings scheme executive supplemental savings plan essp savings scheme open executives accrue benefits us government limits imposed rsp us executives participating us plan benefit contributions base salary rsp essp benefit contributions plus matched contributions total base salary bonus less bonus deferred dabp gsk annual report remuneration report estimates total future potential remuneration remuneration packages tables provide estimates potential total future remuneration executive directors respect remuneration opportunity granted range potential outcomes provided executive director sir andrew witty ceo total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum simon dingemans cfo total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum dr moncef slaoui chairman global rd vaccines total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum assumptions underlying scenario outlined scenarios cidcid benefits estimated based upon actual amounts received respect totals include items required included taxable benefits including related carrying executive directors role secondment expenses cidcid executive director assumed defer annual bonus maximum permitted amount matching award shown dabp reflects amount shown dabp reflects matching award amount bonus deferred individual included annual bonus cidcid amounts shown dabp psp based bonus amounts relevant multiples salary respectively include amounts respect dividends reinvested performance periods actual amounts recorded remuneration dabp psp respectively calculated using share ads prices vesting dates include amounts respect related dividends reinvested relevant performance periods cidcid dabp psp subject performance measures three year periods respectively threshold cidcid none pay performance would payable threshold cidcid minimum levels pay performance would payable assumed performance executive director would result individual performance multiplier therefore increase financial performance element bonus cidcid threshold levels vesting awards dabp psp discussed detail maximum cidcid assumed annual bonus payable maximum percentages set awards dabp psp vest full remuneration granted recorded follows earned awarded recorded remuneration respect annual report salary benefits annual bonus dabp bonus deferred psp gsk annual report strategic review financial review risk governance remuneration financial statements investor information committee sets remuneration reviewing ceos remuneration primarily set reference uk crossindustry comparator group committee gives consideration remuneration policy levels committee also referenced pay group european wider employee population group well ensuring companies selected based size complexity remuneration consistent industry broader market norms committee sets total remuneration reference case committees review ceos median level executives pay comparator group proposed remuneration continued identify competitive benchmarking total remuneration following principal elements gap relation global pharmaceutical european considered crossindustry groups highlighted diagram cidcid base salary summary total package competitive positioning cidcid annual bonus comparison purposes assumed ceo company achieves target performance total remuneration based benchmarking criteria cidcid dabp psp awards assumed awards vest maximum amount dabp assumed executive chooses defer maximum annual bonus committee also considers pension arrangements significant proportion executives total remuneration package based pay performance particular emphasis longterm sharebased incentives closely align executives interests shareholders balance fixed pay pay performance elements remuneration varies depending performance committee uses two primary pay comparator groups uk crossindustry global pharmaceutical comparator group comparator group anglo american france sanofi uk crossindustry global pharmaceutical european crossin dustry astrazeneca switzerland novartis group group group barclays roche holdings lower quartile median median upper quartile bg group uk astrazeneca previous position new position bhp billiton usa abbvie bp amgen fixed pay british american tobacco bristolmyers squibb diageo eli lilly base salary hsbc johnson johnson reckitt benckiser merck base salaries set reference relevant rio tinto pfizer comparator group level considered appropriate royal dutch shell secure retain talent needed deliver gsks standard chartered strategic priorities salary levels reviewed annually tesco influenced wider pay environment unilever executives role experience performance vodafone committee considers prevailing economic conditions abbott laboratories included global pharmaceutical comparator market competitiveness executives package group january abbott laboratories separated two publicly traded companies going forward anticipated abbvie positioning relativities pay across broader gsk workforce researchbased pharmaceuticals company included remuneration average salary increases employees benchmarking group included tsr comparator group executive directors approximately uk usa amgen included remuneration benchmarking included tsr comparator group committee decided give executive directors salary noted table global pharmaceutical increases line average salary increases sir andrew comparator group also used basis tsr comparator witty simon dingemans dr moncef slaoui received group features longterm incentive awards base salary increase committee decided onwards exclude abbvie table sets base salaries executive directors well amgen tsr comparator group last three years since appointment board undertake full review constituents group salaries salary increases typically take effect first year quarter year primary pay comparator group executive directors shown table base salary change primary pay comparator group sir andrew witty uk global simon dingemans na director crossindustry pharmaceutical dr moncef slaoui sir andrew witty cid simon dingemans cid simon dingemans joined board january dr moncef slaoui cid gsk annual report remuneration report benefits financial measures bonus threshold target maximum payable achievement executives receive benefits including healthcare car target bonus threshold reflects stretching nature personal financial advice life assurance matching shares bonus targets sharereward plan measures executive director set simon dingemans accumulating benefits gsks pension plans receives cash lieu money purchase personal pension contribution executive director financial performance performance dr moncef slaoui seconded uk november sir andrew witty core time intended secondment would group operating period two years course emerged simon dingemans profit individual core group business need remain uk objectives dr moncef slaoui rd profit coming year oversee implementation new performance interest tax integrated way working rd parts vaccines business create strong global new product launch capability performance gsks pipeline new medicines length secondment remain review line senior gsk expatriates ceo receives appropriate secondment travel expenses individual performance objectives sir andrew witty set cash value benefits received executive directors board january year board focuses shown strategic priorities developed group pay performance set reasons commercial sensitivity specific objectives kept confidential following end financial year board reviews performance generally safeguards risk management set objectives determine appropriate bonus committee believes payment performance payable performance specifically committee want reward failure chairman global rd vaccines views important incentive payouts made circumstances performance outcomes reflect bonus measures rd employees including dr moncef slaoui genuine achievements original targets linked pipeline performance robust governance structure established ensure bonus payable fairly reflects given nature gsks business increased focus risk rd productivity performance well achievement within group committee taken number steps profit targets performance targets reviewed rd ensure performance related pay underpins effective risk bonus compensation review committee includes management sir andrew witty companys two designated scientific cidcid chairman audit risk committee provides input expert nonexecutive directors professor sir roy anderson audit risk committees review groups performance dr daniel podolsky oversight risk factors relevant remuneration executives decisions ceo sets individual objectives executives line cidcid terms cia existing clawback mechanism company strategy makes recommendations committee strengthened extensions mechanism include regarding performance objectives end effect annual bonus payable year recommendations considered committee executive directors cet members required determines level bonuses payable defer minimum annual bonus dabp separate recoupment committee also established ontarget maximum bonuses executive investigate relevant claims misconduct directors given table cidcid also safeguards relating business ontarget bonus maximum specific performance measures lti plans set base salary base salary detail sir andrew witty cidcid longterm incentive awards good leavers normally vest simon dingemans end original vesting period rather year dr moncef slaoui departure ensures continued alignment shareholders table sets bonuses earned executive interests following cessation employment directors last three years since appointment annual bonus annual bonus designed drive achievement sir andrew witty gsks annual financial strategic business targets simon dingemans na delivery personal objectives dr moncef slaoui majority annual bonus opportunity based formal simon dingemans appointed board january review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multipliergsk annual report strategic review financial review risk governance remuneration financial statements investor information longterm incentive plans performance measures longterm incentives take form maximum number shares focus committee improve award number shares received executive depends alignment executive remuneration arrangements performance performance period key strategic priorities provide closer link shareholder returns payments consultation shareholders dabp psp executives notional dividends reinvested paid awards made executives comprise two businessspecific proportion shares earned performance measures business diversification performance rd new product performance together adjusted free deferred annual bonus plan cash flow relative tsr deferred annual bonus plan encourages longterm board recognises possibility companys goals shareholding discourages excessive risk taking helps may evolve time therefore committee intends review focus gsks key strategic priorities performance measures periodically ensure remain appropriate annual bonus earned may deferred shares ads appropriate three years company match details performance measures targets performance shares ads oneforone depending companys thresholds longterm incentive awards given performance measures outlined table set three year performance period safeguards vesting levels participation last three years executive directors shown table together maximum addition setting robust targets committee also matching awards granted respect deferrals implemented number safeguards ensure targets met bonuses sustainable way performance outcome reflects genuine achievement original targets therefore represents delivery value shareholders total bonus deferred matching executive director award performance measure impact acquisition sir andrew witty shares divestment quantified adjusted event simon dingemans na shares major adjustment calculation performance measures dr moncef slaoui ads disclosed shareholders vesting terms cia awards made beyond table sets principal safeguards executives required defer bonus earned performance measures shares ads appropriate three years may also choose invest bonus earned ie performance measure safeguards vesting maximum business diversification cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid performance opportunistic events eg pandemics unless performance share plan committee considers add shareholder value provided performance share plan ensures focus delivery underlying performance sufficiently gsks strategic priorities longterm shareholder positive returns relative pharmaceutical companies cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid performance share plan awards made vest reduced market growth depending companys performance three year achieved performance period measures outlined rd new product cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid limit six times base salary maximum initial value performance made period towards performance shares may granted individual gsks target return rd investment one year cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid table shows award levels opportunistic events eg pandemics unless executive director line policy committee considers add shareholder value provided award level award level award level underlying performance sufficiently positive base salary base salary base salary award adjusted free cash flow cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid sir andrew witty may include exchange rate movements major shares legal taxation settlements special simon dingemans pension contributions shares dr moncef slaoui ads sir andrew wittys psp awards subject year vesting period years total additional performance criteria apply period gsk annual report remuneration report performance targets inevitably measures linked directly strategy commercially sensitive particular committee consider appropriate disclose targets business diversification performance rd new product performance grant may result competitive harm however targets disclosed fully remuneration report end performance period together details extent met committee also undertaken provide updates achievements date targets performance period performance targets set table awards made onwards dermatology removed separate category business diversification performance measure dermatology brands commercialised within pharma consumer healthcare regional organisations much focus business emerging markets principal contribution dermatology continue captured within emerging markets consumer healthcare japan elements diversification measure strategic objectives longterm incentive measures awards award vesting schedule awards grow business diversification performance incentivises growth global diversified business designed focus turnover major proportion cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid award emerging markets asia pacific japan achievement available threshold pharmaceuticals businesses excluding vaccines threshold aggregate revenue target business maximum divisions threeyear performance period reflect strong growth previous periods market growth deliver rd new product performance recognises importance rd future maximum business growth expressed measure threshold revenue target based new product sales business diversification incentivise better rd performance new performance products defined products launched performance period two preceding years rd new product therefore performance period performance products launched years included measurement aggregate threeyear revenue target awards new product sales reflect growth historic performance simplify adjusted free cash flow recognises importance effective working three year capital cash management adjusted free reductions targets reflect number cash flow targets vesting factors including adjustment loss threshold certain product sales recur including threshold billion number older genericised brands revised billion expectations performances european billion businesses higher levels capital maximum billion investment working capital required commercialise product pipeline relative tsr proportion vesting focuses delivery value shareholders relative tsr using comparator group comprising gsk nine global pharmaceutical companies relative tsr measured three years using twelvemonth averaging period tsr measured local currency tsr rank position upper quartile performancegsk annual report strategic review financial review risk governance remuneration financial statements investor information historical vesting gsks ltis following table shows vesting levels gsks deferred annual bonus performance share share option awards executives since tsr vesting percentage indicates gsks relative tsr performance median comparator group performance period deferred annual bonus plan performance share plan share option plan vesting vesting vesting vesting adjusted free tsr tsr cash flow total eps year measure measure measure vesting measure grant performance period na na na na na na na na na psp awards made included respect relative tsr respect adjusted free cash flow three year performance period remaining respect relative tsr four year performance period ending december assessed next year allemployee share plans share ownership requirements executives participate various allemployee share plans align interests executives either uk usa including sharereward sharesave shareholders executives required build sharereward plan uk hm revenue customs approved maintain significant holdings shares gsk time plan open uk employees terms participants current share ownership requirements sor set table contribute month gross salaries purchase gsk shares company matches number gsk shares bought month arrangement sir andrew witty share ownership requirement simon dingemans contribute month buy shares ceo x base salary sharereward plan executive directors x base salary sharesave plan uk hm revenue customs approved cet members x base salary plan open uk employees participants may save month net salaries fixed term three years shareholdings purpose sor march end savings period option buy gsk achievement sor based upon average share price shares discount market price set working days preceding date launch savings contract sir andrew witty simon holdings sor dingemans make monthly contributions sharesave plan purposes increase achievement dilution limits december march shareholding sor awards made plans incorporate dilution limits sir andrew witty consistent guidelines provided association british simon dingemans insurers limits rolling ten year period plans rolling ten year period executive share plans dr moncef slaoui estimated dilution existing awards made last years executives required continue satisfy shareholding december follows requirements minimum twelve months following retirement company actual limit actual limit gsk employee share plans executive share plans gsk annual report remuneration report pensions us pension arrangements pensions provide important tool creating longterm usa gsk operates cash balance pension plan provides annual contribution interest sum culture loyalty accumulated cash balance account contractual executives participate groups senior executive pension promise provide specific levels retirement income plan plans pension arrangements structured accordance incorporates executive pension credit senior us executives plans operated executives country contribution rates plan range likely retire details individual arrangements executive base salary depending grade current senior us executives directors set pages eligible executive pension credit new executives eligible participate either defined capped employees usa benefits cap contribution scheme uk depending personal provided unfunded nonqualified plan circumstances relevant tax restrictions cash balance gsk also operates us retirement savings plan rsp k pension plan usa savings scheme open us employees executive existing obligations legacy defined benefit schemes supplemental savings plan savings scheme open executives uk continue honoured accrue benefits us government limits imposed rsp contributions plans invested range funds uk pension arrangements value accumulated funds paid leaving company combined contribution rates plans company currently operates defined contribution plan plus matched contributions legacy final salary plans closed new entrants total base salary bonus less bonus deferred executives participating defined contribution plan receive dabp company contribution base salary also opportunity receive matched contributions line policy members pension plan since uk government announced series changes taxation pensions continue impact pensions employees within gsk taxation changes significant negative consequences effectiveness pensions much reduced pensions continue important tool creating longterm culture promoting employee retention therefore committee decided existing pension promises would honoured employees pensions impacted changes would opportunity pension new limit delivered via gsks existing unfunded scheme time legacy final salary plans provide twothirds final salary normal retirement age plans actuarial reduction factors apply participant leaves employment accord age effect april cap pensionable earnings introduced limits pensionable earnings increases per annum cap applies employees including executive directors legacy defined benefit schemes ukgsk annual report strategic review financial review risk governance remuneration financial statements investor information update performance ongoing awards following introduction lti performance measures directly linked gsks strategic objectives committee undertook provide update performance outstanding lti awards noted actual vesting levels determined based performance full three year performance periods interim positions provided regarded indication management performed date regarded predictions final vesting levels awards performance period december committee reviewed performance deferred annual bonus plan performance share plan awards granted executive directors performance achieved two years december follows estimate likely vesting based performance date strategic performance maximum total objectives measures award performance achieved date vesting award grow business sales across vaccines consumer heathcare dermatology diversification emerging markets asia pacific japan billion performance continued level would deliver vesting threshold maximum detailed update performance provided annual report sets details performance deliver rd new performance target award measures sales new product rd products launched basis total sales performance billion continued level would deliver performance threshold vesting detailed update performance provided annual report sets details performance simplify adjusted free target range aggregate threeyear adjusted free cash cash flow flow billion threshold vesting billion maximum vesting based performance measure definition adjusted free cash flow billion continued level would deliver vesting threshold maximum relative tsr period january december gsks tsr ranked th using revised pharmaceutical comparator group gsk nine companies set ranking position remains level would deliver vesting revised vesting schedule set threshold maximum potential total vesting awards vesting schedules performance criteria given pages report levels performance measure maintained end performance period december vesting awards would shown however performance measured end three year period performance date necessarily indication final vesting level committee reviewed performance two year period remains view targets awards new measures remain suitably robust stretching actual targets together details extent met disclosed full time vesting gsk annual report remuneration report awards performance period december committee reviewed performance deferred annual bonus plan performance share plan awards granted executive directors performance achieved year december follows estimate likely vesting based performance date strategic performance maximum total objectives measures award performance achieved date vesting award grow business vaccines diversification cervarix sales lower benefited hpv performance vaccination catchup programme japan complete led overall decline vaccines sales billion excluding cervarix vaccines sales performed well increasing increase driven strong sales infanrixpediarix rotarix boostrix synflorix consumer healthcare consumer healthcare sales flat year billion excluding noncore otc brands divested sales increased reflecting strong growth across oral care nutrition total wellness partly offset small decline skin health regional basis growth europe flat growth usa growth rest world emerging markets asia pacific japan excluding vaccines dermatology emerging markets asia pacific pharmaceuticals businesses excluding vaccines dermatology sales billion year representing strong growth respiratory combined good performance number established brands newer oncology business japan sales excluding vaccines dermatology billion japan pharmaceuticals sales grew strong performances recently launched products lamictal avodart volibris partly offset impact mandatory biennial price cut increasing generic competition paxil dermatology sales dermatology declined million primarily result decline usa suffered impact generic competition evoclin extina duac emap sales grew million reflecting strong growth promoted brands dermovate bactroban emap performance continued impacted ongoing supply issues close resolution overall performance continued level would deliver vesting threshold maximum deliver rd new performance target awards measures sales new rd product products launched basis sales new products performance billion includes strong sales votrient duodartjalyn promacta lamictal xr gsk track deliver target longterm rate return rd spend overall performance continued level would deliver vesting threshold maximum simplify adjusted free awards target range aggregate threeyear adjusted cash flow free cash flow billion threshold vesting billion maximum vesting based performance measure definition adjusted free cash flow period billion performance continued level would deliver vesting threshold maximum relative tsr period january december gsks tsr ranked th using revised pharmaceutical comparator group gsk nine companies set ranking position remains level would deliver vesting revised vesting schedule set threshold potential total vesting awards vesting schedules performance criteria given pages report levels performance measure maintained end performance period december vesting awards would shown however performance measured end three year period performance date necessarily indication final vesting level committee reviewed performance year remains view targets awards new measures remain suitably robust stretching actual targets together details extent met disclosed full time vestinggsk annual report strategic review financial review risk governance remuneration financial statements investor information remuneration committee committee meetings usually begin closed session members committee company secretary role committee external adviser present individuals may also invited attend committee meetings year executives role committee set companys remuneration committee attendees involved decisions policy gsk able recruit retain motivate present discussions regarding executives policy regularly reviewed ensure remuneration consistent companys scale scope operations attendees committee meetings include supports business strategy growth plans helps drive creation shareholder value regular attends attendee attendee required terms reference ceo cid committees full terms reference available cfo cid companys website terms reference reviewed head human resources cid minimum annual basis last revised december head reward cid light best practice corporate governance company secretary secretary developments committee cid governance committee adviser deloitte llp cid board considers members committee adviser committee independent nonexecutive directors accordance uk committee access external advice required deloitte corporate governance code exception sir christopher llp deloitte appointed committee provide gent chairman company independent independent advice executive remuneration appointment year deloitte provided independent commentary matters committee met six times member consideration committee updates best practice attending follows legislative requirements market practice attendance deloitte also provided consulting tax assurance services committee full gsk year provide advice executive member meetings remuneration matters committee members since tom de swaan may committee conducted formal review deloittes chairman january performance july established set criteria sir crispin daviscid enabled full consideration committees needs chairman may july deloitte member remuneration consultants group december voluntarily operates code conduct relation sir christopher gent january executive remuneration consulting uk code judy lewent january na conduct found wwwremunerationconsultantsgroupcom sir deryck maughan july towers watson pay governance provided additional market larry culpcid january data committee james murdochcid october commitment shareholders tom de swaan sir deryck maughan james murdoch unable attend one meeting personal reasons meetings committee engages regular dialogue shareholders unable attend reviewed papers provided views holds annual meetings gsks largest investors discuss matters consideration committee chairman advance take feedback remuneration policy governance matters tom de swaan also chairman audit risk committee particular committee discusses significant changes december succeeded judy lewent policy measures used assess performance cid sir crispin davis stepped committee december james murdoch retired board may larry culp resigned annual meetings held november sir crispin davis board september shared progress remuneration matters last months addition six scheduled meetings committee also met proposals sir christopher gent chairman updated quorate basis four occasions principally approve attendees corporate governance developments tom de swaan formal grant based performance vesting longterm also attendance incentive awards accordance gsks remuneration policy companys agm may resolution approve remuneration report passed votes cast favour gsk annual report remuneration report principal activities matters addressed committees principal activities matters addressed set remuneration items specific month overall annual bonus ltis governance matters january approve executives review approve review lti measures set committees agenda remuneration including executives targets salaries ceo cfo bonuses review draft remuneration chairman rd approve bonus report remuneration environment calculation principles update set ceo bonus objectives february overview bonuses review lti performance employees cet targets outcomes approve lti award vesting set lti award targets march grant lti awards approve remuneration executives report approve deferred annual bonus plan elections matching awards may review cia clawback consider review review voting outcomes draft requirements annual bonus plan remuneration report review uk government remuneration consultations july review cia final clawback grant interim lti review agm feedback arrangements awards executives approve remuneration new cet appointee review general market developments review ceos cfos pay competitiveness october review chairmans fees review bonus approve changes lti review uk government agree salary review approval process plans give effect remuneration proposals process executives executives cias executive financial planning committee work review cfos pay recoupment plan competitiveness november annual meetings investors december review executives consider feedback remuneration market data annual meetings competitiveness investors annual committee evaluation results gsk annual report strategic review financial review risk governance remuneration financial statements investor information executive director terms conditions outside appointments considered nominations committee ensure would cause conflict interest executive director contracts approved chairman behalf board companys policy remuneration earned policy set provides framework contracts appointments may kept individual executive executive directors chairman nonexecutive directors policy fees set notice period calendar months company aims provide chairman non termination executive directors fees competitive paid employing company companies equivalent size complexity subject executive limits contained gsks articles association termination payment x annual salary chairman ceo responsible evaluating payable termination company making recommendations board fees payable vesting ltis rules relevant incentive plan nonexecutive directors approved shareholders review chairmans fees pension based existing arrangements terms relevant pension plan sir christopher gent took role chairman january since fees increased march noncompete clause months termination increased notice date arrangement sir christopher received fees shares deferred steps board ability impose month noncompete period nonsolicitation restriction executive considered important company following review sir christopher gents performance ability protect groups intellectual property staff light committee believes would appropriate provide mitigation independently sourced data board decided increase contracts chairmans fees change took effect january request chairman contracts new executives normally include bonus increase delivered gsk shares therefore element termination payment approximately sir christophers total fee per terms contracts seek balance commercial imperatives annum delivered shares best practice company considers important individual work elsewhere notice review nonexecutive director fees period may make compensatory payment respect bonus nonexecutive director fees last increased march period restraint since increase time commitment following table sets details executive directors demands responsibility placed nonexecutive directors service contracts fees reviewed july although market shortfall noted decided fees would increased current directors date contract effective date expiry date time sir andrew witty june may august following review independently sourced data simon dingemans september january april board agreed appropriate increase standard dr moncef slaoui december december august annual fee effect january fees continue delivered shares deferred termination payments made respect part nonexecutive director steps board notice period extending beyond contract expiry date increases supplemental fees entitlements nonexecutive directors fees applying january follows addition contractual provisions outlined event dr moncef slaouis service agreement terminated per annum employing company following apply standard annual cash retainer fee cidcid case outstanding awards due glaxosmithkline supplemental fees annual investment plan closed new deferrals effect first quarter provided chairman audit risk committee agreement terminated cause dr moncef slaoui must exercise bonus investment rights within six months senior independent director termination receive deferred amounts income scientificmedical experts cidcidcidcidcidcidcidcidcidcid chairmen remuneration corporate cidcid line policy applicable us senior executives responsibility committees dr moncef slaoui may become eligible future date receive continuing medical dental insurance retirement nonexecutive director undertaking intercontinental travel meetings per meeting outside appointments executives ir christopher gent chairman corporate responsibility committee board encourages executives hold one external directorship receive additional fee listed become established role broaden experience development help increase pool candidates nonexecutive directors gsk annual report remuneration report nonexecutive directors share allocation plan exchange rate enhance link directors shareholders gsk fees paid us dollars converted following requires nonexecutive directors receive significant part exchange rates fees form shares ads least nonexecutive directors total fees excluding exchange rate period rate applied us chairman paid form shares ads allocated january december us share ads account nonexecutive directors may also january december us take opportunity invest part balance january december us fees share ads account exchange rate set annually based average daily rate shares ads notionally awarded non last quarter year prior payment rate executive directors allocated interest accounts set reviewed moves significantly year table included within directors interests table accumulated balances tsr performance graph shares ads together notional dividends subsequently reinvested paid nonexecutive directors following graph sets performance company leave board upon leaving nonexecutive directors relative ftse index company receive either shares ads cash amount equal constituent pharmaceutical performance comparator value shares ads date leaving date group five year period december measured payment later common currency basis graph prepared accordance regulations defined basis preparation letters appointment indication likely vesting awards terms engagement nonexecutive directors granted companys incentive plans set letters appointment available inspection companys registered office agm tsr performance nonexecutive director initial appointment subsequent reappointment subject election thereafter periodic reelection shareholders nonexecutive directors letters appointment contain provision notice periods compensation appointments terminated following table shows date initial letter appointment nonexecutive director nonexecutive director date letter appointment sir christopher gent may professor sir roy anderson september dr stephanie burns february stacey cartwright march glaxosmithkline total return sir crispin davis june glaxosmithkline pharma peers return index lynn elsenhans may ftse total return index judy lewent march index includes abbott laboratories astrazeneca bristolmyers squibb sir deryck maughan may eli lilly johnson johnson merck novartis pfizer roche holdings sanofi dr daniel podolsky july tom de swaan december jing ulrich may hans wijers january sir robert wilson june appointed effect april sir christopher gents letter appointment agreed would serve company deputy chairman december january chairman conclusion agm following third anniversary appointment extended term three years mutual agreement effect reelection director agm held may previously announced extended period five years effect january subject annual reelection agmsgsk annual report strategic review financial review risk governance remuneration financial statements investor information directors emoluments total remuneration addition statutory disclosure total emoluments year also provided figures total remuneration includes value ltis earned relevant performance periods ended year compen total value total sation total value total fees annual emolu ltis remune fees annual loss emolu ltis remune salary benefits bonus ments earned ration salary benefits bonus office ments earned ration footnote executive directors sir andrew witty abc simon dingemans bcd dr moncef slaoui ac total executive directors nonexecutive directors professor sir roy anderson stacey cartwright e sir crispin davis sir christopher gent james murdoch f tom de swaan sir robert wilson lynn elsenhans e dr stephanie burns larry culp f judy lewent e sir deryck maughan dr daniel podolsky jing ulrich e total nonexecutive directors former directors julian heslop abg dr jeanpierre garnier total former directors total remuneration directors us payroll reported dollars translated average exchange rate year none directors received reimbursement expenses year requiring separate disclosure regulations defined basis preparation analysis value ltis earned sir andrew witty dr moncef slaoui julian heslop set b sir andrew witty simon dingemans participate salary sacrifice schemes including sharereward julian heslop also participated early retirement march c sir andrew witty simon dingemans dr moncef slaoui elected participate gsks deferred annual bonus plan respect bonuses sir andrew witty deferred bonus simon dingemans deferred bonus dr moncef slaoui deferred bonus simon dingemans joined board january remuneration recorded date participate gsks pension plans instead received lieu money purchase pension contribution respect life assurance contributions included benefits e lynn elsenhans jing ulrich joined board july stacey cartwright judy lewent joined board april fees recorded dates f james murdoch retired board may larry culp resigned board september g julian heslop retired early march received one years annual salary months ontarget bonus compensation loss office set terms contract gsk annual report remuneration report nonexecutive directors fees table sets value fees received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set cash sharesads total cash sharesads total fees nonexecutive directors professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson lynn elsenhans dr stephanie burns larry culp judy lewent sir deryck maughan dr daniel podolsky jing ulrich total fees table sets accumulated number shares ads held nonexecutive directors december share allocation plan relation fees received board members together movements accounts year number shares ads december allocated dividends december share allocation plan footnote elected reinvested paid nonexecutive directors shares professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson ads dr stephanie burns larry culp b lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrich james murdoch retired board may elected receive shares share allocation plan end first quarter b larry culp resigned board september balance share allocation plan net tax transferred december gsk annual report strategic review financial review risk governance remuneration financial statements investor information directors interests following interests directors company office december connected persons shown accordance fsa listing rules shares ads march december january march december january footnote executive directors sir andrew witty abc simon dingemans ab dr moncef slaoui bcdef nonexecutive directors professor sir roy anderson g dr stephanie burns g stacey cartwright g sir crispin davis g lynn elsenhans gh sir christopher gent g judy lewent g sir deryck maughan g dr daniel podolsky g tom de swaan g jing ulrich gh sir robert wilson g one glaxosmithkline ads represents two glaxosmithkline shares includes shares purchased glaxosmithkline sharereward plan follows march december january sir andrew witty simon dingemans b includes shares ads resulting deferral bonus subsequent reinvestment dividends deferred annual bonus plan totals shown include vested exercised bonus deferrals matching awards exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities exercise march december january shares sir andrew witty simon dingemans ads dr moncef slaoui c totals march include shares ads vested elements awards performance share plan deferred annual bonus plan less sold satisfy tax liabilities vested amounts see pages includes shares annual investment plan reached end deferral periods exercised dr moncef slaoui totalling shares march december january shares amounts include reinvested dividends represent gross share balances prior sale shares satisfy tax liabilities exercise e includes ads purchased within us retirement savings plan us executive supplemental savings plan essp totalling ads march ads december january ads ads respect essp included totals directors interests annual report brought forward numbers dr moncef slaoui increased ads accordingly f includes ads awarded dr moncef slaouis connected person share value plan svp see totalling ads march ads december january ads ads respect svp included totals directors interests annual report brought forward numbers dr moncef slaoui increased ads accordingly g includes shares ads received part fees described nonexecutive directors share allocation plan dividends received shares ads converted shares ads december h lynn elsenhans jing ulrich joined board july holdings disclosed date gsk annual report remuneration report longterm incentive plans value ltis earned value ltis earned current former executive directors includes amounts vesting gsks lti plans deferred annual bonus plan performance share plan relevant performance periods ended reporting year together amounts vesting sharesave plan contracts ended year totals analysed follows executive directors sir andrew witty dr moncef slaoui total vesting deferred annual bonus plan award performance share plan award performance share plan award sharesave total executive directors former directors julian heslop vesting performance share plan award performance share plan award sharesave total former directors share option sharesave plan awards respect options granted share option plan sop sharesave plan sharesave remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration options outstanding december march movements periods gains realised exercise shown executive directors december december options shares granted exercised march sir andrew witty simon dingemans dr moncef slaoui granted options shares date grant number vesting lapse plan grant price shares date date sir andrew witty sharesave simon dingemans sharesave exercised options shares market date number price gain date grant exercise shares grant price exercise sir andrew witty december december march options ads footnote lapsed lapsed dr moncef slaoui total ads options dr moncef slaoui includes interests connected person also employee gskgsk annual report strategic review financial review risk governance remuneration financial statements investor information share option sharesave plan awards continued following table shows gain exercise options set analysed remuneration subsequent gain loss result investment decision market remuneration investment net date vesting price date gainloss gain plan grant date vesting exercise year sir andrew witty sharesave former directors options shares december march julian heslop options outstanding december earliest latest vesting lapse dates options market price glaxosmithkline share ads yearend given table executive directors weighted average vesting date lapse date sir andrew witty grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested total share options december weighted average vesting date lapse date simon dingemans grant price number earliest latest earliest latest total share options options market price yearend unvested weighted average vesting date lapse date dr moncef slaoui grant price number earliest latest earliest latest shares options market price yearend vested options market price yearend vested total share options december ads options market price yearend vested unvested options market price yearend vested total ads options december ads option totals include ads options held dr moncef slaouis connected person also employee gsk former directors weighted average vesting date lapse date julian heslop grant price number earliest latest earliest latest total share options options market price yearend vested gsk granted share options executive directors annual basis directors hold options various share option plans referred note financial statements employee share schemes none nonexecutive directors interest option companys shares highest lowest closing prices year ended december glaxosmithkline shares ads respectively market price glaxosmithkline share december december glaxosmithkline ads december table sets share options granted performance periods performance targets whether options vested december march performance target vesting status annualised growth percentage grant footnote performance period march december eps award vesting february award lapsed lapsed rpi february award lapsed unvested rpi rpi rpi rpi performance targets options met result lapsed third fourth anniversaries date grant gsk annual report remuneration report deferred annual bonus plan awards deferred annual bonus plan dabp awards form nilcost options made executive directors annually based individuals voluntary bonus deferral election company match shares ads oneforone depending companys performance three year performance period award vests executive director may choose exercise award time years date grant amount remuneration receivable respect matching shares ads calculated using share ads price date relevant dabp award vests executive director chooses exercise nilcost options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration sir andrew witty shares performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested vested lapsed unvested march sir andrew witty vested shares number shares market price vesting gain remuneration sir andrew witty exercised shares vested march shares respect matching award granted remain within dabp vested unexercised simon dingemans shares performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march dr moncef slaoui ads performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march vesting schedules dabp awards award vested line three year relative tsr vesting schedule applied psp award see awards vesting criteria psp awards respectively see pages vesting schedule dabp award set detail gsk annual report strategic review financial review risk governance remuneration financial statements investor information performance share plan awards performance share plan psp awards made executive directors annual basis directors hold awards various psp plans referred note financial statements employee share schemes amount remuneration receivable respect performance shares calculated using share ads price date relevant psp award vests psp awards made sir andrew witty three year performance periods however deeds award specify awards subject two year vesting period five years total two year period additional performance criteria awards lapse sir andrew dismissed cause remuneration respect awards therefore considered realised full following determination remuneration committee vesting levels initial awards ie full remuneration recognised end three year performance periods executive directors sir andrew witty shares performance period market price grant unvested december granted dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested march sir andrew witty vested shares number shares market price vesting gain remuneration remuneration simon dingemans shares performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march dr moncef slaoui ads performance period market price grant unvested december granted dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested march psp totals include psp awards held dr moncef slaouis connected person also employee gsk awards subject performance criteria relevant employees cet gsk annual report remuneration report performance share plan awards continued dr moncef slaoui vested ads performance period number ads market price vesting gain remuneration remuneration former directors julian heslop shares performance period market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march julian heslop vested shares number shares market price vesting gain remuneration remuneration terms psp number shares ads vesting determined following end relevant performance period dependent gsks performance period committee adjusted comparator group relative tsr removing schering plough wyeth following delistings revised vesting schedule accordingly january abbott laboratories separated two publicly traded companies committee concluded neither companies relevant comparator performance purposes excluded tsr comparator group outstanding future awards vesting schedule revised accordingly comprises gsk nine companies revised comparator group set dividends reinvested performance shares ads awarded executives throughout performance period date final award terms psp us participants may defer receipt part vested awards following vesting schedules apply psp awards made executive directors cet members vesting schedule psp award set detail business diversification performance vesting schedule maximum performance expressed award award performance period percentage award vesting percentage threshold rd new product performance vesting schedule maximum performance expressed award award performance period percentage award vesting percentage threshold adjusted free cash flow vesting schedule cash flow targets award award performance period bn percentage award vesting gsk annual report strategic review financial review risk governance remuneration financial statements investor information performance share plan awards continued relative tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median award award performance period tsr rank nine companies percentage award vesting ue commercial sensitivity targets business diversification performance rd new product performance measures disclosed along outcomes remuneration reports share value plan awards dr moncef slaoui ads market price unvested unvested unvested date december december march plan year grant granted vested vested total executive director dr moncef slaoui eligible receive awards share value plan awards shown reflect holdings dr moncef slaouis connected person also employee gsk awards subject threeyear vesting periods vesting contingent continued employment gsk gains arising vesting included total remuneration dr moncef slaoui set pension benefits defined benefit plans accrued annual pension benefits transfer values retirement executive directors office year set companies act requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year fsas listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable change transfer value accrued accrued change personal transfer transfer accrued change benefit benefit accrued contributions value value change benefit accrued december december benefit made december december transfer year net benefit net executive director year year value inflation inflation sir andrew witty dr moncef slaoui na dr moncef slaoui na shown net contributions made individual gsk annual report remuneration report pension benefits continued directors senior management sir andrew witty participates glaxo wellcome final salary information provided compensation interests plan accrual rate th final pensionable salary per directors senior management group group annum benefits accrued glaxo wellcome purpose group defined nonexecutive uk pension arrangements augmented trustees executive directors members cet company plans reflect distribution surplus augmentation secretary financial year total compensation apply element sir andrew wittys pension earnings paid members group periods march served capacity aggregate increase transfer value sir andrew witty calculated accordance accrued pension benefits net inflation pensions regulation represents present value aggregate payment defined contribution schemes potential payments pension plan members group awarded dr moncef slaoui member us cash balance pension plan shares ads deferred annual bonus plan supplemental cash balance pension plan provides shares ads performance share executive pension credit gsk makes annual contributions plan shares ads share value plan dr moncef slaouis pension plans base salary options granted members group share fund increases interest rate set annually advance based option plan notional shares ads granted year us treasury bond rate provide cash sum deferred investment award plan members group retirement plan entitlement spouses pension awarded reinvestment dividends shares pension increases ads deferred annual bonus plan shares ads performance share plan notional transfer value cash sum increased shares deferred investment award plan dr moncef slaoui year result contributions paid company accumulation march group comprising persons owned interest shares ads constituting less issued share capital company group also held dr moncef slaoui active participant belgium fortis date options purchase shares ads plan may plan defined benefit plan shares ads awarded deferred lump sum payable normal retirement age annual bonus plan including shares ads vested plan transfer value cash sum dr moncef slaouis plan exercised shares ads awarded increased year result performance share plan including shares ads accumulation interest company vested deferred shares ads awarded contributions plan share value plan notional shares awarded deferred investment award plan holdings defined contribution plans issued various executive share plans described note dr moncef slaoui also member us retirement savings financial statements employee share schemes plan k savings scheme open us employees executive supplemental savings plan savings scheme open basis preparation executives accrue benefits us government limits imposed us retirement savings plan contributions plans remuneration report prepared accordance invested range funds value accumulated companies act large mediumsized companies funds paid retirement contributions groups accounts reports regulations paid two schemes gsk respect regulations meets relevant requirements fsa listing dr moncef slaoui rules accordance regulations following sections remuneration report subject audit directors simon dingemans joined gsk january emoluments total remuneration nonexecutive directors fees accumulating benefits gsks pension plans receives longterm incentive plans including share option sharesave cash contribution lieu money purchase pension contribution plan awards deferred annual bonus plan awards performance share plan awards share value plan awards pension directors interests contracts benefits opinion thereon expressed remaining sections subject audit pages except described note financial statements related referred within audited sections remuneration party transactions end financial year report approved board directors signed director connected person material interest behalf contract significance group company tom de swaan remuneration committee chairman march gsk annual report strategic review financial review risk governance remuneration financial statements investor information financial directors statement responsibilities independent auditors report financial statements statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap squeezing production times review manufacturing standards processes identified opportunities reduce downtime switching manufacturing lines one consumer product another simple improvements freed capacity produce million tubes toothpaste see trakcorc niai gsk annual report directors statement responsibilities directors statement responsibilities relation disclosure information auditors group financial statements directors office date report directors responsible preparing annual report confirmed remuneration report group financial statements cidcid far aware relevant audit information accordance applicable law regulations companys auditors unaware company law requires directors prepare financial statements cidcid taken steps ought financial year law directors required taken director make aware prepare group financial statements accordance relevant audit information establish companys international financial reporting standards ifrs adopted auditors aware information european union preparing group financial statements directors also elected comply ifrs issued confirmation given interpreted accordance international accounting standards board iasb provisions section companies act company law directors must approve group financial going concern basis statements unless satisfied give true fair view state affairs group profit loss pages contain information performance group period group financial position cash flows net debt position preparing financial statements directors borrowing facilities information including treasury risk required management policies exposures market credit risk hedging activities given note financial statements cidcid select suitable accounting policies apply financial instruments related disclosures making consistently enquiries directors reasonable expectation cidcid make judgements accounting estimates reasonable group adequate resources continue operational existence prudent foreseeable future reason continue adopt going concern basis preparing financial statements cidcid state group financial statements comply ifrs adopted european union ifrs issued iasb internal control subject material departures disclosed explained board audit risk committee reviewed group financial statements assessment risks internal control framework operates directors responsible keeping adequate accounting gsk considered effectiveness system internal records sufficient show explain companys control operation group year covered report transactions disclose reasonable accuracy time date approval board directors financial position group enable ensure group financial statements remuneration report uk corporate governance code comply companies act article ias board considers glaxosmithkline plc applies principles regulation also responsible safeguarding assets provisions uk corporate governance code maintained group hence taking reasonable steps financial reporting council described corporate prevention detection fraud irregularities governance section pages complied group financial statements year ended december provisions required financial services authoritys listing comprising principal statements supporting notes rules auditors considered directors statement set financial statements pages report compliance relation points uk corporate responsibilities auditors relation group governance code specified review financial statements set independent auditors annual report report group financial statements year ended december annual report year ended december included annual report published comprising report directors remuneration report hardcopy printed form made available website financial statements additional information investors directors responsible maintenance integrity approved board directors signed annual report website accordance uk legislation behalf governing preparation dissemination financial statements access website available outside uk comparable legislation may different sir christopher gent current directors whose names functions listed chairman corporate governance section annual report march confirms best knowledge cidcid group financial statements prepared accordance ifrs adopted eu ifrs issued iasb give true fair view assets liabilities financial position profit group cidcid strategic review financial review risk sections pages include fair review development performance business position group together description principal risks uncertainties facesgsk annual report strategic review financial review risk governance remuneration financial statements investor information independent auditors report independent auditors report separate opinion relation ifrs issued iasb members glaxosmithkline plc explained note group financial statements group audited group financial statements glaxosmithkline addition complying legal obligation apply ifrs plc year ended december comprise adopted european union also applied ifrs issued consolidated income statement consolidated statement international accounting standards board iasb comprehensive income consolidated balance sheet consolidated statement changes equity consolidated opinion group financial statements comply ifrss cash flow statement related notes financial issued iasb reporting framework applied preparation opinion matter prescribed companies applicable law international financial reporting standards ifrss adopted european union act opinion information given directors report respective responsibilities directors auditors financial year group financial statements prepared explained fully directors statement responsibilities consistent group financial statements set directors responsible preparation group financial statements satisfied matters required report give true fair view responsibility audit express exception opinion group financial statements accordance nothing report respect following applicable law international standards auditing uk ireland standards require us comply auditing companies act required report practices boards ethical standards auditors opinion report including opinions prepared cidcid certain disclosures directors remuneration specified law companys members body accordance chapter made part companies act purpose cidcid received information explanations giving opinions accept assume responsibility require audit purpose person report shown whose hands may come save expressly listing rules required review agreed prior consent writing cidcid directors statement set relation going scope audit financial statements concern cidcid part corporate governance statement relating audit involves obtaining evidence amounts companys compliance nine provisions uk disclosures financial statements sufficient give reasonable corporate governance code specified review assurance financial statements free material misstatement whether caused fraud error includes cidcid certain elements report shareholders board assessment whether accounting policies appropriate directors remuneration groups circumstances consistently applied adequately disclosed reasonableness significant accounting matters estimates made directors overall presentation reported separately parent company financial financial statements addition read financial statements glaxosmithkline plc year ended december nonfinancial information annual report identify material information directors remuneration report inconsistencies audited financial statements become described audited aware apparent material misstatements inconsistencies consider implications report company passed resolution accordance section companies act senior statutory auditors opinion financial statements name stated opinion group financial statements cidcid give true fair view state groups affairs december profit cash flows year ended cidcid properly prepared accordance ifrs adopted pricewaterhousecoopers llp european union chartered accountants statutory auditors london cidcid prepared accordance requirements march companies act article las regulation gsk annual report financial statements consolidated income statement year ended december restated restated notes turnover cost sales gross profit selling general administration research development royalty income operating income operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p comparative information restated consistency presentation set note presentation financial statements consolidated statement comprehensive income year ended december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement cash flow hedge reclassified goodwill share comprehensive incomeexpense associates joint ventures comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic review financial review risk governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity approved board march sir christopher gent chairman gsk annual report financial statements consolidated statement changes equity year ended december shareholders equity non share share retained controlling total capital premium earnings reserves total interests equity january profit year comprehensive income year total comprehensive income year distributions noncontrolling interests dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expense year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans january profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic review financial review risk governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired investments associates joint ventures proceeds disposal subsidiary interest associate decrease liquid investments interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares purchase noncontrolling interests increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities decrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments decrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report notes financial statements presentation financial statements set note segment information segments turnover operating profit disclosed amended description business reflect changes groups internal management structure together certain changes therapeutic classifications glaxosmithkline major global healthcare group turnover product addition charges amortisation engaged creation discovery development manufacture impairment intangible assets related marketed products marketing pharmaceutical products including vaccines reported cost sales rather sga comparative overthecounter otc medicines healthrelated consumer information restated accordingly adjustment products gsks principal pharmaceutical products include medicines increases cost sales decreases sga million following therapeutic areas respiratory antivirals central amounts previously reported nervous system cardiovascular urogenital metabolic anti bacterials oncology emesis dermatology rare diseases implementation new accounting standards immunoinflammation vaccines hiv effect january gsk implemented compliance applicable law ifrs amendments ifrs disclosures transfers financial assets ias deferred tax recovery underlying assets financial statements prepared accordance revisions material impact current period companies act article ias regulation international accounting standards ias international financial financial period reporting standards ifrs related interpretations adopted financial statements cover financial year january european union december comparative figures financial financial statements also compliance ifrs issued years january december appropriate international accounting standards board january december composition financial statements parent company financial statements consolidated financial statements drawn sterling financial statements parent company glaxosmithkline functional currency glaxosmithkline plc accordance plc prepared accordance uk gaap uk ifrs accounting presentation financial statements comprise accounting presentation company balance sheet presented accounting policies given cidcid consolidated income statement cidcid consolidated statement comprehensive income accounting principles policies cidcid consolidated balance sheet cidcid consolidated statement changes equity consolidation cidcid consolidated cash flow statement consolidated financial statements include cidcid notes financial statements cidcid assets liabilities results cash flows company subsidiaries including esop trusts composition group cidcid groups share results net assets associates list subsidiary associated undertakings opinion joint ventures directors principally affected amount profit net assets group given note principal group companies financial statements entities consolidated made december year accounting principles policies entities group power govern financial financial statements prepared using historical operating policies accounted subsidiaries cost convention modified revaluation certain items group ability exercise joint control entities stated accounting policies going concern basis accounted joint ventures group ability exercise significant influence accounted associates financial statements prepared accordance results assets liabilities associates joint ventures groups accounting policies approved board incorporated consolidated financial statements using described note accounting principles policies information equity method accounting application accounting policies including areas estimation judgement given note key accounting interests acquired entities consolidated date judgements estimates group acquires control interests sold deconsolidated date control ceases preparation financial statements conformity generally accepted accounting principles requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimatesgsk annual report strategic review financial review risk governance remuneration financial statements investor information ccounting principles policies continued revenue revenue recognised income statement goods transactions balances subsidiaries eliminated services supplied made available external customers profit tax taken sales subsidiaries orders received title risk loss passed customer products sold customers outside group reliable estimates made relevant deductions relevant proportion profits transactions joint ventures relevant obligations fulfilled earnings associates also deferred products sold third process regarded complete parties transactions noncontrolling interests recorded directly equity deferred tax relief unrealised intragroup profit turnover represents net invoice value deduction accounted extent considered recoverable discounts allowances given accruals estimated future rebates returns methodology assumptions used goodwill capitalised separate item case subsidiaries estimate rebates returns monitored adjusted regularly part cost investment case joint ventures light contractual legal obligations historical trends past associates goodwill denominated currency experience projected market conditions market conditions operation acquired evaluated using wholesaler thirdparty analyses market cost acquisition fair value net research data internally generated information value added tax assets acquired difference recognised directly sales taxes excluded revenue income statement group copromotes product third party records business combinations sale group records share revenue copromotion income within turnover nature copromotion activities business combinations accounted using acquisition group records costs sales pharmaceutical turnover accounting method identifiable assets liabilities contingent includes copromotion revenue million million liabilities acquired measured fair value acquisition date million consideration transferred measured fair value includes fair value contingent consideration royalty income recognised accruals basis accordance consideration transferred exceeds fair value net assets terms relevant licensing agreements liabilities contingent liabilities acquired together expenditure noncontrolling interest excess recorded goodwill costs acquisition charged income statement expenditure recognised respect goods services received period incurred supplied accordance contractual terms provision made obligation exists future liability respect equity subsidiary acquired non past event amount obligation reliably controlling interest recognised either fair value estimated manufacturing startup costs validation noncontrolling interests share net assets subsidiary achievement normal production expensed incurred casebycase basis changes groups ownership advertising promotion expenditure charged income percentage subsidiaries accounted within equity statement incurred shipment costs intercompany transfers foreign currency translation charged cost sales distribution costs sales customers included selling general administrative expenditure foreign currency transactions booked functional currency group company exchange rate ruling date restructuring costs recognised provided transaction foreign currency monetary assets liabilities appropriate respect direct expenditure business retranslated functional currency rates exchange ruling reorganisation plans sufficiently detailed well balance sheet date exchange differences included advanced appropriate communication affected income statement undertaken consolidation assets liabilities including related goodwill research development overseas subsidiaries associates joint ventures translated research development expenditure charged income sterling rates exchange ruling balance sheet date statement period incurred development results cash flows overseas subsidiaries associates expenditure capitalised criteria recognising asset joint ventures translated sterling using average rates met usually regulatory filing made major exchange market approval considered highly probable property plant exchange adjustments arising opening net assets equipment used research development capitalised profits year retained overseas subsidiaries associates depreciated accordance groups policy joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge environmental expenditure groups net investment operations taken separate environmental expenditure related existing conditions resulting component equity past current operations current future translating sterling assets liabilities results benefit discernible charged income statement group cash flows overseas subsidiaries associates joint ventures recognises liability sitebysite basis reliably reported currencies hyperinflationary economies estimated liability includes groups portion total adjustments made material reflect current price levels costs also portion potentially responsible parties loss net monetary assets charged consolidated costs probable able satisfy income statement respective shares cleanup obligation recoveries reimbursements recorded assets virtually certain gsk annual report notes financial statements accounting principles policies continued property plant equipment property plant equipment ppe stated cost legal disputes purchase construction less provisions depreciation provision made anticipated settlement costs legal impairment financing costs capitalised within cost disputes group outflow resources qualifying assets construction considered probable reliable estimate made depreciation calculated write cost less residual value likely outcome addition provision made legal ppe excluding freehold land using straightline basis expenses arising claims received disputes expected useful life residual values lives reviewed respect product liability claims related certain products appropriate adjusted annually normal expected useful sufficient history claims made settlements lives major categories ppe enable management make reliable estimate provision required cover unasserted claims certain cases incurred freehold buildings years reported ibnr actuarial technique used determine leasehold land estimate buildings lease term years group may become involved legal proceedings respect plant machinery years possible make reliable estimate expected equipment vehicles years financial effect could result ultimate resolution proceedings cases appropriate disclosure disposal ppe cost related accumulated depreciation cases would included provision would made costs impairments removed financial statements associated claims made group third parties net amount less proceeds taken income statement charged income statement incurred leases pensions postemployment benefits leasing agreements transfer group substantially costs providing pensions defined benefit schemes benefits risks ownership asset treated finance calculated using projected unit credit method spread leases asset purchased outright assets period benefit expected derived included ppe computer software capital elements employees services consistent advice qualified leasing commitments shown obligations finance actuaries pension obligations measured present value leases assets held finance leases depreciated basis estimated future cash flows discounted rates reflecting consistent similar owned assets lease term shorter yields high quality corporate bonds interest element lease rental included income statement leases operating leases rental costs pension scheme assets measured fair value balance charged income statement straightline basis sheet date actuarial gains losses differences lease term expected actual returns assets effect changes actuarial assumptions recognised statement goodwill comprehensive income year arise goodwill stated cost less impairments goodwill deemed groups contributions defined contribution plans charged indefinite useful life tested impairment income statement incurred costs post least annually employment liabilities calculated similar way defined benefit pension schemes spread period fair value interest acquired entitys assets benefit expected derived employees services liabilities contingent liabilities exceeds consideration paid accordance advice qualified actuaries excess recognised immediately gain income statement employee share plans intangible assets incentives form shares provided employees share option share award schemes intangible assets stated cost less provisions amortisation impairments fair values options awards calculated grant dates using blackscholes option pricing model charged licences patents knowhow marketing rights separately income statement relevant vesting periods acquired acquired part business combination amortised estimated useful lives generally exceeding group provides finance esop trusts purchase company years using straightline basis time shares open market meet obligation provide shares available use estimated useful lives determining employees exercise options awards costs running amortisation charge take account patent lives applicable esop trusts charged income statement shares held well value obtained periods nonexclusivity esop trusts deducted reserves transfer asset lives reviewed appropriate adjusted annually made reserves retained earnings vesting contingent milestone payments recognised point periods related share options awards reflect ultimate contingent event becomes certain development costs proceeds receivable employees exercise incurred group associated acquired licences patents knowhow marketing rights written income statement incurred unless criteria recognition internally generated intangible asset met usually regulatory filing made major market approval considered highly probablegsk annual report strategic review financial review risk governance remuneration financial statements investor information ccounting principles policies continued inventories inventories included financial statements lower acquired brands valued independently part fair value cost including raw materials direct labour direct costs businesses acquired third parties brand related production overheads net realisable value cost value substantial longterm brands generally determined first first basis prelaunch either contractual legal nature sold separately inventory held asset high probability rest businesses acquired brands amortised regulatory approval product point provision estimated useful lives years except made carrying value recoverable amount considered useful economic life indefinite provision reversed point high probability costs acquiring developing computer software regulatory approval determined internal use internet sites external use capitalised intangible fixed assets software site supports trade receivables significant business system expenditure leads creation trade receivables carried original invoice amount less durable asset erp systems software amortised seven provisions doubtful debts provisions made ten years computer software three five years evidence risk nonpayment taking account ageing impairment noncurrent assets previous experience general economic conditions trade receivable determined uncollectable written firstly carrying values noncurrent assets reviewed provision available income statement impairment either standalone basis part larger cash subsequent recoveries amounts previously provided generating unit indication assets might credited income statement longterm receivables impaired additionally goodwill intangible assets indefinite discounted effect material useful lives intangible assets yet available use tested impairment annually provision impairment trade payables charged income statement year concerned trade payables initially recognised fair value held impairments goodwill reversed impairment losses amortised cost equates nominal value longterm payables noncurrent assets reversed discounted effect material change estimates used determine recoverable amounts extent revised recoverable amounts cash cash equivalents exceed carrying values would existed net depreciation amortisation impairments recognised cash cash equivalents comprise cash hand current balances banks similar institutions highly liquid investments investments associates joint ventures generally maturities three months less readily convertible known amounts cash insignificant investments associates joint ventures carried risk changes value consolidated balance sheet groups share net assets date acquisition postacquisition retained profits borrowings losses together goodwill arising acquisition borrowings initially recorded amount proceeds availableforsale investments received net transaction costs borrowings subsequently carried amortised cost difference proceeds liquid investments investments classified available net transaction costs amount due redemption forsale investments initially recorded fair value plus recognised charge income statement period transaction costs remeasured subsequent reporting relevant borrowing dates fair value unrealised gains losses availableforsale investments recognised directly comprehensive income taxation impairments arising significant prolonged decline fair value equity investment reduce carrying amount current tax provided amounts expected paid applying asset directly charged income statement tax rates enacted substantively enacted balance sheet date disposal impairment investments gains losses deferred comprehensive income deferred tax provided full using liability method reclassified income statement dividends equity temporary differences arising tax bases assets investments recognised income statement liabilities carrying amounts financial statements groups right receive payment established equity investments deferred tax assets recognised extent probable recorded noncurrent assets unless expected future taxable profits available sold within one year temporary differences utilised deferred tax provided temporary differences arising investments subsidiaries purchases sales equity investments accounted associates joint ventures except timing trade date purchases sales availableforsale reversal temporary difference controlled investments accounted settlement date probable temporary difference reverse foreseeable future deferred tax provided using rates tax enacted substantively enacted balance sheet date gsk annual report notes financial statements accounting principles policies continued amounts estimated may fully reflect final outcome amounts subject change dependent derivative financial instruments hedging upon amongst things types buying group product sales mix derivative financial instruments used manage exposure level accrual reviewed adjusted regularly market risks principal derivative instruments used gsk light contractual legal obligations historical trends past foreign currency swaps interest rate swaps forward foreign experience projected market conditions market conditions exchange contracts group hold issue derivative evaluated using wholesaler thirdparty analyses market financial instruments trading speculative purposes research data internally generated information future events derivative financial instruments classified heldfortrading could cause assumptions accruals based carried balance sheet fair value derivatives designated change could affect future results group hedging instruments classified inception cash flow hedges net investment hedges fair value hedges taxation changes fair value derivatives designated cash flow current tax provided amounts expected paid hedges recognised comprehensive income extent deferred tax provided temporary differences tax hedges effective ineffective portions recognised bases assets liabilities carrying amounts rates profit loss immediately amounts deferred comprehensive enacted substantively enacted balance income reclassified income statement hedged sheet date item affects profit loss deferred tax assets recognised extent probable net investment hedges accounted similar way future taxable profits available cash flow hedges temporary differences utilised based managements assumptions relating amounts timing future taxable changes fair value derivatives designated fair value profits factors affecting tax charge future years set hedges recorded income statement together note taxation change groups effective tax rate changes fair value hedged asset liability would changed total tax charge year changes fair value derivative instruments approximately million qualify hedge accounting recognised immediately group open tax issues number revenue income statement authorities outflow funds believed probable discounting reliable estimate outcome dispute made management provides best estimate liability time effect money material balances discounted estimates take account specific circumstances current values using appropriate rates interest unwinding dispute relevant external advice inherently judgemental discounts recorded finance income finance expense could change substantially time new facts emerge dispute progresses details relating significant unresolved disputes key accounting judgements estimates set note taxation gsk continues believe made adequate provision liabilities likely arise preparing financial statements management required open assessments open issues exist ultimate liability make estimates assumptions affect amounts assets matters may vary amounts provided dependent liabilities revenue expenses reported financial statements upon outcome negotiations relevant tax authorities actual amounts results could differ estimates necessary litigation proceedings following considered key accounting judgements estimates made legal disputes turnover gsk provides anticipated settlement costs outflow resources considered probable reliable estimate may revenue recognised title risk loss passed made likely outcome dispute legal customer reliable estimates made relevant deductions expenses arising claims group estimates relevant obligations fulfilled take account specific circumstances dispute earnings process regarded complete relevant external advice inherently judgmental could change gross turnover reduced rebates discounts allowances substantially time new facts emerge dispute product returns given expected given vary progresses details status various uncertainties involved product arrangements buying groups arrangements significant unresolved disputes set note purchasing organisations dependent upon submission legal proceedings claims time initial recognition sale accruals made time sale estimated rebates discounts allowances payable returns made based available market information historical experiencegsk annual report strategic review financial review risk governance remuneration financial statements investor information k ey accounting judgements intangible assets estimates continued intangible assets acquired gsk third parties costs acquisition capitalised licences compounds companys directors taken legal advice established development amortised point provisions taking account relevant facts available use estimated useful lives may include circumstances matter accordance accounting periods nonexclusivity estimated useful lives reviewed requirements respect product liability claims related certain annually impairment tests undertaken events occur products sufficient history claims made settlements call question carrying values assets brands acquired enable management make reliable estimate provision businesses capitalised independently required cover unasserted claims group may become separable expected life one year brands involved legal proceedings respect possible amortised straightline basis estimated useful make reliable estimate expected financial effect lives exceeding years except end useful result ultimate resolution proceedings economic life foreseen brands amortised cases appropriate disclosure cases would included subject annual impairment tests provision would made contingent liability quantified december provisions legal initial valuations valuations subsequent impairment disputes amounted billion billion tests based established market multiples riskadjusted future cash flows estimated useful life asset ultimate liability legal claims may vary amounts limited discounted using appropriate interest rates set provided dependent upon outcome litigation note intangible assets assumptions relating proceedings investigations possible settlement negotiations future cash flows estimated useful lives discount rates position could change time therefore based business forecasts therefore inherently assurance losses result outcome judgemental future events could cause assumptions used legal proceedings exceed amount provisions impairment reviews change consequent adverse reported groups financial statements material amount effect future results group property plant equipment pensions postemployment benefits set note property plant equipment carrying costs providing pensions postemployment values property plant equipment tested impairment benefits charged income statement accordance indication values assets might ias employee benefits period benefit impaired impairment determined reference higher derived employees services costs assessed fair value less costs sell value use measured assessing basis assumptions selected management riskadjusted future cash flows estimated useful life assumptions include future earnings pension increases asset discounted using appropriate interest rates ranges discount rates expected long term rates return assets estimated useful lives applied category property plant mortality rates disclosed note pensions equipment set note accounting principles postemployment benefits policies assumptions relating future cash flows estimated useful lives discount rates based business forecasts expected long term rates return bonds determined therefore inherently judgemental given large number based portfolio mix indexlinked government individual items property plant equipment corporate bonds equity risk premium added considered likely reasonably possible change equities assumptions applied impairment test one item would discount rates derived aa rated corporate bond yields lead material adverse effect future results group except countries deep market corporate however future events could cause assumptions used bonds government bond yields used sensitivity analysis impairment tests change consequent adverse effect provided note pensions postemployment future results group benefits reduction discount rate would lead increase net pension deficit approximately million goodwill increase annual pension cost approximately goodwill arising business combinations capitalised million selection different assumptions could affect allocated appropriate cash generating unit deemed future results group indefinite life amortised annual impairment tests relevant cash generating units performed impairment tests based established market multiples riskadjusted future cash flows discounted using appropriate interest rates assumptions used impairment tests set note goodwill case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill assumptions relating future cash flows discount rates based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests change consequent adverse effect future results group gsk annual report notes financial statements new accounting requirements amendment ias presentation items comprehensive income issued june amendment ias employee benefits issued june implemented gsk january amendment implemented gsk january changes required disclosures financial statements amendment eliminates ability defer recognition gains particularly respect statement comprehensive income losses corridor method requires remeasurements amendment ifrs disclosures offsetting financial assets presented comprehensive income requires past service cost financial liabilities issued december recognised income statement year plan implemented gsk january amendment requires amendment rather deferring portion related unvested additional disclosures financial assets financial liabilities benefits requires return plan assets recognised income offset balance sheet statement calculated using rate discount rate applied pension obligation makes several minor amendment ias offsetting financial assets financial accounting disclosure changes liabilities issued december implemented gsk january amendment provides additional revised standard expected increase pension charge guidance financial assets financial liabilities may approximately million standard applied offset estimated pension charge would increased approximately million million increase ifrs financial instruments first issued november effect reflects reduction uk us discount rates amended october implemented compared gsk current effective date january standard eventually replace ias covers revised standard implemented prior year classification measurement derecognition financial assets information restated onto comparable basis financial liabilities iasb intends expand ifrs add following new amended accounting standards ifric new requirements impairment hedge accounting interpretations issued iasb likely affect become complete replacement ias due course future annual reports although current forms none expected material impact results financial exchange rates position group group uses average exchange rates prevailing ifrs consolidated financial statements issued may period translate results cash flows overseas replaces parts ias separate financial statements subsidiaries joint ventures associated undertakings previously dealt consolidated financial statements sic sterling period end rates translate net assets consolidation special purpose entities standard uses control undertakings currencies influence single basis determining whether entity translations relevant exchange rates consolidated ifrs joint arrangements issued may standard average rates requires entity report share assets liabilities revenue expenses joint operation financial statements apply us equity method accounting joint ventures consolidated euro financial statements yen ifrs disclosures interests entities issued may period end rates standard requires disclosures related financial us effects risks associated entitys investments euro subsidiaries joint arrangements associates unconsolidated yen structured entities amendment ias investments associates joint ventures issued may standard requires equity method accounting applied investments associates joint ventures consolidated accounts eu endorsements ifrs ifrs ifrs amended ias require implementation january implemented gsk january accordance iasbs implementation timetable ifrs fair value measurement issued may implemented gsk january standard provides guidance fair value measurement introduces consistent disclosure requirements situations another standard permits requires fair value measurementgsk annual report strategic review financial review risk governance remuneration financial statements investor information segment information group revised segment information disclosures reflect changes internal reporting structures effect january pharmaceuticals vaccines businesses emerging markets asia pacific excluding australasia combined one segment emap addition classification certain products changed including cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidzovirax dermatology therapy area antivirals therapy area cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid allocates intragroup profit product sale market sale recorded profit analyses presented basis cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid costs attributed segments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid segment cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid movements financial instruments investments profits global asset disposals items operating income restated restated turnover segment pharmaceuticals vaccines cidcidcidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines turnover cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid restated restated pharmaceuticals vaccines turnover therapeutic area cidcidcidcidcidcidcidcidcidcidcid antivirals cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid metabolic antibacterials cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid dermatology cidcidcidcidcidcidcidcidcidcidcidcidcid immunoinflammation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid vaccines cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk annual report notes financial statements segment information continued restated restated consumer healthcare turnover category total wellness cidcidcidcidcidcidcidcidcid nutrition cidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid segment profit restated restated pharmaceuticals vaccines cidcidcidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines operating profit cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidprofit cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid noncore items total operating profit finance income finance costs profit disposal interest associates cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid profit taxation taxation profit taxation year depreciation amortisation segment restated restated pharmaceuticals vaccines cidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines depreciation amortisation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid noncore depreciation amortisation total depreciation amortisation gsk annual report strategic review financial review risk governance remuneration financial statements investor information segment information continued ppe intangible asset goodwill impairment segment restated restated pharmaceuticals vaccines cidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines impairment cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid noncore impairment total impairment ppe intangible asset impairment reversals segment restated restated pharmaceuticals vaccines cidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines impairment reversals cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid noncore impairment reversals total impairment reversals gsk annual report notes financial statements segment information continued restated net assets segment pharmaceuticals vaccines cidcidcidcidcid europe emap japan cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pharmaceuticals vaccines net operating assets cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid net operating assets net debt investments associates joint ventures derivative financial instruments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid assets held sale net assets trading unallocated pharmaceuticals segment includes assets centrally managed pharmaceutical vaccine cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid standard cost product charged businesses geographical information cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid restated restated turnover location customer cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid external turnover turnover location subsidiary cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid turnover including intersegment turnover cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid intersegment turnover cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid external turnover gsk annual report strategic review financial review risk governance remuneration financial statements investor information segment information continued operating profit location cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid total operating profit restated net operating assets location cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid net operating assets restated noncurrent assets location cidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcid noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating income milestone income cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid disposal businesses assets legal settlements cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid fair value remeasurements contingent consideration recognised business combinations fair value adjustments derivative financial instruments cidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid brands million million costs reported associated disposal cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk annual report notes financial statements operating profit following items included operating profit employee costs note advertising distribution costs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid amortisation intangible assets impairment intangible assets goodwill net reversals net foreign exchange losses inventories cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid minimum lease payments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid fees payable companys auditor associates audit parent company consolidated financial statements cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid auditrelated assurance services including attestation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid audit auditrelated services taxation compliance taxation advice cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid services cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid audit cidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk annual report strategic review financial review risk governance remuneration financial statements investor information employee costs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pension postemployment costs including augmentations note cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance charge pension postemployment costs year includes credit million following change policy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cost sharebased incentive plans analysed follows cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcid average number persons employed group including directors year number number number manufacturing cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid average number group employees excludes temporary contract staff numbers group employees end cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid nil nil cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid pension postemployment costs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk annual report notes financial statements major restructuring costs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid following areas cidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees finance income interest income arising cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid availableforsale investments derivatives fair value profit loss loans receivables cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid fair value adjustments derivatives fair value profit loss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid derivatives fair value profit loss relates swap interest incomegsk annual report strategic review financial review risk governance remuneration financial statements investor information finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidfrom comprehensive income cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid movements amounts owed noncontrolling interests cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid derivatives fair value profit loss relates swap interest expense associates joint ventures associates cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidlosses joint ventures cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid july cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid total turnover cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcid total profit cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid included summarised income statement information represent estimated earnings aspen group year gsk annual report notes financial statements taxation taxation charge based profits year cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid deferred taxation reconciliation taxation rate group profits cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid differences overseas taxation rates cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcid intercompany stock profit impact share based payments tax profit associates cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid prior year items disposal associate tax unremitted earnings cidcidcidcidcidcidcidcidcidcidcidcidcid tax rate within restructuring charge million comprising predominantly deferred tax hence non cash relating cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid normal rates tax territory effect reduction taxation charge increased earnings per share p cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid arising inventory held group yearend applying tax rate country inventory held rather cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tax items charged equity statement comprehensive income cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid deferred taxation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid defined benefit plans fair value movements cash flow hedges fair value movements availableforsale investments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid items charged statement comprehensive income except tax share based paymentsgsk annual report strategic review financial review risk governance remuneration financial statements investor information taxation continued issues relating taxation cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate provision deferred tax liabilities million made respect taxation would arise distribution profits retained certain overseas subsidiaries provision made grounds group able control timing reversal remaining temporary differences probable reverse foreseeable future aggregate amount unremitted profits balance sheet date approximately billion billion unprovided deferred tax unremitted earnings december estimated million million relates taxes payable cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid exemption tax repatriated profits subject certain exceptions movement deferred tax assets liabilities cidcidcidcidcidcidcidcidcidcid manu cidcidcidcidcid cidcidcidcidcid accelerated intra post cidcidcidcidcid facturing cidcidcidcidcid option net cidcidcidcidcidcid capital group employment tax cidcidcidcidcidcidcid restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total deferred tax assets january deferred tax liabilities january january exchange adjustments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid statement cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid comprehensive income cidcidcidcidcidcidcidcidcidcidcidcid transfer current tax december deferred tax assets december deferred tax liabilities december deferred tax credit income relating changes tax rates million million million deferred cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid expenses tax deduction available paid basis gsk annual report notes financial statements taxation continued tax losses cidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcid trading losses expiring cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid years available indefinitely december deferred tax asset addition group capital losses december approximately billion billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses factors affecting tax charge future years global organisation many factors could affect future effective tax rate group mix profits across different territories transfer pricing disputes tax authorities location research development activity cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid part ongoing phased reduction main rate corporation tax main rate reduce april cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid patent box regime apply reduced rate corporation tax income patents effect april july cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid business internal trading arrangements substantially decreasing administrative complexity deliver supply chain working capital efficiencies noncash tax charges totalling approximately million expected next two years arising unwinding deferred profit inventory existing inventory produced prior restructuring leaves supply chain earnings per share pence pence pence cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid diluted earnings per share cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions cidcidcidcidcid dilution share options awards diluted gsk annual report strategic review financial review risk governance remuneration financial statements investor information dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend cidcidcidcidcidcidcidcidcidcidcidcid pence cidcidcidcidcidcidcidcidcidcidcidcid pence cidcidcidcidcidcidcidcidcidcidcidcid pence first interim july july july cidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcid third interim january january january fourth interim april april april annual total cidcidcidcidcidcidcidcidcidcidcidcid april total cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid paid namely third fourth interim dividends supplemental dividend first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant cidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcid assets buildings vehicles construction total cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid exchange adjustments additions additions business combinations cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid disposals writeoffs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid transfer assets held sale cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid exchange adjustments additions additions business combinations cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid disposals writeoffs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid transfer assets held sale cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid gsk annual report notes financial statements property plant equipment continued plant cidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcid assets buildings vehicles construction total depreciation january exchange adjustments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid disposals writeoffs transfer assets held sale depreciation december exchange adjustments cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment million million net book value million cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid million accumulated depreciation million million impairment nil million net book cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid million arising major restructuring programmes cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid impairments deemed longer apply reversals credited cost salesgsk annual report strategic review financial review risk governance remuneration financial statements investor information goodwill cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid exchange adjustments additions business combinations note movements contingent consideration balances cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid net book value january net book value december cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid businesses cash generating unit cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid japan pharmaceuticals vaccines cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid maxinutrition group cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid europe pharmaceuticals vaccines cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid emap pharmaceuticals vaccines cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid emap pharmaceuticals vaccines novamin technology inc cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cash flows cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cash generating units significant relative total balance gsk annual report notes financial statements goodwill continued recoverable amounts cash generating units assessed using either fair value less costs sell model value use model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid across large parts group discount rate adjusted appropriate specific country currency risks cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid posttax discount rate applied projected riskadjusted posttax cash flows terminal value cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid valuation basis cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid advertising promotion investment profit margins terminal growth rate discount rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid support needed innovation expansion cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid period specific projected cash flows years terminal growth rate discount rate terminal growth rate discount rate cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcid cidcidcidcid europe pharmaceuticals vaccines pa emap pharmaceuticals vaccines pa japan pharmaceuticals vaccines pa cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcid cidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcid cidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcid cidcidcidcid terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rates used fair value less costs sell calculations cash generating units reflect impact future generic competition take account new product launches pharmaceutical vaccines cash generating units comprise collection smaller cash generating units including assets indefinite cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid smaller cash generating units including brands indefinite lives carrying value billion billion cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwillgsk annual report strategic review financial review risk governance remuneration financial statements investor information intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications transfer assets held sale cost december exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications transfer fromto assets held sale cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december gsk annual report notes financial statements intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses restated restated cost sales selling general administration research development charge impairments year includes impairments horizant alli viiv healthcare compound lersivirine net book value computer software includes million million internally generated costs licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development net book value includes million million internally generated costs note acquisitions disposals gives details additions business combinations year book values largest individual items follows dolutegravir benlysta flulavalfluviral lovaza selzentry arzerra duac toctino fraxiparine others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident corega biotene poligrip others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology generally using five year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment brandsgsk annual report strategic review financial review risk governance remuneration financial statements investor information investments associates joint ventures joint associated joint associated ventures undertakings total ventures undertakings total january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement december group held one significant associated undertaking december december group owned million shares aspen pharmacare holdings limited aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets investment book value december million million market value million million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors movements year includes deferred profit provided sale classic brands business group market aspen gsk made additional capital contributions million shionogiviiv healthcare joint venture million october gsk acquired share shionogiviiv healthcare joint venture previously held shionogi co ltd date accounted entity subsidiary company see note acquisitions disposals summarised balance sheet information respect groups associates set total assets aspen pharmacare holdings limited others total liabilities aspen pharmacare holdings limited others net assets summarised balance sheet information respect aspen pharmacare holdings limited based preliminary results information analysts forecasts available december investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interest one joint venture japan vaccine co ltd daiichi sankyo co ltd joint venture holds development commercial rights existing preventative vaccines parent companies supply globally recommended vaccines including human papillomavirus hpv vaccine rotavirus vaccine seasonal flu vaccine mumps vaccine diptheria pertussis dtp vaccine measles rubella vaccine mrv japan gsk annual report notes financial statements investments january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures equity investments converted subsidiary acquisition business disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million increase primarily arising additions fair value adjustments additions year include investments theravance inc million disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement investments include assets impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report strategic review financial review risk governance remuneration financial statements investor information trade receivables trade receivables net provision bad doubtful debts prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million provision bad doubtful debts million provision million due state hospital authorities greece ireland italy portugal spain trade receivables also include million million due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale land buildings plant equipment vehicles assets construction intangible assets inventory noncurrent assets transferred assets held sale expected carrying amounts recovered principally disposal sale considered likely held lower carrying amount fair value less costs sell decrease assets held sale primarily results divestment certain noncore consumer healthcare otc products transfer retained assets related alli assets held sale disposal otc brands completed gross proceeds million profit disposal million tax gsk annual report notes financial statements trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals payables include million nil respect maximum potential amount payable noncontrolling shareholders gsk consumer healthcare ltd groups consumer healthcare subsidiary india voluntary open offer purchase additional shares announced november purchase completed february discussed note post balance sheet events customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group trade payables include million million due associates joint ventures pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes reduction uk pension scheme cost relates oneoff adjustments arising capping future pensionable salary increases change basis future discretionary pension increases rpi cpi certain legacy plans details see costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sectionsgsk annual report strategic review financial review risk governance remuneration financial statements investor information pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds expected rate return equities represents groups long term view includes higher risk premium bonds past reflecting current low bond yields projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections long term rate improvement per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans currently return seeking assets liability matching assets uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group changed policy towards granting discretionary pension increases smithkline beecham defined benefit schemes result change discretionary pension increases pensions accruing prior based increases consumer price index instead retail price index change also apply revaluation deferred pensions certain scheme participants left service prior year group also introduced limit uk defined benefit schemes per year rate pensionable pay may increase consequence benefits related final pensionable pay expected lower previously case combined impact two changes credit income statement million similar reduction pension obligation group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report notes financial statements pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service creditcost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service credit expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial losses recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gainslosses recorded statement comprehensive income past service credit million reflects adjustments related capping future pensionable salary increases change basis future discretionary pension increases rpi cpi certain legacy plans details see amounts included within settlements curtailments include million million million augmentation costs arising major restructuring programmes see note provisions total actuarial losses recorded statement comprehensive income since january amount milliongsk annual report strategic review financial review risk governance remuneration financial statements investor information pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets december uk scheme purchased insurance contract guarantee payment specified pensioner liabilities included within assets present value scheme obligations table value million million uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report notes financial statements pensions postemployment benefits continued uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk usa rest world group group movements fair values assets assets january exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets december exchange adjustments expected return assets actuarial lossesgains employer contributions scheme participants contributions benefits paid assets december exchange adjustments expected return assets actuarial lossesgains employer contributions scheme participants contributions benefits paid settlements curtailments assets december uk defined benefit schemes include defined contribution sections account balances totalling million december million million group made special funding contributions uk pension schemes totalling million million million million million million us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreement following valuation additional contributions expected million contributions based discount rate inflation assumption next review contribution levels progress based actuarial valuation december employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefitsgsk annual report strategic review financial review risk governance remuneration financial statements investor information pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations january exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations december unrecognised past service cost recognised balance sheet december uk defined benefit schemes include defined contribution sections obligations totalling million december million million liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter us pension postretirement healthcare schemes amended changes resulted oneoff gain million recognised income statement december us postretirement healthcare scheme obligation million million million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement december group unrecognised past service cost million million million primarily relates effect change us postretirement healthcare scheme amounted million million million defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded gsk annual report notes financial statements pensions postemployment benefits continued postretirement pensions benefits history experience gains losses uk usa rest world group group experience gains scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience lossesgains scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience gainslosses scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets december experience gainslosses scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience losses scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes gsk annual report strategic review financial review risk governance remuneration financial statements investor information pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs revisions ias decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect decrease annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised acquisition subsidiary reclassifications movements transfer pension obligations december settled within one year settled one year december gsk annual report notes financial statements provisions continued legal disputes group involved substantial number legal disputes including notification possible claims set note legal proceedings provisions legal disputes include amounts relating product liability principally relating avandia paxil poligrip antitrust principally relating wellbutrin flonase lamictal government investigations principally relating colorado investigation settlement avandiarelated investigations awp nominal price investigations cidra puerto rico manufacturing settlement contract terminations selfinsurance environmental cleanup property rental charge year million million net reversals estimated insurance recoveries primarily related provisions product liability cases regarding paxil poligrip products various government investigations various federal government investigations resolved year within existing pretax provision tax cost approximately million lower provided result tax credit recorded year however due evolving state litigation environment gsk utilised tax benefit arising recording offsetting additional pretax provision approximately million equating tax cost million related matters recorded legal charge sga net effect movements total earnings neutral discount provisions decreased million million calculated using riskadjusted projected cash flows riskfree rates return movement includes decrease million million arising change discount rate year respect product liability claims related certain products sufficient history claims made settlements enable management make reliable estimate provision required cover unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters may subject negotiation litigation many years litigation proceedings including various appeal procedures often take many years reach resolution outofcourt settlement discussions also often protracted group potential settlement discussions number disputes amounts provided based current assessment progress disputes estimates billion amount provided december settled within one year december expected million million provision made legal disputes reimbursed third party insurers amount included within receivables balances note noncurrent assets note trade receivables discussion legal issues see note legal proceedings major restructuring programmes october group announced significant new operational excellence programme improve effectiveness productivity operations see note major restructuring costs following several expansions estimated total costs expected approximately billion expanded programme expected deliver annual pretax savings approximately billion time substantially complete provisions staff severance payments made management made formal decision eliminate certain positions communicated groups employees affected provision made staff severance payments made immediately pension augmentations arising staff redundancies million million charged year transferred pension obligations provision shown note pensions postemployment benefits asset writedowns recognised impairments property plant equipment note property plant equipment majority amounts provided expected utilised next two years employee related provisions employee related provisions include certain medical benefits disabled employees spouses usa december provision benefits amounted million million employee benefits reflect variety provisions severance costs jubilee awards longservice benefits provisions included provisions contingent consideration respect business acquisitions principally stiefel laboratories inc contingent consideration payable upon certain criteria met certain specified dates future aggregate provision items amounts million december milliongsk annual report strategic review financial review risk governance remuneration financial statements investor information noncurrent liabilities accruals deferred income payables increase payables primarily arises contingent consideration million nil relating acquisition shionogiviiv healthcare joint venture contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december nil million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings bank loans overdrafts commercial paper obligations finance leases european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange longterm borrowings us us medium term note new york stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange bank loans obligations finance leases net debt gsk annual report notes financial statements net debt continued current assets liquid investments classified availableforsale investments december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents december approximately approximately cash cash equivalents balances december earning interest floating fixed rates amount million million respectively million million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk us billion billion commercial paper programme billion billion billion billion issue december also billion five year committed mediumterm facilities billion billion day committed facilities facilities put place september december undrawn liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates range pledged assets group pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions december million groups cash balance held escrow account connection groups offer purchase shares gsk consumer healthcare ltd groups consumer healthcare subsidiary india noncontrolling shareholders addition million assets included note noncurrent assets form part net debt pledged collateral future rental payments operating lease arrangements entered human genome sciences inc acquired year finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations december bearing interest floating fixed rates amount million million respectively million milliongsk annual report strategic review financial review risk governance remuneration financial statements investor information share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes december issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december december december number shares issuable employee share schemes note number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million million shares cancelled monthly purchases shares follows average share price excluding number shares commission stamp duty february march april may june july august september october november december total company expects make share repurchases billion exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period january february details substantial shareholdings refer gsk annual report notes financial statements movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary december exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary december exchange movements overseas net assets december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans share comprehensive expense associates joint ventures comprehensive expense year non retained controlling earnings reserves interests total exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans share comprehensive expense associates joint ventures comprehensive expense year gsk annual report strategic review financial review risk governance remuneration financial statements investor information movements equity continued non retained controlling earnings reserves interests total exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement fair value movement subsidiary acquisition actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report notes financial statements related party transactions gsk held interest aspen pharmacare holdings limited december gsk distributed million million products aspens extensive distribution network december balance due gsk aspen million million balance payable gsk aspen million million gsk also disposed majority classic brands business australia aspen million cash october gsk acquired shareholding shionogi viiv healthcare joint venture shionogi co ltd return minority shareholding viiv healthcare company accounted business acquisition intangible assets net liabilities million million respectively recognised gain million arising primarily fair value gsks existing shareholding recorded income statement together negative goodwill million december gsk held interest viiv healthcare shire canada subsidiary viiv healthcare ulc primarily comarkets combivir trizivir epivir certain territories december balance payable viiv healthcare shire canada million million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million vaccine products joint venture december balance due gsk jvc million balance payable gsk jvc million aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance expense depreciation amortisation intangible assets impairment assets written profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital decreaseincrease inventories decrease trade receivables increasedecrease receivables increase trade payables increasedecrease payables decreaseincrease pension provisions sharebased incentive plans fair value adjustments cash generated operations decrease pension provisions primarily reflects legal settlements billion special contributions defined benefit pension schemesgsk annual report strategic review financial review risk governance remuneration financial statements investor information reconciliation net cash flow movement net debt net debt beginning year decrease cash bank overdrafts cash inflow liquid investments net increase longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year analysis changes net debt exchange reclassifications acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commerical paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes net debt information significant changes net debt see note net debt gsk annual report notes financial statements acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions human genome sciences inc august gsk completed acquisition issued share capital human genome sciences inc hgs us based biopharmaceutical company focused development protein antibody drugs treatment immunoinflammation diseases cash total consideration million represented million cash acquired million intangible assets million goodwill million net assets consideration comprised cash million gain million arising settlement preexisting collaborations gain recognised within operating income income statement goodwill arising acquisition business reflects potential business synergies realisation full value benlysta albiglutide darapladib assets simplifying optimising rd commercial manufacturing operations complete ownership assets goodwill recognised expected deductible income tax purposes results acquired business reported part us europe emap japan pharmaceuticals vaccines operating segments transaction accounted using purchase method accounting proforma turnover hgs business full year million since acquisition gsk recorded turnover million hgs products hgs products fully integrated gsk business practicable separately identify impact acquisition group profit year acquisition costs expensed arising acquisition amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax asset trade liabilities goodwill cash consideration gain settlement preexisting collaborations total consideration shionogiviiv healthcare joint venture october gsk acquired share shionogiviiv healthcare joint venture previously held shionogi co ltd assets acquired include investigational medicine dolutegravir early stage integrase inhibitor compounds compounds development currently generate revenue net assets acquired comprise million intangible assets million deferred tax liability negative goodwill million arising differing assessments valuations parties recognised gain within operating income income statement total consideration comprised equity stake viiv healthcare valued million fair value gsks existing investment joint venture million contingent consideration payable cash future valued million together deferred tax asset million loss settlement preexisting relationships million contingent consideration payable based percentage future sales performance compounds developed joint venture become marketed products total amount payable unlimited results acquired business reported part viiv healthcare transaction accounted using purchase method accounting acquisition costs expensed arising acquisition amounted milliongsk annual report strategic review financial review risk governance remuneration financial statements investor information acquisitions disposals continued fair value book value adjustments fair value net assets acquired intangible assets deferred tax provision negative goodwill consideration settled shares viiv healthcare contingent consideration deferred tax contingent consideration fair value investment joint venture converted subsidiary loss settlement preexisting relationships total consideration acquisitions year gsk completed two smaller acquisitions cash total purchase price million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision trade liabilities goodwill cash consideration contingent consideration fair value equity investment converted subsidiary gain settlement preexisting relationships total consideration acquisitions made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions market participants none goodwill recognised expected deductible income tax purposes results acquisitions reported part europe pharma research development reportable operating segments group recognised settlement gain million result measuring fair value relationships existed prior acquisition date gain recognised operating income income statement acquisition costs expensed arising acquisitions totalled million contingent consideration january exchange adjustments additions remeasurement goodwill remeasurement income statement settlement december gsk annual report notes financial statements acquisitions disposals continued investments associates joint ventures gsk made cash contributions million shionogiviiv healthcare joint venture prior acquisition subsidiary made cash investments million new joint venture group holds share gsk also made cash investments million associates increasing share one associate human shionogi associates genome viiv joint joint cash flows sciences venture acquisitions ventures total cash consideration paid cash cash equivalents acquired cash consideration net cash acquired total cash consideration payable contingent consideration cash consideration net cash acquired acquisitions year gsk completed four subsidiary acquisitions cash total purchase price million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision liabilities goodwill cash consideration fair value investment joint venture converted subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions businesses addition goodwill million recognised respect fair value adjustments prior year acquisitions none goodwill recognised expected deductible income tax purposes results acquisitions reported part consumer healthcare emerging markets pharmaceuticals vaccines reportable operating segments group recognised loss million result remeasuring fair value associate held prior acquisition date loss reported loss disposal interest associates income statement acquisition costs expensed arising acquisitions totalled milliongsk annual report strategic review financial review risk governance remuneration financial statements investor information acquisitions disposals continued investments associates joint ventures gsk made cash contributions million joint venture group share made cash investments associates totalling million transferred million equity investment associates group increased shareholding disposals gsk disposed one subsidiary cash outflow disposal million net cash disposed february gsk disposed entire shareholding quest diagnostics inc us clinical laboratory business listed new york stock exchange sale comprised secondary public offering accompanying repurchase shares quest diagnostics together generated profit disposal million tax associates joint cash flows acquisitions ventures total cash consideration paid cash cash equivalents acquired cash consideration net cash acquired total cash consideration payable deferred consideration cash consideration net cash acquired net cash outflowproceeds disposals net cash disposed acquisitions laboratorios phoenix sacyf june gsk acquired issued share capital laboratorios phoenix sacyf leading pharmaceutical business focused development marketing sale branded generic overthecounter products latin america cash purchase price million included million net cash million intangible assets million goodwill million net liabilities goodwill arising acquisition business reflects potential business synergies sales growth increase gsks market presence following acquisition established market participant none goodwill recognised expected deductible income tax purposes results phoenix reported part emerging markets pharmaceuticals vaccines operating segment transaction accounted using purchase method accounting proforma results laboratorios phoenix sa cyf full year turnover million loss tax major restructuring million since acquisition gsk recorded turnover million tax losses major restructuring million business transaction costs expensed arising acquisition laboratorios phoenix sacyf amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total cash consideration gsk annual report notes financial statements acquisitions disposals continued acquisitions year gsk completed three smaller subsidiary acquisitions cash total purchase price million included million net cash fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill cash consideration fair value investment associate converted subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisition established market participants addition goodwill million recognised respect consideration prior year acquisition none goodwill recognised expected deductible income tax purposes results acquisitions reported primarily part emerging markets pharmaceuticals vaccines reportable operating segment group recognised gain million result measuring fair value associate held prior acquisition date gain reported profit disposal interest associates income statement acquisition costs expensed arising acquisitions totalled million investments associates joint ventures gsk made cash noncash contributions million joint venture group share million joint venture group share investment associate million increase groups share investments associates totalling million associates joint cash flows phoenix acquisitions ventures total cash consideration paid cash cash equivalents acquired cash consideration net cash acquired total cash consideration payable deferred consideration cash consideration net cash acquired gsk annual report strategic review financial review risk governance remuneration financial statements investor information commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangements angiochem inc five prime therapeutics inc md anderson cancer centre new arrangements offset reduced commitments due prior year transactions including amendments agreements amicus therapeutics inc astex pharmaceuticals inc chroma therapeutics inc regulus therapeutics inc xenoport inc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million commitments provided groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases post balance sheet event february gsk completed acquisition shares glaxosmithkline consumer healthcare ltd india take groups shareholding cost approximately million gsk annual report notes financial statements f inancial instruments related net cash inflow operating activities billion disclosures billion excluding legal settlements free cash flow billion billion excluding legal settlements gsk reports sterling pays dividends sterling profits expect deliver continued dividend growth part role corporate treasury monitor manage longterm share buyback programme targeting share external internal funding requirements financial risks repurchases billion depending market conditions support strategic objectives gsk operates global basis primarily subsidiary companies manage capital liquidity risk ensure subsidiaries able operate going concerns gsks policy borrow centrally order meet anticipated optimise returns shareholders appropriate funding requirements cash flow forecast funding balance debt equity treasury activities governed requirements monitored tmg monthly basis policies procedures approved board directors strategy diversify liquidity sources using range recently july facilities maintain broad access funding markets treasury management group tmg meeting chaired december gsk billion cash cash chief financial officer takes place monthly basis review equivalents liquid investments billion borrowings treasury activities members receive management information repayable within one year gsk also access shortterm finance relating treasury activities internal audit reviews treasury us billion commercial paper programme billion internal control environment regularly billion issue programme december gsk uses variety financial instruments finance operations gsk billion five year committed medium term derivative financial instruments manage market risks facilities billion day committed facilities operations derivatives principally comprising forward facilities put place september december foreign currency contracts interest rate currency swaps undrawn consider level committed facilities used swap borrowings liquid assets currencies required adequate given current liquidity requirements group purposes manage exposure financial risks european medium term note programme billion changes foreign exchange rates interest rates december billion notes issue gsk hold issue derivatives speculative purposes programme also us shelf registration statement treasury policies specifically prohibit activity december billion billion notes transactions financial instruments undertaken manage issue programme gsks longterm borrowings mature risks arising underlying business activities speculation dates capital management gsks longterm credit ratings remained unchanged since february currently gsk rated stable outlook gsks financial strategy supports groups strategic priorities standard poors stable outlook moodys investors regularly reviewed board gsk manages capital service moodys shortterm credit ratings p structure group appropriate mix debt standard poors moodys respectively equity order optimise returns shareholders whilst maintaining credit ratings provide us flexibility access market risk debt capital markets attractive terms financial architecture designed drive growth earnings per share generate interest rate risk management cash order maximise returns groups strategy gsks objective reduce effective net interest cost free cash flow generate deployed deliver returns rebalance mix debt fixed floating interest rates shareholders reinvested business depending time policy interest rate risk management limits amount returns attractive continue apply strict floating interest payments prescribed percentage financial returnsbased criteria cash flow return operating profit investment order allocate capital assess investment opportunities use series interest rate swaps redenominate one bonds floating interest rates duration swaps capital structure group consists net debt matches duration principal instrument interest billion see note net debt shareholders equity rate derivative instruments accounted fair value hedges billion see consolidated statement changes equity relevant liability total capital including provided noncontrolling interests billion billion net debt increased billion year primarily due payments billion settle groups significant ongoing us federal government investigations within existing provisions billion cash cost acquisition hgs balance well groups strong cash generation proceeds disposal consumer healthcare otc brands enabled financing share repurchases billion increased dividend payments billion despite increase net debt billion net finance expense year broadly similar reflecting benefits strategy improve funding profile group target reduce average effective net funding cost approximately basis points around achieved one year earlier plannedgsk annual report strategic review financial review risk governance remuneration financial statements investor information financial instruments related disclosures continued foreign exchange risk management foreign currency transaction exposures arising internal external trade flows hedged exposure overseas operating subsidiaries transaction risk minimised matching local currency income local currency costs purpose internal trading transactions matched centrally manage intercompany payment terms reduce foreign currency risk foreign currency cash flows hedged selectively management corporate treasury tmg possible manage cash surpluses borrowing requirements subsidiary companies centrally using forward contracts hedge future repayments back originating currency order reduce foreign currency translation exposure seek denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts major currencies also used reduce exposure investment overseas group assets see net investment hedges section note details tmg reviews ratio borrowings assets major currencies monthly credit risk group considers maximum credit risk december million december million total groups financial assets exception investments comprising equity investments bear equity risk rather credit risk see details groups total financial assets december gsks greatest concentration credit risk billion bank deposits hsbc aaaa greatest concentration credit risk billion investments bearing credit exposure us government rated aaaaa moodys standard poors respectively treasuryrelated credit risk gsk sets global counterparty limits gsks banking investment counterparties based longterm credit ratings moodys standard poors corporate treasurys usage limits monitored daily corporate compliance officer cco operates independently corporate treasury breach limits would reported cfo immediately cco also monitors credit rating counterparties changes ratings occur notifies corporate treasury changes made investment levels authority limits appropriate addition report relationship banks credit ratings presented annually tmg approval reviewed regularly gsk managed exposure credit risk actively recent years reducing surplus cash balances particular usa europe middle east africa part treasury strategy regionalise cash management concentrate cash centrally much possible gsk continued maintain conservative approach counterparty risk throughout period table sets credit exposure counterparties rating liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table although isda agreements amount risk net position counterparty million invested baabbb rated investments includes bank deposits hdfc bank state bank india bbva venezuela china merchants bank counterparties used either local cash management purposes local investment purposes gsk sole shareholder million invested babb rated counterparties december december comprise bank balances held operating companies overseas aaaa aaaa aa aa aa baabbb baabbb baabbb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total aaaa aaaa aa aa aa baabbb baabbb baabbb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys standard poors using published conversion tables gsk annual report notes financial statements financial instruments related following methods assumptions used estimate disclosures continued fair values cidcid cash cash equivalents approximates centrally managed cash reserves amounted billion carrying amount december available within months excludes billion centrally managed cash held viiv healthcare cidcid liquid investments based quoted market prices owned subsidiary group invested centrally managed calculated based observable inputs case marketable liquid assets bank deposits aaaaaa rated us treasury securities based principal amounts case non treasury repo money market funds bear credit exposure marketable securities short repricing periods us government aaaaa rated cidcid investments equity investments traded active wholesale retail credit risk market determined reference relevant stock exchange quoted bid price equity investments determined outside usa customer accounts reference current market value similar instruments groups trade receivables balance reference discounted cash flows underlying net assets usa line pharmaceutical companies group sells products small number wholesalers cidcid shortterm loans overdrafts commercial paper addition hospitals pharmacies physicians groups approximates carrying amount short sales three largest wholesalers amount approximately maturity instruments groups us pharmaceuticals vaccines turnover cidcid longterm loans based quoted market prices case december group trade receivables due european us medium term notes fixed rate three wholesalers totalling million million borrowings approximates carrying amount case group exposed concentration credit risk respect floating rate bank loans loans wholesalers one encounters financial difficulty could materially adversely affect cidcid contingent consideration business acquisitions groups financial results january based present values expected future contractual cash flows groups credit risk monitoring activities relating wholesalers include review quarterly financial information cidcid interest rate swaps foreign exchange contracts based standard poors credit ratings development gsk internal contractual cash flows using market sourced data risk ratings establishment periodic review credit limits exchange rates interest rates balance sheet date however group believes credit risk provision cidcid receivables payables approximates required excess normal provision bad doubtful carrying amount debts see note trade receivables cidcid companyowned life insurance policies based cash fair value financial assets liabilities surrender value table presents carrying amounts fair cidcid lease obligations approximates carrying amount values groups financial assets liabilities december december fair value investments gsk shares fair values financial assets liabilities included december employee share ownership plan amount instrument could exchanged esop trusts held gsk shares carrying value million current transaction willing parties forced million fair value million liquidation sale million based quoted market price shares represent purchases esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earningsgsk annual report strategic review financial review risk governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair carrying fair value value value value notes cash cash equivalents availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables certain noncurrent assets scope ias b financial assets fair value profit loss noncurrent assets scope ias ab derivatives designated fair value profit loss ad derivatives classified held trading ias ad total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts commercial paper total borrowings excluding obligations finance leases e obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss noncurrent liabilities scope ias ac derivatives designated fair value profit loss ad derivatives classified held trading ias ad total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets well trade payables provisions noncurrent liabilities reconciled relevant notes gsk annual report notes financial statements financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies noncurrent liabilities classified level comprise contingent consideration business acquisitions level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january losses recognised income statement gains recognised comprehensive income contingent consideration liabilities businesses acquired year equity investment converted subsidiary acquisition business equity investment additions equity investment disposals transfers level exchange december million movement total financial instruments measured fair value using level valuation methods year arises principally contingent consideration liabilities million entered result business acquisitions year net losses million million attributable level financial instruments held end year reported operating incomegsk annual report strategic review financial review risk governance remuneration financial statements investor information financial instruments related disclosures continued million total carrying value financial liabilities measured using level valuation methods december contingent consideration acquisition former shionogiviiv healthcare joint venture consideration expected paid several years vary line sales dolutegravir regulatory applications marketing approval submitted european union usa canada december probability success applied valuing contingent consideration success obtaining regulatory approval would result increase liability charge income statement approximately million regulatory approval obtained contingent consideration payable liability released income statement table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuation liability increasedecrease financial liability lossgain income statement change key inputs increase sales forecasts decrease sales forecasts increase market interest rates decrease market interest rates b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies assets include tax receivables pension surplus balances prepayments outside scope ias fair value fair value loans financial loans financial profit loss receivables instruments total profit loss receivables instruments total trade receivables note noncurrent assets note following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days provision bad doubtful debts made total million million balance million million relates receivables due state hospital authorities greece ireland italy portugal spain total receivables due state hospital authorities countries current past due net provisions million million c trade payables provisions noncurrent liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities liabilities include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias december financial liabilities measured fair value profit loss fair value financial financial profit loss liabilities instruments total instruments total trade payables note provisions note noncurrent liabilities note gsk annual report notes financial statements financial instruments related disclosures continued derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities fair value hedges interest rate swaps principal amount million million net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million nil derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments analysed current noncurrent total foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts consisting primarily currency swaps net liability fair value million million net liability represent hedges intercompany loans deposits external debt legal provisions designated accounting hedges fair value movements taken income statement period offset exchange gains losses related intercompany lending borrowing external debt legal provisions fair value hedges group designated series interest rate swaps fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance expense carrying value bonds designated hedging relationship includes million million deemed hedged item fair value hedge relationship net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro japanese yen foreign operations shown table carrying value bonds designated hedging relationship includes million million deemed hedging instrument net investment hedge relationship cash flow hedges december group entered nondeliverable foreign exchange contract designated cash flow hedge foreign exchange exposure arising recognition liability denominated indian rupee groups consolidated financial statements december group designated cash flow hedgesgsk annual report strategic review financial review risk governance remuneration financial statements investor information financial instruments related disclosures continued e debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing group holds interest rate swaps designated fair value hedges convert million fixed rate debt maturity one two years million maturity two three years floating rate exposure f sensitivity analysis foreign exchange interest rate sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations december financial instruments affected market risk include cash cash equivalents borrowings trade receivables payables derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes foreign exchange interest rates foreign exchange sensitivity table shows indicative basis groups sensitivity foreign exchange rates us dollar euro yen financial instruments three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies concluded cent yen movement rates sterling reasonable analysis financial instruments considered sensitive foreign exchange rates functional currency entity holds obligations finance leases intercompany loans fully hedged maturity certain nonderivative financial instruments net debt excluded present material exposure foreign exchange sensitivity group assets liabilities financial instruments included calculation movement income statement table relates primarily hedging instruments legal provisions trade receivables payables whilst hedging instruments provide economic hedges related remeasurement provisions included calculation increase increase income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease income million million nil us dollar euro yen exchange rates respectively million million million gsk annual report notes financial statements financial instruments related disclosures continued movements equity table relate hedging instruments foreign exchange derivatives external debt designated net investment hedge hedge group assets denominated euro yen decrease decrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increase equity nil million million us dollar euro yen exchange rates respectively nil million nil table presents groups sensitivity foreign exchange rates based composition net debt shown note adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows increase increase decrease decrease net debt net debt net debt impact nonfunctional foreign currency exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease net debt million million million us dollar euro yen exchange rates respectively million million million interest rate sensitivity table shows indicative basis groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last three years concluded basis points increase reasonable benchmark debt maturity less one year floating rate calculation interest rate movements derivative financial instruments designated fair value hedges deemed immaterial effect group income statement due compensating amounts carrying value debt basis points movement interest rates deemed material effect equity increase increase decrease decrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates interest rates could decreased basis points currently less maximum increasedecrease income would therefore limited million nil nil sterling us dollar euro interest rates respectively million million million g contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report strategic review financial review risk governance remuneration financial statements investor information financial instruments related disclosures continued contractual cash flows nonderivative financial liabilities derivative instruments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities billion year results part issuance billion new us european medium term notes future interest cash flows issuance billion shortterm commercial paper offset repayment billion european medium term notes matured contingent consideration liabilities arising business acquisitions add billion undiscounted expected future cash flows following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purposes table though practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year increased compared december due higher levels hedging intercompany loans external debt reflected increased principal amounts shown table receivables payables receivables payables due less one year one two years two three years gross contractual cash flows employee share schemes group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline plc grant price savingsrelated share option schemes share award schemes addition gsk operates performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options employees cost scheme readily equates potential gain made employee grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving grants share option schemes awards performance share plan normally granted employees acquire shares ads gsk plc circumstances settled cash options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant share options awarded directors effect grant cet subject performance criteria option pricing purposes valuing options awards arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option share award schemes years years years weighted average share price grants year shares ads plans dividends reinvested gsk annual report notes financial statements employee share schemes continued volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value january options granted options exercised options lapsed december options granted options exercised options lapsed december options granted options exercised options lapsed december range exercise prices options outstanding year end weighted average market price exercise weighted average remaining contractual life years years years share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year share option share option savingsrelated options exercisable schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december december december gsk annual report strategic review financial review risk governance remuneration financial statements investor information employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted onwards directors members cet performance conditions based four equally weighted measures three year performance period first measure based achievement adjusted free cash flow targets second measure based relative tsr performance comparator group remaining two measures based businessspecific performance measures business diversification rd new product performance details calculation measures see remuneration report pages awards granted directors members cet award based achievement adjusted free cash flow targets three year measurement period remaining award based relative tsr performance comparator group described pages half tsr element award measured three years half four years awards granted directors members cet prior subject single performance condition compares gsks tsr period tsr companies comparator group period awards made eligible employees prior performance conditions consist two parts applies award first part performance condition compares gsks eps growth increase uk retail prices index three year measurement period second part performance condition compares gsks tsr period tsr companies comparator group period awards granted onwards first part performance condition continues based eps second part performance condition based strategic operational business measures three year measurement period specific employees business area shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december year shares ads awarded dividends reinvested included share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted ads weighted number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december gsk annual report notes financial statements employee share schemes continued deferred investment award plan group operates deferred investment award plan whereby awards granted form notional shares certain senior executives cost awards typically vest threeyear period commencing fourth anniversary date grant award initially vesting subsequent two years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december year additional shares additional ads awarded dividends reinvested employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report strategic review financial review risk governance remuneration financial statements investor information principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group december details given principal country operation location headquarters business sector business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford glaxochem pte ltd ph h brentford setfirst limited phch h brentford wellcome foundation limited ph p cambridge domantis limited ph r brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph brentford viiv healthcare trading services uk limited ph e f austria vienna glaxosmithkline pharma gmbh ph belgium wavre glaxosmithkline pharmaceuticals sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark brndby glaxosmithkline consumer healthcare ch e brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch marly le roi viiv healthcare sas ph st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h munich glaxosmithkline gmbh co kg ph h greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h milan glaxosmithkline consumer healthcare spa ch verona glaxosmithkline manufacturing spa ph p luxembourg mamer glaxosmithkline international luxembourg sarl phch f h netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph gsk annual report notes financial statements principal group companies continued europe location subsidiary sector activity republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limited ii ph dungarvan stafford miller ireland limited ii ch p dungarvan glaxosmithkline dungarvan limited ii ch p sligo stiefel laboratories ireland limited ii ph p romania brasov europharm holding sa phch bucharest glaxosmithkline gsk srl ph r russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa research triangle park stiefel laboratories inc ph p marietta corixa corporation ph p r philadelphia glaxosmithkline llc phch e p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc phch f cambridge sirtris pharmaceuticals inc ph r research triangle park viiv healthcare company ph rockville human genome sciences inc ph p r americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r mississauga glaxosmithkline consumer healthcare inc ch laval id biomedical corporation quebec ph e p r mexico mexico city glaxosmithkline mexico sa de cv phch e p asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h r hong kong glaxosmithkline limited phch shanghai glaxosmithkline biologicals shanghai ltd ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ch e p india mumbai glaxosmithkline pharmaceuticals limited ph p new delhi glaxosmithkline consumer healthcare limited iii ch e p r malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch e p r philippines makati glaxosmithkline philippines inc phch e singapore singapore glaxo wellcome manufacturing pte ltd ph e p r singapore glaxosmithkline pte ltd phch e south korea seoul glaxosmithkline korea limited ph ch thailand bangkok glaxosmithkline thailand limited phch mgsk annual report strategic review financial review risk governance remuneration financial statements investor information principal group companies continued japan location subsidiary sector activity japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r buenos aires laboratorios phoenix sociedad anonima industrial comercial financiera ph e p brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae phch e p nigeria lagos glaxosmithkline consumer nigeria plc phch e p south africa johannesburg glaxosmithkline south africa pty limited phch e p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa associate south africa johannesburg aspen pharmacare holdings limited iv phch p r incorporated singapore ii exempt provisions section companies amendment act ireland iii c onsolidated subsidiary undertaking accordance section companies act grounds dominant influence february groups shareholding increased following completion open offer undertaken glaxosmithkline pte ltd iv e quity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report notes financial statements legal proceedings netherlands action brought sandoz pharmaceuticals sandoz hexal district court hague january group involved significant legal administrative revoked supplementary protection certificate spc proceedings principally product liability intellectual property tax extends protection product september antitrust governmental investigations well related private revocation action basic patent covering seretide litigation group makes provision proceedings combination ireland filed high court dublin regular basis summarised note accounting principles behalf ivax july high court handed decision policies note provisions group may become june finding patent invalid obviousness involved significant legal proceedings respect group filed appeal decision october trial possible make reliable estimate expected financial effect date set appeal could result ultimate resolution proceedings cases appropriate disclosures cases would currently generic salmeterolfluticasone proportionate included provision would made fixed combination products uk belgium france germany ireland netherlands respect legal proceedings described provision made group july group entered settlement agreement unable make reliable estimate expected financial effect sandoz pursuant parties resolved pending litigation stage group believe information relating groups combination patents seretide europe amount sought plaintiffs known would settlement agreement provides group pursue meaningful respect legal proceedings due legal action combination patents sandoz block number factors including limited stage launch generic salmeterolfluticasone propionate product proceedings entitlement parties appeal decision european country sandoz received regulatory approval clarity theories liability damages governing salmeterolfluticasone proportionate product european law intellectual property claims include challenges validity country date enforceability groups patents various products processes well assertions noninfringement patents argatroban loss cases could result loss patent protection december encysive pharmaceuticals inc encysive product issue consequences loss could mitsubishi kasei corporation mitsubishi group filed significant decrease sales product could materially action united states district court southern district affect future results operations group new york barr laboratories inc barr infringement legal expenses incurred provisions related legal claims mitsubishis pharmaceutical composition patent covering charged selling general administration costs provisions argatroban pursuant licence mitsubishi encysive made taking appropriate legal specialist advice developed argatroban treatment heparininduced outflow resources considered probable thrombocytopenia holds new drug application approved reliable estimate made likely outcome dispute us food drug administration fda encysive licensed respect product liability claims related certain products us marketing rights argatroban group mitsubishi sufficient history claims made settlements enable patent expires june barr teva pharmaceuticals inc management make reliable estimate provision required teva filed abbreviated new drug application anda cover unasserted claims december groups fda certification invalidity unenforceability aggregate provision legal disputes including noninfringement mitsubishi patent june tax matters described note taxation billion group partners prevailed teva trial judge ultimate liability legal claims may vary amounts ruling mitsubishis patent covering formulation injectable provided dependent upon outcome litigation argatroban infringed invalid august proceedings investigations possible settlement negotiations united states court appeal federal circuit affirmed decision result courts decision teva precluded groups position could change time therefore launching generic product june assurance losses result outcome legal proceedings exceed material march group filed suit us district court amount amount provisions reported groups district new jersey enjoin hikma pharmaceuticals hikma financial accounts happen could material launching generic argatroban product pfizer adverse impact results operation group acquired encysive mitsubishi joined suit reporting period judgments incurred groups licensors trial held july july settlements entered significant matters court found patent valid infringed hikma described announced launching product december intellectual property arzerrabenlystacabilly patents february group filed declaratory action advairseretide united states district court northern district california number companies challenged groups patents declaration us patent known cabilly ii covering advairseretide salmeterolfluticasone propionate patent owned jointly genentech inc city certain european jurisdictions including uk belgium hope invalid unenforceable infringed groups france germany ireland netherlands february product arzerra ofatumumab approved fda actions brought mylan pharmaceuticals inc hexal refractory chronic lymphocytic leukaemia cll genentech pharmaceuticals hexal neolab ltd ivax international city hope counterclaimed infringement suit subsequently federal court munich revoked groups german transferred united states district court middle seretide combination patent lack inventive step district californiagsk annual report strategic review financial review risk governance remuneration financial statements investor information legal proceedings continued may group settled earlier patent challenge avodart teva pharmaceuticals inc teva terms april obtaining third cabilly patent cabilly settlement teva permitted launch generic iii patent genentech filed suit group united dutasteride product fourth quarter earlier states district court middle district california alleging certain circumstances tevas generic dutasteride product group lonza manufacturer arzerra infringed approved fda december cabilly iii patent making selling arzerra group december anchen notified group filed contractually required defend indemnify lonza claims anda jalyn paragraph iv certification alleging related arzerra cabilly patents genentech also sued patent expires invalid unenforceable group human genome sciences inc hgs claiming infringed jalyn combination dutasteride tamsulosin infringement making selling benlysta covered three patents cover avodart subsequently cabilly ii iii patents hgs groups prior licensor benlysta group received similar notices impax laboratories inc acquired group watson challenging one patents covering jalyn group settled litigation genentech cabilly ii group sued anda applicants jalyn united states cabilly iii patents relating arzerra may relating district court district delaware cases benlysta december group obtained consolidated trial avodart cases january worldwide royaltybearing license regard products group anchen settled litigation terms would allow anchen enter market jalyn fourth quarter march genentech biogen idec filed suit earlier certain circumstances trial held group united states district court southern january remaining defendants decision district california alleging groups sale arzerra yet rendered induces contributes infringement patent claims treatment cll anticd monoclonal antibody benlysta group counterclaimed patent invalid infringed october district court issued ruling september uk court appeal refused appeal construed claims manner arzerra would eli lilly company eli lilly asserting human genome infringe patent genentech biogen idec stipulated sciences inc hgs uk patent ep benlysta judgment infringement filed appeal claim invalid grounds lacked necessary information construction issue united states court appeals required work invention described claims covered federal circuit december appeal heard antibodies antibody claim insufficiency argument uk november decision yet rendered high court uk supreme court previously decided patent valid grounds initial revocation avodartjalyn brought eli lilly patent claims cytokine blys antibody binds blys benlysta november banner pharmacaps inc banner notified belimumab eli lilly petitioned uk supreme court hear group filed anda market generic version appeal antibody claim insufficiency argument decision avodart dutasteride banners notification contained paragraph uk supreme court whether grant appeal pending iv certification alleging two patents expiring one patent expiring patent covering compound eli lilly also requested declaration supplementary dutasteride invalid infringed banners proposed protection certificate spc filed hgs extend uk patent generic dutasteride product based upon eli lillys antiblys mab invalid august decision issued uk court appeal refer group subsequently received similar notices anchen questions court justice european union cjeu pharmaceuticals anchen roxane laboratories roxanne relating whether product protected basic patent watson laboratories inc watson mylan pharmaceuticals inc force judge ordered remaining issues mylan apotex inc apotex variously challenging included referral go factfinding trial uk either patent patents high court trial date set july uk high group filed suit banner anchen united states court cjeu reference likely heard early district court district delaware january november eli lilly brought action uk patents infringement avodart patents consequence stay court revocation european patent owned biogen idec fda approval banners anchens products covering use antibody b lymphocyte stimulatory effect earlier may decision adverse also known blys treatment autoimmune diseases group separate complaint filed roxane watson group exclusively licensed patent responsible court june september defending action march similar action group filed suit mylan impax august brought lilly equivalent biogen idec patent ireland group filed suit apotex thirtymonth stays european patent also challenged parallel proceedings fda approval subsequent generic products extend merck serono european patent office october past anchenbanner stay may biogen patent revoked technical board appeal except august suit apotex cases epo automatically rendered various national patents avodart jalyn described consolidated invalid cases moot proceeding closed original case anchen banner trial held european patent revoked parallel proceedings january decision yet rendered european patent office revocation action direct effect ability group market benlysta validity patents cover benlysta gsk annual report notes financial statements legal proceedings continued lovaza march group received notice teva pharmaceuticals epzicom usa inc teva par pharmaceuticals inc par apotex inc november group received notice teva apotex filed andas paragraph iv certification alleging pharmaceuticals usa inc teva filed anda two patents covering lovaza omegaacid ethyl esters paragraph iv certification epzicom combination invalid unenforceable infringed patents expire march lamivudine abacavir certification challenged april group licensee patents patent covering hemisulfate salt abacavir expires marketing rights usa puerto rico pronova group sue teva patent june biopharma norge pronova owner patents sued viiv healthcare received notice teva amended teva par apotex united states district court anda epzicom contain paragraph iv certification two district delaware group party suits additional patents listed orange book alleging patents march pronova entered agreement invalid unenforceable infringed patents challenged apotex settle patent litigation usa related lovaza new certification relate method treating hiv using settlement grants apotex licence enter us market combination expiring certain crystal form generic version lovaza first quarter terms lamivudine expiring august viiv healthcare settlement confidential filed suit teva combination patent united states district court district delaware stay place trial involving teva par held march april fda approval tevas anda earlier december may united states district court district decision adverse viiv healthcare matter delaware ruled pronovas favour finding pronovas patent claims district court consolidated discovery epzicom case valid would infringed teva par court enjoined viiv healthcares patent infringement suit lupin ltd relating fda approval tevas pars products par teva trizivir cases involve patent covering appealed court appeals federal circuit combination lamivudine abacavir trial scheduled either june briefing completed january september judge decides join case parties await hearing trizivir matter trial june pronova group also received paragraph iv notices endo pharmaceuticals endo mylan pharmaceuticals inc lexiva mylan sandoz inc sandoz strides arcolab ltd strides april ranbaxy laboratories limited ranbaxy notified advising submitted andas fda generic viiv healthcare filed paragraph iv certification alleging form lovaza pronova chosen assert patents patent claiming polymorphic form fosamprenavir calcium endo mylan sandoz strides awaiting ruling active ingredient lexiva invalid infringed patent litigation teva par united states district court expires viiv healthcare sue patent district delaware july mylan pharmaceuticals inc mylan notified trizivir viiv healthcare filed anda lexiva paragraph iv certification asserting patents claiming may viiv healthcare received notice lupin ltd active ingredient expiring ii polymorphic form lupin filed anda containing paragraph iv certification active ingredient expiring invalid unenforceable trizivir triple combination lamivudine azt abacavir infringed mylan second generic file anda alleging three patents listed orange book trizivir lexiva first generic company challenge basic either invalid unenforceable infringed patents relate compound patent active ingredient method treating hiv using triple combination expiring hemisulfate salt abacavir expiring august viiv healthcare licensor vertex certain crystal form lamivudine expiring june pharmaceuticals incorporated filed patent infringement suit viiv healthcare filed suit lupin patent mylan patent claiming active ingredient covering triple combination united states district court patent claiming polymorph us district court district delaware october district court district delaware mylan subsequently filed declaratory consolidated case discovery viiv healthcares patent judgment action viiv healthcare alleging polymorph infringement suit involving teva pharmaceuticals usa inc patent invalid infringed viiv healthcare stipulated epzicom pending court stay place fda noninfringement patent claiming polymorph trial approval lupins anda earlier november scheduled may infringement basic active decision adverse viiv healthcare matter trial scheduled ingredient patent lexiva begin june october ranbaxy filed petition inter parties veramyst review us patent trademark office uspto alleging basic compound patent covering active ingredient invalid november group received notice sandoz inc collateral attack patent run parallel filed anda paragraph iv certification veramyst court challenge viiv healthcare responded uspto fluticasone furoate nasal spray challenging three patents listed asserted petition granted orange book veramyst invalid unenforceable infringed three patents expire december group filed suit sandoz united states district court district delaware three patents stay fda approval sandozs generic product place earlier court decision adverse group may trial scheduled begin december gsk annual report strategic review financial review risk governance remuneration financial statements investor information legal proceedings continued group reached agreements settle substantial majority us claims relating paxil use pregnancy product liability february number claims related use pregnancy still pending including several scheduled trial preclinical clinical trials conducted development philadelphia mass tort program matters potential products determine safety efficacy dismissed without payment products use humans following approval regulatory canada nationwide class action certified british bodies notwithstanding efforts drugs vaccines columbia lawsuit alleging cardiovascular defects children whose introduced marketplace unanticipated safety issues mothers taken paxil pregnancy another purported class may become believed evident group action canada making similar allegations pending currently defendant number product liability lawsuits related groups pharmaceutical consumer healthcare final court approval class settlement received certified products significant matters described statewide class action seeking restitution alleged violations group able make reliable estimate expected california unfair competition law relating symptoms financial effect matters discussed category discontinuing use paxil included provision matters provision legal uk late public funding withdrawn disputes also noted note provisions hundreds claimants received funding pursue litigation avandia alleging paxil caused suffer withdrawal reactions dependency legal services commissions decision group named product liability lawsuits behalf withdraw funding remains subject appeal special individuals asserting personal injury claims arising use cases review panel claimants claimants avandia federal cases filed group part discontinued claims multidistrict litigation proceeding pending united states district court eastern district pennsylvania cases poligrip also filed number state courts cases filed state court beginning number product liability lawsuits claims philadelphia coordinated mass tort program filed group state federal courts cases state court california coordinated los usa including purported class actions alleging zinc angeles additionally number purported class actions super poligrip causes copper depletion permanent neurologic seeking economic damages behalf third party payers injury federal cases consolidated denture cream consumers asserting claims arising various state federal adhesive multidistrict litigation mdl united states district laws including racketeer influenced corrupt organizations court southern district florida established act rico state unfair trade practices andor consumer protection june group procter gamble defendants laws addition three subrogation actions initiated united litigation included mdl four purported class actions health group inc humana brought asserting economic loss claims state consumer protection laws group june united states court appeals claims medical monitoring putative class third circuit ruled medicare advantage organisations actions dismissed two current exceptions one united health group humana medical plan federal state court case pennsylvania one state court case small cause action medicare act december claims court tennessee state court cases group filed petition certiorari us supreme court consolidated philadelphia mass tort program mtp seeking review third circuits decision december january vast majority individual cases previously humana asked district court certify action class pending mdl mtp dismissed fewer action behalf medicare advantage organisations group ten active cases mdl three active cases mtp opposed motion still pending group one individual lawsuit well february group reached agreements settle five purported class actions asserting consumer fraud claims substantial majority federal state cases pending also filed remain pending canada unfiled usa eleven purported class actions avandia pending claims uk elsewhere group voluntarily withdrew canada group reached agreement principle zinccontaining formulations super poligrip market resolve single purported consumer class action israel early paxil paxil cr group received numerous lawsuits claims alleging use paxil paroxetine caused variety injuries lawsuits recent years alleged use paxil pregnancy resulted birth child birth defects health issues lawsuits claims alleged patients took paxil committed attempted commit suicide acts violence patients suffered symptoms discontinuing treatment paxil gsk annual report notes financial statements legal proceedings continued average wholesale price united states department justice doj number states sales marketing regulation putative classes private payers several years group able make reliable estimate investigating andor bringing civil litigation regarding allegations expected financial effect matters discussed category numerous pharmaceutical companies including group violated included provision matters provision federal state fraud abuse laws result way average legal disputes except noted matters wholesale price awp wholesale acquisition cost wac group made provision also noted note determined reported various drugs reimbursed provisions medicare medicaid insurance programmes group reached million civil settlement colorado investigation federal government resolve allegations relating pricing marketing zofran kytril doj settlement group february group received subpoena united also amended thenexisting corporate integrity agreement states attorneys office colorado regarding groups sales requirement settlement group received final promotional practices relating nine largest selling products approval million nationwide private payer class action period january investigation settlement relating groups price reporting multidistrict later taken united states attorneys office litigation proceeding united states district court district massachusetts expanded present respect district massachusetts advair july group announced reached agreement united states government multiple states number states respective attorneys general district columbia conclude groups counties new york state filed civil lawsuits significant ongoing united states federal government investigations state federal courts group many drug specifically colorado investigation groups sales companies claiming damages restitution due awp andor marketing practices begun february ii united states wac price reporting pharmaceutical products covered department justices investigation possible inappropriate use states medicaid programmes states seek recovery behalf nominal price exception medicaid rebate program states payers cases behalf instate iii department justices investigation development patients consumers marketing avandia settlement payment billion group separately resolved awp claims state medicaid settlement resolved criminal civil liabilities related programmes almost states doj settlement investigations payment covered groups existing separate negotiations litigation concerning awp issues provisions funded existing cash resources continuing two states illinois wisconsin terms settlement gsk pleaded guilty cidra puerto rico manufacturing site misdemeanour violations us federal food drug cosmetic act related certain aspects marketing paxil october group finalised agreement paediatric use wellbutrin certain uses failure us attorneys office district massachusetts us include information initiation status certain department justice respect investigation avandia studies periodic annual reports submitted groups former manufacturing facility cidra puerto rico fda additionally part agreement group entered agreement comprehensive settlement pending corporate integrity agreement cia office inspector claims group arising investigation group general oig us department health human paid total million million resolve civil services cia also covers portion gsks manufacturing criminal allegations sb pharmco puerto rico inc subsidiary operations related groups settlement events group pleaded guilty certain charges cia early groups former manufacturing facility us government entered july covers portion cidra puerto rico manufacturing operations compliance matters related date states district columbia agreed join groups settlement investigation federal settlement agreement receive portion hiv division enquiry share settlement payment agreement july group received subpoena eastern avandiarelated matters district new yorks us attorneys office regarding sales noted july group reached agreement marketing practices three hiv products well educational us government number states district programmes grants payments physicians regarding drug columbia resolve federal governments avandia investigation used treat hivinfected adults september settlement resolved claims federalstate medicaid group advised us government concluded programs november group agreed pay investigation declined intervene qui tam lawsuit filed million settle claims states district united states district court eastern district new york columbia state consumer protection laws regarding february group moved dismiss lawsuit marketing promotion avandia attorneys general offices states kentucky louisiana maryland mississippi new mexico south carolina utah west virginia filed suit group asserting various statutory common law claims relating development marketing avandia regard state louisiana groups products group also defending action county santa clara california brought californias consumer protection laws seeking civil penalties restitutiongsk annual report strategic review financial review risk governance remuneration financial statements investor information legal proceedings continued eu sector enquiry january european commission requested nominal pricing information group number pharmaceutical may group advised us department companies relating patent settlement agreements affecting justice investigating certain groups nominal european union european economic area markets request pricing bundled sale arrangements nominal price information second monitoring exercise exception best price reporting requirements medicaid commission patent settlement agreements pharmaceuticals drug rebate programme group also received subpoenas sector results exercise published july requests documents information delaware january commission repeated exercise michigan related groups nominal price arrangements third patent settlement monitoring exercise group matters resolved part groups settlement responded february january agreement federal government announced july commission repeated exercise requested information group entered nominal price arrangements group group responded february since december provision made matter lovaza eu enquiry tyverb combivir april group received subpoena office december group viiv healthcare received inspector general us department health human request information european commission regarding services requesting production documents relating groups application direct pharmacy distribution groups marketing promotion lovaza group complied product tyverb viiv healthcares product combivir request us government declined take action group viiv healthcare provided requested investigation matter finally resolved approximately information provision made matter time groups settlement agreement federal uk office fair trading competition act investigation government announced july august uk office fair trading oft launched paxilseroxat formal investigation group pharmaceutical group settled lawsuit filed new york state companies potential infringement competition act attorney generals office alleging group failed disclose investigation focuses whether litigation settlements data use paxil children adolescents group potential suppliers generic paroxetine group made class settlements lawsuits brought formulations entered object consumers thirdparty payers respectively economic effect prevention restriction distortion competition damages allegedly resulting prescriptions paxil children uk ii group infringed dominant position adolescents group denied liability settlements making payments potential suppliers generic paroxetine plaintiffs voluntarily dismissed similar purported class aim restricting development full generic competition action filed behalf governmental entities paid uk group terminated agreements issue prescriptions paxil minors remains similar purported oft investigation covers issues also investigated class action canada seeking economic damages behalf european commission respect paroxetine individuals third party payers governmental entities european union also part european purchased paxil use patients age commission pharmaceutical sector enquiry march commission announced formally concluded enquiry secdoj fcpa enquiry action march oft decided focus investigation potential anticompetitive aspects paroxetine us securities exchange commission sec us settlement agreements dropped investigation relation department justice initiated industrywide enquiry potential abuse dominance however february oft whether pharmaceutical companies may engaged decided reopen dominance aspects matter violations foreign corrupt practices act relating sale pharmaceuticals including argentina brazil canada china group cooperating oft investigation germany italy poland russia saudi arabia group one group provided information documentation response companies asked respond enquiry ofts requests held meetings oft cooperating sec doj provision september discuss matter november oft made matter advised proceed statement objection issued april subject ofts final internal review antitrustcompetition provision made matter group able make reliable estimate expected financial effect matters discussed category included provision matters provision legal disputes except noted matters group made provision also noted note provisions gsk annual report notes financial statements legal proceedings continued commercial corporate group able make reliable estimate expected wellbutrin sr financial effect matters discussed category december january february lawsuits included provision respect matters provision several purported class actions filed legal disputes set note provisions united states district court eastern district pennsylvania provision made following matters except group behalf direct indirect purchasers indicated wellbutrin sr complaints alleged violations us antitrust laws securitieserisa class actions sham litigation fraud patent office group obtaining enforcing patents covering wellbutrin sr stiefel complaints followed introduction generic competition wellbutrin sr april district appellate court rulings july class action suit brought behalf current generic manufacturer infringe groups patents former employees stiefel laboratories inc stiefel filed united states district court southern district florida november district court approved groups complaint alleges stiefel officers directors settlement certified class direct purchasers violated us employee retirement income security act erisa settlement concluded january group federal state securities laws inducing stiefel employees reached agreement principle settle claims indirect sell shares employee stock plan back stiefel purchasers million hearing final approval greatly undervalued price without disclosing employees settlement district court scheduled june stiefel sold group july wellbutrin xl district court denied plaintiffs motion class certification october district court granted defendants actions filed biovail corporation biovail motions summary judgment dismissing one group united states district court eastern district remaining plaintiffs litigation trial claims one pennsylvania purported classes direct indirect plaintiff timothy finnerty took place may resulted purchasers allege unlawful monopolisation antitrust million jury verdict favour mr finnerty violations related enforcement biovails wellbutrin xl securities claims group appealed verdict patents filing biovail citizen petitions direct separately group settled mr finnertys erisa claims indirect purchaser classes certified district five separate lawsuits stiefel charles stiefel former court granted groups motion partial summary judgement ceo stiefel also filed individual former stiefel primarily immunity grounds november district employees case asserts claims similar contained court also granted groups motion stay proceedings class action lawsuits pending federal court except limited amount ongoing discovery light us florida georgia supreme courts grant petition ftc v watson reverse payment patent litigation case december us securities exchange commission sec filed formal complaint stiefel charles stiefel flonase united states district court district florida alleging purported direct indirect purchaser class actions filed stiefel principals violated federal securities laws united states district court eastern district inducing stiefel employees sell shares employee pennsylvania alleging group illegally maintained monopoly stock plan back company greatly undervalued price power market flonase charged plaintiffs without disclosing employees company supracompetitive prices additionally suit filed roxane sold trial date yet scheduled group laboratories inc generic competitor seeking lost profits made provision stiefel litigation groups alleged actions unlawfully delaying roxanes entry avandia erisa litigation market predicate allegations filing group allegedly sham citizen petitions subsequent putative class action suit filed group litigation december group reached agreement august united states district court southern settle litigation direct purchasers payment district new york complaint alleged group million agreement settle indirect purchaser officers directors certain employees made misleading public class indirect purchasers payment million statements avandia alleged misleading hearings approve class action settlements scheduled statements exposed value groups stock dropped june plaintiff brought suit behalf participants groups retirement plans claiming group lamictal individual defendants breached fiduciary duties plan purported direct indirect purchaser class actions filed participants employee retirement income security united states district court district new jersey act erisa alleging group teva pharmaceuticals unlawfully plaintiffs subsequently amended complaint add allegations conspired delay generic competition lamictal resulting concerning wellbutrin sr paxil include additional group overcharged separate count accuses group defendants individual members groups benefits monopolising market motions group teva committees may district court dismissed dismiss amended complaint purported direct purchaser plaintiffs complaint prejudice june plaintiffs filed class granted purported direct purchaser class appeal united states court appeals second appealed decision group also plans move circuit september court appeals ruled purported indirect purchaser class dismissed groups favour affirming lower courts dismissal complaint matter concludedgsk annual report strategic review financial review risk governance remuneration financial statements investor information legal proceedings continued november purported class action filed group united states district court northern district benlysta securities litigation new york behalf groups pharmaceutical sales representatives working new york previous six years november class action suit filed united plaintiff makes similar allegations set forth states district court district maryland alleging flsa cases well claims new york wage hour human genome sciences inc hgs certain individual laws closely follow flsa january plaintiff filed officers directors group made statements similar purported class action florida state court alleging clinical trials benlysta failed disclose suicides among trial groups pharmaceutical sales representatives entitled participants withholding information overtime flsa court issued stay activities defendants caused hgs stock artificially inflated harming new york case parties agreed ask court stay anyone purchased hgs stock inflated price november activities florida case united states supreme court second action filed federal court two decided applicability outside sales exemption cases combined may group hgs filed pharmaceutical sales representatives united states motions dismiss suits oral argument heard september supreme court found favour group determined courts ruling awaited pharmaceutical sales representatives exempt overtime flsa wage hour lawsuits described wage hour claims arizona california florida new york dismissed december two purported class actions filed without payment plaintiffs group behalf groups us pharmaceutical sales environmental matters representatives actions filed transferred united states district court central district california group notified potential responsibility relating initially alleged representatives exempt past operations past waste disposal practices certain employees california law andor us fair labor standards sites primarily usa matters subject act flsa consequently entitled overtime pay among litigation including proceedings initiated us federal things plaintiffs subsequently amended complaints state governments waste disposal site remediation costs assert class action limited solely pharmaceutical sales tort actions brought private parties representatives working california asserting claims group advised may responsible party californias wage hour laws approximately sites appear national group moved summary judgment dismissing claims priority list created comprehensive environmental response putative class representatives ground compensation liability act superfund proceedings exempt employees appeals pending united states seek require operators hazardous waste facilities court appeals ninth circuit cases involving transporters waste sites generators hazardous manufacturers virtually factual legal arguments waste disposed sites clean sites reimburse district court deferred ruling summary judgment motion us government cleanup costs instances stayed activity case appellate court group involved alleged generator hazardous waste ruled least one companies pending cases although superfund provides defendants jointly ninth circuit deferred ruling companies pending cases severally liable cleanup costs proceedings frequently california supreme court issued opinion case resolved basis nature quantity waste disposed addressing application administrative exemption generator site groups proportionate liability california state law january california supreme court cleanup costs substantially determined issued ruling case requesting briefing effect sites referred ruling california supreme court companies pending pharmaceutical sales representative cases groups potential liability varies greatly site site cost investigation study remediation third case filed united states district court district sites could time substantial group routinely accrues arizona august sought establish nationwide amounts related share liability matters collective action behalf groups us pharmaceutical sales representatives ground representatives exempt employees flsa november district court granted groups motion summary judgment dismissed lawsuit ground sales representatives exempt employees outside sales exemption flsa plaintiffs appealed decision united states court appeals ninth circuit february ninth circuit issued opinion favour group affirming judgment united states district court district arizona finding groups pharmaceutical sales representatives exempt employees outside sales exemption flsa therefore entitled overtime pay plaintiffs filed petition seeking review decision united states supreme court june united states supreme court affirmed decision ninth circuit gsk annual report financial statements glaxosmithkline plc prepared uk gaap directors statement responsibilities disclosure information auditors relation companys financial directors office date report statements confirmed cidcid far aware relevant audit directors responsible preparing parent company information companys auditors unaware glaxosmithkline plc financial statements remuneration report accordance applicable law regulations cidcid taken steps ought taken director make aware company law requires directors prepare financial statements relevant audit information establish companys financial year law directors elected auditors aware information prepare parent company financial statements accordance united kingdom accounting standards applicable law confirmation given interpreted accordance united kingdom generally accepted accounting practice provisions section companies act company law directors must approve parent company financial statements unless satisfied give true going concern basis fair view state affairs company period making enquiries directors reasonable expectation preparing financial statements directors company adequate resources continue operational required existence foreseeable future reason continue adopt going concern basis preparing financial statements cidcid select suitable accounting policies apply consistently uk corporate governance code cidcid make judgements accounting estimates reasonable board considers glaxosmithkline plc applies principles prudent provisions uk corporate governance code maintained cidcid state regard parent company financial statements financial reporting council described corporate applicable uk accounting standards followed governance section pages complied subject material departures disclosed explained provisions required financial services authoritys listing parent company financial statements rules auditors considered directors statement compliance relation points uk corporate directors responsible keeping adequate accounting records governance code specified review sufficient show explain companys transactions disclose reasonable accuracy time financial position company enable ensure parent company sir christopher gent financial statements remuneration report comply chairman companies act also responsible safeguarding march assets company hence taking reasonable steps prevention detection fraud irregularities parent company financial statements year ended december comprising balance sheet year ended december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended december included annual report published hardcopy printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic review financial review risk sections annual report include fair review development performance business position company group taken whole together description principal risks uncertainties facesgsk annual report strategic review financial review risk governance remuneration financial statements investor information independent auditors report independent auditors report opinion matters prescribed companies act members glaxosmithkline plc opinion audited parent company financial statements glaxosmithkline plc year ended december cidcid part directors remuneration report audited comprise company balance sheet uk gaap related properly prepared accordance companies act notes ah financial reporting framework applied preparation applicable law united kingdom cidcid information given directors report financial year accounting standards united kingdom generally accepted parent company financial statements prepared accounting practice consistent parent company financial statements respective responsibilities directors auditors matters required report explained fully directors statement responsibilities exception set directors responsible nothing report respect following matters preparation parent company financial statements companies act requires us report satisfied give true fair view responsibility opinion audit express opinion parent company financial statements accordance applicable law international cidcid adequate accounting records kept parent standards auditing uk ireland standards require company returns adequate audit us comply auditing practices boards ethical standards received branches visited us auditors cidcid parent company financial statements part report including opinions prepared directors remuneration report audited companys members body accordance chapter agreement accounting records returns part companies act purpose cidcid certain disclosures directors remuneration specified law giving opinions accept assume responsibility made purpose person report shown whose hands may come save expressly cidcid received information explanations agreed prior consent writing require audit scope audit financial statements matters audit involves obtaining evidence amounts reported separately group financial statements disclosures financial statements sufficient give reasonable glaxosmithkline plc year ended december assurance financial statements free material company passed resolution accordance section misstatement whether caused fraud error includes companies act senior statutory auditors assessment whether accounting policies appropriate name stated parent companys circumstances consistently applied adequately disclosed reasonableness significant accounting estimates made directors overall presentation financial statements addition read pricewaterhousecoopers llp financial nonfinancial information annual report chartered accountants statutory auditors identify material inconsistencies audited financial london statements become aware apparent material march misstatements inconsistencies consider implications report opinion financial statements opinion parent company financial statements cidcid give true fair view state companys affairs december cidcid properly prepared accordance united kingdom generally accepted accounting practice cidcid prepared accordance requirements companies act gsk annual report financial statements glaxosmithkline plc prepared uk gaap company balance sheet uk gaap december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current assetsliabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board march sir christopher gent chairman glaxosmithkline plc registered number gsk annual report strategic review financial review risk governance remuneration financial statements investor information notes company balance sheet expenditure uk gaap expenditure recognised respect goods services received supplied accordance contractual terms provision presentation financial statements made obligation exists future liability respect past event amount obligation reliably description business estimated glaxosmithkline plc parent company gsk major global investments subsidiary companies healthcare group engaged creation discovery development manufacture marketing pharmaceutical investments subsidiary companies held cost less products including vaccines overthecounter otc medicines provision impairment healthrelated consumer products impairment investments preparation financial statements carrying value investments reviewed impairment financial statements prepared going concern indication investment might impaired basis drawn accordance uk generally accepted provision resulting impairment review charged accounting practice uk gaap uk accounting income statement year concerned presentation december comparative figures share based payments december appropriate comparative figures reclassified ensure consistent presentation issuance company subsidiaries grant current year information companys options represents additional capital contributions permitted section companies act company subsidiaries additional investment subsidiaries profit loss account company presented results corresponding increase shareholders equity annual report additional capital contribution based fair value grant issued allocated underlying grants vesting period accounting convention standards taxation balance sheet prepared using historical cost convention complies applicable uk accounting standards current tax provided amounts expected paid applying tax rates enacted substantially enacted accounting principles policies balance sheet date preparation balance sheet conformity generally company accounts taxation deferred accelerated accepted accounting principles requires management make reason timing differences originated estimates assumptions affect reported amounts reversed balance sheet date deferred tax assets assets liabilities disclosure contingent assets liabilities recognised extent considered recoverable date balance sheet actual amounts could differ future taxable profits estimates deferred tax measured average tax rates balance sheet prepared accordance expected apply periods timing differences companys accounting policies approved board described expected reverse deferred tax liabilities assets note b discounted b accounting policies financial guarantees foreign currency transactions liabilities relating guarantees issued company behalf subsidiaries initially recognised fair value amortised foreign currency transactions recorded exchange rate life guarantee ruling date transaction forward rate hedged forward exchange contract foreign currency assets liabilities c operating profit translated rates exchange ruling balance sheet date fee relating audit forward rate company charged operating profit dividends paid received dividends paid received included accounts period related dividends actually paid received gsk annual report financial statements glaxosmithkline plc prepared uk gaap notes company balance sheet uk gaap continued fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company outstanding guarantees billion debt instruments amount due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note egsk annual report strategic review financial review risk governance remuneration financial statements investor information notes company balance sheet uk gaap continued g share capital share premium account share ordinary shares p premium number share capital authorised december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december december december number shares issuable outstanding options number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million million shares cancelled company expects make share repurchases billion exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period january february h reserves profit reserves loss account total january profit attributable shareholders dividends shareholders shares purchased cancelled held treasury share capital contribution relating share based payments december profit attributable shareholders dividends shareholders shares purchased cancelled held treasury share capital contribution relating share based payments december profit glaxosmithkline plc year million million dividends million million gave retained profit million million cost shares purchased cancelled held treasury shares million profit loss account reserve december stood million million million unrealised million gsk annual report investor product development pipeline products competition intellectual property quarterly trend information five year record share capital share price dividends annual general meeting us law regulation tax information shareholders analysis shareholdings shareholder services contacts glossary terms index join conversation improved broadened communications channels inform engage stakeholders find visiting new website wwwgskcom follow us twitter gsk join conversationgsk annual report strategic review financial review risk governance remuneration financial statements investor information pipeline pharmaceuticals vaccines product development pipeline key inlicense alliance relationship third party nda new drug application usa month first submission phase evaluation clinical pharmacology usually conducted volunteers month first regulatory approval maa first eu phase ii etermination dose initial evaluation efficacy conducted approval letter small number patients bla biological license application phase iii l arge comparative study compound versus placebo andor established maa marketing authorisation application europe treatment patients establish clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla biopharmaceuticals tumour necrosis factor receptor tnfr acute lung injury domain antibody glucagon like peptide glp agonist obesity halflife improving domain antibody immunomodulator solid tumours fibroblast growth factor ligand trap cancer otelixizumab cd monoclonal antibody sc iv rheumatoid arthritis myelinassociated glycoprotein monoclonal stroke ii antibody recombinant human angiotensin converting acute lung injury ii enzyme beta amyloid monoclonal antibody geographic retinal atrophy ii il monoclonal antibody type diabetes ii belimumab b lymphocyte stimulator monoclonal idiopathic membranous nephropathy ii antibody iv belimumab b lymphocyte stimulator monoclonal myaesthenia gravis ii antibody iv mapatumumab tumor necrosis factorrelated apoptosis advanced hepatocellular carcinoma ii inducing ligand receptor trailr monoclonal antibody mepolizumab il monoclonal antibody nasal polyposis ii ofatumumab cd human monoclonal antibody sc multiple sclerosis ii ozanezumab neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis ii monoclonal antibody arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia first line therapy iii use relapsed patients arzerra ofatumumab cd human monoclonal antibody diffuse large b cell lymphoma relapsed patients iii arzerra ofatumumab cd human monoclonal antibody follicular lymphoma refractory relapsed patients iii benlysta belimumab b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc benlysta belimumab b lymphocyte stimulator monoclonal vasculitis iii antibody iv mepolizumab il monoclonal antibody severe asthma iii sirukumab il human monoclonal antibody sc rheumatoid arthritis iii albiglutide glp agonist type diabetes submitted jan raxibacumab protective antigen inhibitor inhalation anthrax approved dec cardiovascular metabolic sodium dependent glucose transport type diabetes sglt inhibitor ileal bile acid transport ibat inhibitor selective androgen receptor modulator heart failure endogenous gut peptide stimulator obesity prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii camicinal motilin receptor agonist delayed gastric emptying ii losmapimod p kinase inhibitor acute coronary syndrome also copd ii retosiban oxytocin antagonist threatened preterm labour ii ronacaleret calcium receptor antagonist allogeneic haematopoietic stem cell mobilisation ii darapladib lppla inhibitor atherosclerosis also diabetic macular oedema iii immunoinflammation sirt activator psoriasis ii janus kinase jak inhibitor systemic lupus erythematosus psoriasis ii ccr chemokine receptor antagonist rheumatoid arthritis ii vercirnon ccr chemokine receptor antagonist crohn 's disease iii gsk annual report investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla infectious diseases type topoisomerase inhibitor bacterial infections cephalosporin bacterial infections polypeptide deformylase inhibitor bacterial infections ii hepatitis c virus inhibitor hepatitis c ii tafenoquine aminoquinoline plasmodium vivax malaria ii relenza iv zanamivir neuraminidase inhibitor iv influenza iii neurosciences phoshodiesterase inhibitor huntington 's disease lppla inhibitor alzheimer 's disease h receptor antagonist multiple sclerosis ii ht antagonist dementia ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii rilapladib lppla inhibitor alzheimer 's disease ii patrome ipx dopamine precursor dopa decarboxylase parkinson 's disease iii na inhibitor oncology bromodomain inhibitor nut gene midline carcinoma akt protein kinase inhibitor multiple myeloma focal adhesion kinase inhibitor cancer phosphatidylinositol kinase pik inhibitor cancer trametinib mek inhibitor akt protein kinase cancer inhibitor akt protein kinase inhibitor langerhan cell histiocytosis ii akt protein kinase inhibitor ovarian cancer ii dabrafenib braf protein kinase inhibitor nonsmall cell lung cancer ii foretinib mesenchymalepithelial transition factor cancer ii cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist acute myeloid leukaemia ii eltrombopag revoladepromacta thrombopoietin receptor agonist aplastic anaemia ii eltrombopag revoladepromacta thrombopoietin receptor agonist myelodysplastic syndromes ii eltrombopag trametinib mek inhibitor kras mutant nonsmall cell lung cancer second ii line therapy trametinib dabrafenib mek inhibitor braf protein kinase colorectal cancer ii inhibitor trametinib dabrafenib mek inhibitor braf protein kinase metastatic melanoma adjuvant therapy iii inhibitor tyverbtykerb lapatinib human epidermal growth factor breast cancer adjuvant therapy iii receptor epidermal growth factor receptor egfr dual kinase inhibitor tyverbtykerb lapatinib egfr dual kinase inhibitor gastric cancer iii tyverbtykerb lapatinib egfr dual kinase inhibitor head neck squamous cell carcinoma iii resectable disease votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii dabrafenib braf protein kinase inhibitor metastatic melanoma submitted jul jul trametinib mek inhibitor metastatic melanoma submitted feb aug trametinib dabrafenib mek inhibitor braf protein kinase metastatic melanoma submitted feb inhibitor tyverbtykerb lapatinib egfr dual kinase inhibitor metastatic breast cancer combination submitted feb trastuzumab votrient pazopanib multikinase angiogenesis inhibitor sarcoma approved aug apr revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia approved may nov eltrombopag ophthalmology darapladib lppla inhibitor diabetic macular oedema also atherosclerosis iigsk annual report strategic review financial review risk governance remuneration financial statements investor information achieved regulatory review milestones compound type indication phase maa ndabla respiratory cxcr chemokine receptor antagonist copd soluble epoxide hydrolase inhibitor copd phosphoinositide kinase inhibitor asthma copd sodium channel blocker cough fluticasone furoate glucocorticoid agonist longacting beta copd vilanterol agonist muscarinic acetylcholine umeclidinium antagonist muscarinic antagonist beta agonist copd ii lipoxygenaseactivating protein flap asthma ii inhibitor tolllike receptor agonist asthma ii dilmapimod p kinase inhibitor iv acute lung injury acute respiratory distress syndrome ii fluticasone furoate glucocorticoid agonist muscarinic asthma ii acetylcholine antagonist umeclidinium losmapimod p kinase inhibitor oral copd also acute coronary syndrome ii fluticasone furoate glucocorticoid agonist asthma iii relvarbreo longacting beta agonist glucocorticoid copd mortality outcomes iii vilanterol agonist fluticasone furoate umeclidinium muscarinic acetylcholine antagonist copd iii vilanterol longacting beta agonist copd iii relvarbreo longacting beta agonist glucocorticoid asthma submitted jun vilanterol agonist fluticasone furoate relvarbreo longacting beta agonist glucocorticoid copd submitted jun jul vilanterol agonist fluticasone furoate anoro umeclidinium muscarinic acetylcholine antagonist copd submitted jan dec vilanterol longacting beta agonist paediatric vaccines pneumoniae paediatric recombinant conjugated streptococcus pneumoniae disease prophylaxis ii next generation mmr live attenuated measles mumps rubella prophylaxis iii usa nov mosquirix malaria rtss recombinant malaria prophylaxis plasmodium falciparum iii na menhibrix hibmencyttconjugated neisseria meningitis groups c haemophilus approved na jun influenzae type b disease prophylaxis nimenrix menacwytt conjugated neisseria meningitis groups c w disease prophylaxis approved apr ii usa vaccines hiv recombinant hiv disease prophylaxis nthi recombinant nontypeable haemophilus influenzae prophylaxis staphylococcus aureus recombinant conjugated staphylococcus aureus prophylaxis hiv recombinant hiv disease immunotherapy ii tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpes zoster prophylaxis iii flu pre pandemic hn inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis submitted na feb flu vaccine inactivated split quadrivalent seasonal influenza prophylaxis approved mar dec antigenspecific cancer immunotherapeutic prame recombinant treatment resectable nonsmall cell lung cancer immunotherapeutic wt recombinant treatment breast cancer immunotherapeutic magea recombinant treatment bladder cancer ii immunotherapeutic magea recombinant treatment melanoma iii immunotherapeutic magea recombinant treatment nonsmall cell lung cancer iii immunotherapeutic gsk annual report investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla rare diseases migalastat hcl ert pharmacological chaperone enzyme fabry disease ii replacement therapy ert drisapersen antisense oligonucleotide duchenne muscular dystrophy iii exvivo stem cell gene therapy adenosine deaminase severe combined immune iii deficiency adascid migalastat hcl pharmacological chaperone fabry disease iii stiefel latestage assets nonsteroidal antiinflammatory atopic dermatitis ii alitretinoin retinoic acid receptor modulator chronic hand eczema iii na duac low dose clindamycinbenzoyl peroxide gel acne vulgaris submitted nov nov fabior tazarotene foam retinoid foam acne vulgaris approved na may sorilux vitamin analog scalp psoriasis approved na sep hiv viiv healthcare hiv integrase inhibitor longacting hiv infections ii parenteral formulation dolutegravir abacavir hiv integrase inhibitor reverse transcriptase hiv infections iii sulphate lamivudine inhibitors fixed dose combination dolutegravir hiv integrase inhibitor hiv infections submitted dec dec brand names appearing italics trademarks either owned andor licensed glaxosmithkline associated companies optionbased alliances third parties include assets phase later development company disease area phase cancer research uk cancer chemocentryx inflammatory disease ii dynavax technologies cutaneous systemic lupus erythematosus ii isis pharmaceuticals transthyretinmediated amyloidosis iiiii oncomed pharmaceuticals oncology prosensa therapeutics neuroscience ii ranbaxy laboratories respiratory ii telethon institute gene therapy stem cell gene therapy ii affiris alzheimers disease treatment vaccine ii ccx two assetsgsk annual report strategic review financial review risk governance remuneration financial statements investor information pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands usa eu respiratory veramyst fluticasone propionate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired compound compound expired diskus device diskus device hfadevice hfadevice formulation formulation seretideadvair salmeterol xinafoate asthmacopd singulair symbicort expired fluticasone propionate spiriva onbrez combination combination pulmicort foster expired diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expired expired onbrez compound compound expired diskus device diskus device hfadevice formulation ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice formulation formulation antivirals relenza zanamivir influenza tamiflu july valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired requip xl ropinirole parkinsons disease mirapex expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro treximet sumatriptan naproxen migraine zomig maxalt na relpax combination use wellbutrin bupropion depression effexor cymbalta expired expired lexapro cardiovascular urogenital arixtra fondaparinux deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride benlysta belimumab systemic lupus erychematosus coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep see outlook details uncertainty timing followon competition generic competition possible gsk annual report investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands usa eu lovaza omega acid ethyl esters high triglycerides tricor na formulation volibris ambrisentan pulmonary hypertension tracleer revatio na antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections oncology arzerra ofatumumab refractory chronic mabtherarituxan pending lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar expired expired lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patients votrient pazopanib soft tissue sarcoma yondelis sutent metastatic renal cell nexavar afinitor carcinoma vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis b hepb polio hepatitis b hepb pentaxim pentavac inactivated antigens cervarix hpv virus like particles human papilloma virus gardasil silgard vlps adjuvant mpl type aluminium hydroxide fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip subtypes type b antigens fluzone influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip none none subtypes type b antigens fluzone influvac aggripal fluad pandemrix derived split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis emerflu adjuvant prepandrix derived split inactivated influenza prophylaxis aflunov influenza virus antigen adjuvant synflorix conjugated pneumococcal invasive pneumococcal prevenar prevnar na polysaccharide disease hiv combivir lamivudine zidovudine hivaids truvada atripla expired expired combination combination epivir lamivudine hivaids truvada atripla expired expired epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination see note financial statements legal proceedingsgsk annual report strategic review financial review risk governance remuneration financial statements investor information consumer healthcare products competition brand products application markets competition total wellness panadol tablets caplets infant drops paracetamolbased treatment global except usa reckittbenckisers nurofen headache joint pain fever cold symptoms nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin cq original lozenge withdrawal aid nicorette europe nicabate quitting smoking retailers brands also nicorette us eno effervescent rapid relief antacid global hypermarcas estomazil tums chewable tablets pfizers gelusil sanofis rolaids johnson johnsons mylanta oral care sensodyne toothpastes toothbrushes prevention dental global colgatepalmolives mouthwashes sensitivity colgate pro relief polident denture adhesive denture improve comfort global none poligrip cleanser fitted dentures corega clean dentures aquafresh toothpastes toothbrushes prevention caries gum global colgatepalmolives colgate mouthwashes disease bad breath procter gambles crest oralb parodontax toothpastes mouthwashes help stop bleeding gums global colgatepalmolivess gum health colgate progum nutrition lucozade energy sports drinks energy hydration uk ireland pepsicos gatorade africa cocacolas powerade red bull horlicks malted milkbased drinks nutrition uk ireland india mondelezs bournvita foods nestles milo maxinutrition sports nutrition protein nutrition uk myprotein powder bars optimum nutrition skin health physiogel moisturising creams face body care dry germany france italy loreals la roche posay lotions cleansers sensitive irritated skin poland spain beiersdorfs eucerin pierre fabres avene oilatum emollient bath creams soothing treatment eczema uk poland reckittbenckisers e shampoo dry skin conditions markets sanofis emolium gsk annual report financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p diluted earnings per share pence p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p calculation core results described gsk annual report strategic review financial review risk governance remuneration financial statements investor information q q q cer cer cer p p p p p p p p p gsk annual report investor information pharmaceuticals vaccines turnover therapeutic area total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera zovirax valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare metabolic avandia products antibacterials augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatology bactroban duac rare diseases flolan volibris immuno inflammation benlysta pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix nimenrix rotarix synflorix viiv healthcare hiv cer represents growth constant exchange rates represents growth actual exchange ratesgsk annual report strategic review financial review risk governance remuneration financial statements investor information pharmaceuticals vaccines turnover therapeutic area restated total usa europe emap rest world therapeutic area growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera zovirax valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare metabolic avandia products antibacterials augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatologicals bactroban duac rare diseases flolan volibris pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix viiv healthcare hiv cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report investor information viiv healthcare turnover total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer combivir epivir epzicomkivexa lexiva selzentry trizivir total usa europe emap rest world therapeutic area restated restated growth growth growth growth growth major products cer cer cer cer cer combivir epivir epzicomkivexa lexiva selzentry trizivir five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board restated restated restated restated turnover division pharmaceuticals vaccines pharmaceuticals vaccines consumer healthcare group turnover geographic region usa europe emap japan group turnover segment usa europe emap japan viiv healthcare hiv trading unallocated pharmaceuticals pharmaceuticals vaccines consumer healthcare gsk annual report strategic review financial review risk governance remuneration financial statements investor information restated restated restated restated pharmaceuticals vaccines turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis dermatology rare diseases immunoinflammation pharmaceuticals vaccines viiv healthcare hiv consumer healthcare turnover total wellness oral care nutrition skin health financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share financial results core turnover operating profit profit taxation profit taxation pence pence pence core earnings per share core diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report investor information five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees usa europe emap japan manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates day year feb jan dec nov oct sep high low december federal reserve bank new york ceased publishing noon buying rates bank england pm buying rates used subsequent calculations pm buying rate february usgsk annual report strategic review financial review risk governance remuneration financial statements investor information shareholder information share capital control acquired disposed interests shares period review connection details issued share capital number shares held share buyback programme treasury december found note financial statements share capital share premium account share buyback programme shares listed london stock exchange also board authorised issue allot ordinary shares quoted new york stock exchange nyse form article companys articles association power american depositary shares ads ads represents two article authority company make ordinary shares details listed debt listed purchases shares subject shareholder authorities refer note financial statements net debt sought annual basis annual general meeting agm shares purchased company may cancelled holders ordinary shares entitled receive dividends held treasury shares declared companys annual report attend speak general meetings company appoint proxies continued longterm share buyback exercise voting rights programme million shares purchased total cost million shares purchased period january restrictions transfer limitations february holding ordinary shares requirements obtain approval prior transfers ordinary shares carry special rights programme covers purchases shares cancellation regard control company restrictions held treasury shares accordance authority voting rights major shareholders voting rights renewed shareholders agm may per share shareholders company authorised purchase maximum million shares details shares purchased expectations known arrangements financial rights future repurchases cancelled held treasury held person holder shares known shares disclosed note financial statements share agreements restrictions share transfers voting rights capital share premium account shares acquired share schemes plans rank equally exact amount timing future purchases shares issue special rights extent repurchased shares held treasury shares trustees employee share ownership plan trusts waived rather cancelled determined company rights dividends shares held trusts dependent market conditions factors exchange controls limitations affecting market capitalisation security holders market capitalisation based shares issue excluding certain economic sanctions may force treasury shares gsk december billion time time currently applicable laws decrees date gsk fifth largest company market regulations restricting import export capital affecting capitalisation ftse index remittance dividends payments holders companys shares nonresidents uk similarly share price certain economic sanctions may force time time limitations relating nonresidents uk english law companys articles association january right holder vote respect december companys shares decreaseincrease interests voting rights high year low year stated far aware persons significant direct indirect holdings company table sets middle market closing prices information provided company pursuant financial companys share price decreased compares services authoritys fsa disclosure transparency rules dtrs increase ftse index year published regulatory information service share price february companys website february company received notifications uk us accordance fsas dtrs following notifiable interests voting rights companys issued share capital percentage issued shares capital blackrock inc legal general group plc percentage ordinary shares issue excluding treasury shares bny mellon depositary receipts depositary companys ads listed nyse ordinary shares representing companys adr programme managed depositary uk share price uk us ads price us registered name bny nominees limited details number ordinary shares held depositary found gsk annual report shareholder information nature trading market dividends per share following tables set periods indicated high table sets dividend per share per ads low middle market closing quotations pence shares last five years dividend per ads translated us dollars london stock exchange high low closing prices us applicable exchange rates dollars ads nyse year dividend pence us pence per share ordinary shares high low quarter ended march supplemental february january december november october supplemental dividend related disposal certain noncore otc brands north america paid fourth quarter ordinary september dividend quarter ended december quarter ended september dividend calendar quarter ended june quarter exdividend date record date payment date quarter ended march q february february april quarter ended december q may may july quarter ended september q august august october quarter ended june q november november january quarter ended march year ended december financial reporting calendar year ended december year ended december publication date results announcements us dollars per ads ads quarter april high low quarter july quarter ended march quarter october february preliminaryquarter february january annual reportsummary februarymarch december november results announcements october september results announcements issued london stock exchange quarter ended december available news service also sent quarter ended september us securities exchange commission nyse issued quarter ended june media made available website quarter ended march financial reports quarter ended december quarter ended september company publishes annual report shareholder quarter ended june needing full detail annual report summary quarter ended march documents available website date year ended december publication summary sent shareholders shareholders year ended december may elect receive annual report contacting registrar year ended december alternatively shareholders may elect receive notification email publication financial reports registering february wwwshareviewcouk dividends copies previous financial reports available website printed copies obtained registrar uk company pays dividends quarterly continues increase cash gsk response center usa see pages returns shareholders dividend policy ongoing contact details longterm share buyback programme dividends remain essential component total shareholder return company committed increasing dividend longterm details dividends declared amounts payment dates given note financial statements dividendsgsk annual report strategic review financial review risk governance remuneration financial statements investor information directors actual conflict arises postauthorisation board may choose exclude director receipt relevant information directors powers determined uk legislation participation debate suspend director board articles association available website last resort require director resign articles may amended special resolution members nominations committee reviewed register potential directors may exercise companys powers provided conflict authorisations october reported board articles applicable legislation stipulate conflicts appropriately authorised powers must exercised members process authorisation continues operate effectively rules appointment replacement directors contained articles provide directors may independent advice appointed ordinary resolution members board recognises may occasions one resolution directors provided latter instance directors feel necessary take independent legal director appointed way retires first agm following andor financial advice companys expense agreed appointment procedure set website enable articles also provide directors normally subject indemnification directors reelection agm intervals three years annually held office continuous period nine years qualifying third party indemnity provisions defined however board agreed directors wish companies act force benefit directors continue members board seek reelection annually former directors held office signing accordance uk corporate governance code members annual report may remove director passing ordinary resolution special notice given passing special resolution change control essential contracts director may automatically cease director contracts arrangements individually cidcid becomes bankrupt compounds fundamental ability business operate effectively creditors generally company party material agreements would take effect altered terminate upon change control cidcid ceases director virtue companies following takeover bid act articles agreements director would provide cidcid suffering mental physical ill health compensation loss office employment resulting cidcid missed directors meetings continuous takeover except provisions companys share plans may period six months without permission board cause options awards granted plans vest resolves shall cease director takeover details termination provisions companys framework contracts executive directors given cidcid prohibited director law cidcid resigns annual general meeting cidcid offers resign board accepts offer cidcid directors least three number require wednesday may resign queen elizabeth ii conference centre broad sanctuary westminster london swp ee directors conflicts interest agm companys principal forum communication directors duty companies act avoid private shareholders addition formal business situation could direct indirect presentation ceo performance conflict interest possible conflict company duty group future development opportunity applies particular exploitation property information questions asked board chairmen boards opportunity whether company could take advantage committees take questions relating committees articles provide general power board authorise conflicts investors holding shares nominee service arrange nominee service appointed proxy respect nominations committee authorised board shareholding order attend vote meeting grant periodically event annually review potential actual conflict authorisations directors adr holders wishing attend meeting must obtain proxy counted quorum authorisation actual bny mellon depositary receipts enable potential conflicts authorisations granted recorded attend vote business transacted adr holders company secretary register noted board may instruct bny mellon depositary receipts way next meeting shares represented adr voted completing returning voting card provided bank ongoing basis directors responsible informing company secretary new actual potential conflicts documents display may arise changes circumstances may affect authorisation previously given even provided articles association company documents authorisation director absolved statutory referred annual report available inspection duty promote success company companys registered office website made available inspection agm gsk annual report shareholder information donations political organisations political sarbanesoxley act expenditure following number corporate accounting scandals effect january ensure consistent approach usa congress passed sarbanesoxley act sarbanes political contributions across group introduced global oxley wideranging piece legislation concerned largely policy stop voluntarily corporate political contributions financial reporting corporate governance period january december group recommended sec company established make political donations eu noneu organisations disclosure committee committee reports ceo cfo audit risk committee chaired company notwithstanding introduction policy accordance secretary members consist senior managers finance federal election campaign act usa continue legal corporate communications investor relations support employeeoperated political action committee pac facilitates voluntary political donations eligible external legal counsel external auditors internal experts gsk employees invited attend meetings periodically responsibility considering materiality information timely basis pac controlled gsk decisions amounts determining disclosure information responsibility recipients contributions made participating employees timely filing reports sec formal review exercising legal right pool resources make political annual report form f committee met contributions subject strict limitations total times us us donated political organisations gsk employee pac sarbanesoxley requires annual report contains statement whether member audit risk committee agm may shareholders first authorised company arc audit committee financial expert defined sarbanes make donations eu political organisations incur eu oxley statement relevant members political expenditure provisions political parties arc stacey cartwright judy lewent tom de swaan elections referendums act year included biographies pages additional authority since renewed annually companies act disclosure requirements arise section section requires companies continue obtain shareholder approval sarbanesoxley respect disclosure controls procedures make donations eu political organisations internal control financial reporting incur eu political expenditure section corporate responsibility financial however make intend make donations political parties independent election candidates reports make donations eu political organisations incur eu sarbanesoxley also introduced requirement ceo political expenditure cfo complete formal certifications confirming definitions political donations political expenditure cidcid reviewed annual report form f political organisations used legislation wide particular definition eu political organisations may extend cidcid based knowledge annual report form f bodies concerned policy review law reform contains material misstatements omissions representation business community special interest cidcid based knowledge financial statements groups concerned environment financial information fairly present material respects company subsidiaries might wish support result financial condition results operations cash flows definitions may cover legitimate business activities dates periods presented annual report ordinary sense considered political donations political form f expenditure cidcid responsible establishing maintaining disclosure activities designed support political party controls procedures ensure material information independent election candidate authority board made known evaluated effectiveness sought annually precautionary measure ensure controls procedures yearend results company subsidiaries inadvertently breach evaluation contained annual report legislation form f us law regulation cidcid responsible establishing maintaining internal control financial reporting provides reasonable number provisions us law regulation apply assurance regarding reliability financial reporting company shares quoted new york stock preparation financial statements external purposes exchange nyse form ads accordance generally accepted accounting principles nyse rules cidcid disclosed annual report form f changes internal controls financial reporting general nyse rules permit company follow uk period covered annual report form f corporate governance practices instead applied usa materially affected reasonably likely affect materially provided explain significant variations explanation companys internal control financial reporting contained form f filing accessed securities exchange commissions sec edgar database via website nyse rules came effect require us file annual interim written affirmations concerning audit risk committee statement significant differences corporate governancegsk annual report strategic review financial review risk governance remuneration financial statements investor information cidcid disclosed based recent evaluation tax information shareholders internal control financial reporting external auditors arc significant deficiencies material weaknesses summary certain uk tax us federal income tax design operation internal controls financial consequences holders shares adr citizens reporting reasonably likely affect adversely uk usa set complete analysis companys ability record process summarise report possible tax consequences purchase ownership sale financial information fraud regardless materiality securities intended general guide holders involving persons significant role companys advised consult advisers respect tax internal control financial reporting consequences purchase ownership sale shares adr consequences state local tax laws group carried evaluation supervision usa implications current ukus tax conventions participation management including ceo cfo effectiveness design operation groups us holders adr generally treated owners disclosure controls procedures december underlying shares purposes current usauk double taxation conventions relating income gains income tax inherent limitations effectiveness system convention estate gift taxes estate gift tax convention disclosure controls procedures including possibility purposes internal revenue code human error circumvention overriding controls amended code procedures accordingly even effective disclosure controls procedures provide reasonable assurance uk shareholders achieving control objectives summary applies uk resident shareholder holds ceo cfo expect complete certifications shares capital assets report conclusions effectiveness disclosure controls procedures march following certificates taxation dividends filed sec part groups form f uk resident shareholders generally subject uk income tax section managements annual report internal full amount dividends paid grossed amount control financial reporting tax credit tax credit may set individuals income tax liability respect gross dividend repayable accordance requirements section sarbanes shareholders tax liability less associated tax credit oxley following report provided management respect tax year subsequent tax years additional companys internal control financial reporting rate income tax dividends imposed taxpayers whose defined rules af df us securities income uk resident shareholders exchange act corporation taxpayers note dividends generally cidcid management responsible establishing maintaining entitled exemption corporation tax adequate internal control financial reporting group taxation capital gains internal control financial reporting designed provide reasonable assurance regarding reliability financial uk shareholders may liable uk tax gains disposal reporting preparation financial statements shares adr disposals individuals subject external purposes accordance ifrs availability exemption relief annual exempt amount taxable capital gain accruing disposal shares cidcid management conducted evaluation effectiveness adr taxed allowable deductions internal control financial reporting based framework shareholders taxable income tax year exceeds basic rate internal control integrated framework issued committee income tax limit cases taxable capital gain accruing sponsoring organisations treadway commission disposal shares adr may taxed cidcid changes groups internal control combination rates corporation taxpayers may entitled financial reporting materially affected indexation allowance applies reduce capital gains reasonably likely affect materially groups internal extent gains arise due inflation indexation allowance control financial reporting may reduce chargeable gain create allowable loss cidcid management assessed effectiveness internal control inheritance tax financial reporting december conclusion filed part groups form f individual shareholders may liable inheritance tax transfer shares adr tax may charged amount pricewaterhousecoopers llp audited consolidated value shareholders estate reduced result financial statements group year ended transfer way gift disposal less full december also assessed effectiveness market value gift disposal subject groups internal control financial reporting auditing uk inheritance tax us estate gift tax estate gift standard public company accounting oversight tax convention would generally provide tax paid usa board united states audit report filed credited tax payable uk groups form f stamp duty uk stamp duty stamp duty reserve tax sdrt subject certain exemptions payable transfer shares rate consideration transfer gsk annual report shareholder information us shareholders information reporting backup withholding summary applies shareholder citizen dividends payments proceeds sale shares adr resident usa domestic corporation person paid within usa certain usrelated financial otherwise subject us federal income tax net income basis intermediaries subject information reporting may respect shares adr holds shares adr capital subject backup withholding unless us holder corporation assets resident uk uk tax purposes exempt recipient provides taxpayer identification hold shares purposes trade profession vocation number certifies loss exemption occurred carried uk branch agency nonus holders generally subject information reporting backup withholding may required provide certification summary also address tax treatment holders nonus status connection payments received subject special tax rules banks taxexempt amounts withheld allowed refund credit entities insurance companies dealers securities currencies holders us federal income tax liability provided required persons hold shares adr part integrated investment information furnished irs including straddle comprised share adr one positions persons directly indirectly estate gift taxes voting stock company estate gift tax convention us shareholder taxation dividends generally subject uk inheritance tax gross amount dividends received treated foreign source stamp duty dividend income us tax purposes eligible dividend received deduction allowed us corporations dividends uk stamp duty sdrt subject certain exemptions adr payable us dollars dividends shares payable payable transfer shares adr custodian pounds sterling dividends paid pounds sterling included depository rate amount consideration income us dollar amount calculated reference provided transferred sale value transferred exchange rate day dividends received holder consideration subject certain exceptions shortterm hedged positions sdrt would payable transfer agreement individual eligible us holder subject us taxation transfer adr uk stamp duty payable maximum rate respect qualified dividends transfer adr provided instrument transfer executed remains times outside uk stamp duty taxation capital gains transfer adr would payable rate generally us holders subject uk capital gains tax consideration transfer sale underlying shares subject us tax capital gains realised sale would subject certain exceptions result liability uk stamp disposal shares adr gains longterm capital gains duty case may sdrt rate subject reduced rates taxation individual holders shares adr held one year analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary receipts holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value february bny nominees limited held ordinary shares representing issued share capital excluding treasury shares held date february number holders shares usa holdings shares number registered holders ads holdings ads certain shares ads held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holdersgsk annual report strategic review financial review risk governance remuneration financial statements investor information shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate shareview service enables create free online portfolio view register share balance movements update address wwwshareviewcouk dividend payment instructions register votes agm corporate sponsored nominee convenient way manage shares without application form account requiring share certificate service provides downloaded facility hold shares nominee company wwwshareviewcouk sponsored company continue receive requested telephoning equiniti dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join dividend payment direct currently receive dividends cheque dividend bank mandate form bank account post instead paid directly downloaded bank building society account quicker wwwshareviewcouk secure avoids risk cheque going requested telephoning equiniti astray dividend payment direct instead waiting sterling cheque arrive post details service bank account overseas equiniti convert dividend local currency costs involved please contact shareholders send direct local bank account service equiniti available countries worldwide dividend reinvestment plan alternative receiving cash dividends may drip election form drip choose reinvest dividends buy gsk downloaded shares wwwshareviewcouk requested telephoning equiniti duplicate publications mailings receive duplicate copies report please contact equiniti mailings please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificates internet transactions please log please note market trading held corporate sponsored nominee internet wwwshareviewcoukdealing hours pm telephone share dealing service provided uk time monday friday equiniti financial services limited telephone transactions please call excluding uk public holidays uk outside uk individual savings accounts isas company arranged equiniti financial services details available limited provide gsk corporate isa hold gsk wwwshareviewcouk ordinary shares requested telephoning equiniti uk lines open pm monday friday except uk public holidays calls number charged p per minute plus network extras provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report shareholder information adr depositary contacts adr programme administered gsk response center bny mellon depositary receipts tel us toll free po box providence ri investor relations wwwbnymelloncomshareowner investor relations may contacted follows tel us toll free tel outside usa uk email shrrelationsbnymelloncom great west road depositary also provides global buydirect direct ads brentford middlesex purchasesale dividend reinvestment plan adr holders tw gs glaxo wellcome smithkline beecham tel corporate peps usa share centre limited five crescent drive oxford house oxford road aylesbury bucks hp sz philadelphia pa tel tel us toll free tel outside usa sharegift carlton house terrace london swy ah tel wwwsharegiftorg shareholders small number shares value makes uneconomical sell may wish consider donating charity sharegift registered charity donated shares aggregated sold sharegift pass proceeds wide range charities share scam alert receive unsolicited telephone call offering sell buy shares please take extra care caller may part highly organised financial scam uk shareholder please contact financial services authority information similar activities consumer helpline tel uk lines open pm uk time monday friday except uk public holidays corporate responsibility report publishing corporate responsibility report online outline gsks approach performance key corporate responsibility areas health behaviour people planet internet information company including share price available website wwwgskcom information made available website constitute part annual report provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial advisergsk annual report strategic review financial review risk governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc corporate integrity agreement cia n company entered settlement us federal government related past sales marketing practices part settlement company entered corporate integrity agreement us department health human services improvements built existing compliance programmes currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report shareholder information index access medicines investments associates joint ventures accounting principles policies investor relations acquisitions disposals key accounting judgements estimates adjustments reconciling profit tax operating key performance indicators cash flows latestage pipeline summary annual general meeting legal proceedings assets held sale longterm incentive plans associates joint ventures major restructuring costs board movements equity business review net debt cash cash equivalents new accounting requirements chairman othe nonexecutive directors nonexecutive director terms conditions chairmans statement nonexecutive directors fees chief executives review notes financial statements commitments operating profit committee reports intangible assets competition investments consolidated balance sheet noncurrent assets consolidated cash flow statement noncurrent liabilities consolidated income statement operating income consolidated statement changes equity provisions consolidated statement comprehensive income outlook consumer healthcare products competition pensions postemployment benefits contingent liabilities pharmaceutical products competition corporate executive team intellectual property corporate governance pipeline critical accounting policies post balance sheet event directors senior management presentation financial statements directors emoluments total remuneration principal group companies directors interests product development pipeline directors interests contracts products directors statement responsibilities property plant equipment dividends quarterly trend donations political organisations reconciliation net cash flow movement net debt political expenditure registrar earnings per share related party transactions employee costs relations shareholders employee share schemes remuneration report employees research development exchange rates responsible business executive director terms conditions risk factors finance expense segment information finance income segment reviews financial instruments related disclosures share capital control financial position resources share capital share premium account financial review share price financial review shareholder information financial statements glaxosmithkline plc prepared strategy uk gaap taxation five year record taxation information shareholders glossary terms trade payables goodwill trade receivables independent auditors report us law regulation intellectual property trademarks world market inventories gsk glaxosmithkline plc incorporated english public limited company december formed merger glaxo wellcome plc smithkline beecham plc gsk acquired two english companies december part merger arrangements shares listed london stock exchange new york stock exchange giving children better start gsk part global coalition working eliminate ten neglected tropical diseases committed donate million treatments antiparasitic treatment albendazole year help eliminate lymphatic filariasis million treatments fight intestinal worms school age children provided albendazole treatment million school age children including children ghana see printed amadeus silk recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free manufacturing mill holds iso eu ecolabel certificates environmental management snikrep sucram read wwwgskcomwwwgskcom find downloadable pdfs cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid glaxosmithkline plc cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid brentford middlesex tw gs united kingdom tel cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid also search us printed amadeus silk recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free ecf manufacturing mill holds iso eu ecolabel certificates environmental management mill zero landfill extremely low carbon emissions leading wwf approve papers environmentally sustainable uncoated recycled paper